Known history of acute or chronic pancreatitisXx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemiaXx_NEWLINE_xXCNS3 leukemiaXx_NEWLINE_xXPatients may not have features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXPatients must not have treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or features suggestive of AML/MDSXx_NEWLINE_xXPatients must be suspected to have previously untreated acute myelogenous leukemia (AML) or myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)Xx_NEWLINE_xXREGISTRATION STEP 2-RANDOMIZATION: Patients must have morphologically confirmed, previously untreated acute myeloid leukemia (AML) or MDS with excess blasts-2 (MDS-EB-2)\r\n* Patients with acute promyelocytic leukemia (APL), biphenotypic leukemia, blastic transformation of chronic myelogenous leukemia (CML or BCR/ABL), are not eligible\r\n* Patients must have disease present in the blood or bone marrow; patients with only extramedullary disease in the absence of bone marrow or blood involvement are not eligible\r\n* All tests for establishing baseline disease status eligibility must be based on blood and/or bone marrow examination performed within 42 days prior to randomization (registration Step 2)Xx_NEWLINE_xXPatients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AMLXx_NEWLINE_xXPatients with Burkitt leukemia/lymphoma or mature B-cell leukemia are not eligibleXx_NEWLINE_xXPatients with T-lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (T-LL) are not eligibleXx_NEWLINE_xXPatients must have newly diagnosed B lymphoblastic leukemia (2008 World Health Organization [WHO] classification) (also termed B-precursor acute lymphoblastic leukemia) or acute leukemia of ambiguous lineage (ALUL), which includes mixed phenotype acute leukemia (MPAL); for patients with ALUL, the morphology and immunophenotype must be at least 50% B lymphoblasticXx_NEWLINE_xXPatients with known absence of KMT2A-rearrangement leukemia prior to enrollmentXx_NEWLINE_xXPatients with secondary B acute lymphoblastic leukemia (B-ALL) that developed after treatment of a prior malignancy with cytotoxic chemotherapyXx_NEWLINE_xXPatients with promyelocytic leukemia (French-American-British [FAB] M3)Xx_NEWLINE_xXKnown history of chronic myelogenous leukemia (CML)Xx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smearXx_NEWLINE_xXParticipants must have pathologically confirmed, newly diagnosed high-risk acute myeloid leukemia, as defined by at least one of the following criteria:\r\n* Age >= 65 years\r\n* Age >= 18 years with adverse risk karyotype, as per European Leukemia Net Guidelines\r\n* Age >= 18 years with antecedent or underlying myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) or myeloproliferative neoplasm\r\n* Age >=18 years with acute myeloid leukemia (AML) with myelodysplastic syndrome (MDS)-related changes\r\n** Note: For patients in category A, a sample to evaluate patient cytogenetics will be sent at the time of diagnosis per standard clinical care and the absence of favorable risk cytogenetics must be confirmed by day 8; if the cytogenetic analysis reveals that the patient harbors favorable risk cytogenetics, or if the cytogenetic results are not received prior to day 8, the participant will be removed from the study; patients removed due to presence of favorable cytogenetics would be considered to be inevaluable and will be replaced; in addition, patients who receive less than half of their total alisertib dose during induction would be considered to be inevaluable and will be replacedXx_NEWLINE_xXMust not have received systemic antineoplastic therapy including radiation therapy within 14 days of the study enrollment, except hydroxyurea or 6-mercaptopurine for the purposes of cytoreduction; patients may also have received all-trans retinoic acid (ATRA) if there is an early suspicion of acute promyelocytic leukemia (acute promyelocytic leukemia [APL], M3-AML), although if confirmed to have APL these patients will be excluded from the studyXx_NEWLINE_xXPatients with acute bilineal/biphenotypic leukemiaXx_NEWLINE_xXPatient has acute promyelocytic leukemia (APML)Xx_NEWLINE_xXParticipants with a previously documented diagnosis of myelodysplastic syndrome (MDS) (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemiaXx_NEWLINE_xXleukemia refractory to ? 2 induction attempts,Xx_NEWLINE_xXleukemia in 1st relapse with initial CR duration < 6 months,Xx_NEWLINE_xXleukemia in 1st relapse following ? 1 unsuccessful salvage attempts,Xx_NEWLINE_xXleukemia in 2nd or higher relapse,Xx_NEWLINE_xXPatients must have a diagnosis of relapsed or refractory CD22-positive acute leukemia including B-ALL, mixed phenotype leukemia (biphenotypic), or Burkitt’s leukemia based on World Health Organization (WHO) classification; patients with bilineal leukemia are excludedXx_NEWLINE_xXAcute myeloid leukemia (AML), myelodysplastic syndrome (MDS)-refractory anemia with excess blasts (RAEB) (including chronic myelomonocytic leukemia [CMML] with excess blasts and MDS/myeloproliferative neoplasm [MPN] overlap syndrome) not in remission (defined as >= 5% blast in bone marrow or peripheral blood) prior to leukemia cell harvest; patients may receive additional cytoreductive therapy after leukemia cell harvest and before admission for transplant, , at the discretion of the treating physician; for patients with MDS-EB1 (< 10%blasts) or CMML-1, it is recommended that they proceed directly to transplant after the harvest if donor is available; if there is an extended delay, interval therapy with HMA is allowed\r\n* Patients may or may not have active disease at the time of transplant conditioning, but for reduced intensity conditioning (RIC) candidates, it is strongly recommended that disease is cytoreduced such that the pre-transplant admission marrow shows:\r\n** < 30% blasts in a normocellular marrow (>= 50% cellularity), or\r\n** < 50% blasts in a hypocellular marrow (< 50% cellularity)Xx_NEWLINE_xXAcute myeloid leukemia (AML): must have < 5% marrow blasts at the time of transplantXx_NEWLINE_xXAcute lymphocytic leukemia (ALL): must have < 5% marrow blasts at the time of transplantXx_NEWLINE_xXChronic myeloid leukemia (CML): patients in chronic phase 1 (CP1) must have failed or be intolerant of tyrosine kinase inhibitors (TKIs); patients beyond CP1 will be accepted if they have < 5% marrow blasts at time of transplantXx_NEWLINE_xXPatients with a diagnosis of chronic myelomonocytic leukemia (CMML)Xx_NEWLINE_xXPatients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AMLXx_NEWLINE_xXPatients with prior myelodysplastic syndrome or acute myeloid leukemiaXx_NEWLINE_xXPatients with previously untreated acute lymphoblastic leukemia (B-cell or T-cell)Xx_NEWLINE_xXRelapsed or refractory acute myeloid leukemiaXx_NEWLINE_xXDiagnosis of acute promyelocytc leukemiaXx_NEWLINE_xXHas active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, amyloidosis, significant autoimmune, CNS or other malignant diseaseXx_NEWLINE_xXPrimary or secondary plasma cell leukemiaXx_NEWLINE_xXDiagnosis of acute myeloid leukemia (i.e. >= 20% peripheral or marrow blasts)Xx_NEWLINE_xXAML as defined by the WHO Classification persisting or recurring following one or more treatment courses except promyelocytic leukemia (APML) and except AML with myelodysplasia related changes.Xx_NEWLINE_xXConcurrent symptomatic amyloidosis or plasma cell leukemiaXx_NEWLINE_xXRelapsed or refractory acute myelocytic leukemia (AML) with nucleophosmin-1 (NPM1) mutations and no available therapies.Xx_NEWLINE_xXRelapsed or refractory acute promyelocytic leukemia (APL), with no available therapies. Note: Prior exposure to arsenic trioxide is allowed; however, subjects who have failed arsenic trioxide within the last 12 months are not allowed.Xx_NEWLINE_xXRelapsed or refractory chronic myelomonocytic leukemia (CMML), and other MDS/myeloproliferative neoplasm (MPN) overlap syndromes, with no available therapiesXx_NEWLINE_xXPathologic confirmation of the diagnosis of AML, ALL (acute lymphoblastic leukemia), or blast-phase CML (chronic myelogenous leukemia)Xx_NEWLINE_xXRelapsed or refractory acute myeloid leukemia or IPSS-R intermediate/high/very high-risk MDS patientsXx_NEWLINE_xXSubject has a diagnosis of acute promyelocytic leukemia (APL)Xx_NEWLINE_xXRelapsed and refractory acute myeloid leukemia (Cohort 1)Xx_NEWLINE_xXNewly diagnosed acute myeloid leukemia in older patients (>= 65 years) not candidates for intensive induction chemotherapy (Cohort 2)Xx_NEWLINE_xXCOHORT 1: Have histologically or cytologically confirmed relapsed or refractory AML (i.e. >= 5 % blasts by manual differential on bone marrow aspirate / biopsy / flow cytometry), excluding acute promyelocytic leukemia (APL; FAB M3; t [15; 17])Xx_NEWLINE_xXCOHORT 2: Have histologically and cytologically confirmed newly diagnosed AML (i.e. >= 20% blasts by manual differential on bone marrow aspirate/biopsy and/or in peripheral blood), excluding acute promyelocytic leukemia (APL; FAB M3, t [15;17])Xx_NEWLINE_xXKnown history of acute or chronic pancreatitisXx_NEWLINE_xXHave current acute leukemia.Xx_NEWLINE_xXKnown prior progression to acute myeloid leukemia (AML), defined by at least 20% blasts in the blood or bone marrow.Xx_NEWLINE_xXA diagnosis of acute promyelocytic leukemia (APL) or chronic myeloid leukemia (CML) in blast crisis.Xx_NEWLINE_xXAcute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) in first or second remission. Remission is defined as the absence of blasts in the peripheral circulation at the time of enrollment, < 5% blasts in the bone marrow and absence of extramedullary disease including CNS involvement.Xx_NEWLINE_xXChronic Myelogenous Leukemia (CML) in first or subsequent chronic phase failing to respond (or intolerant) to at least two different tyrosine kinase inhibitors. CML in accelerated or blast phase (CML-AP/BP) are eligible without requirement to fail tyrosine kinase inhibitor therapy, but must be in remission at time of enrollment. Remission is defined as the absence of blasts in the peripheral circulation at the time of enrollment, < 5% blasts in the bone marrow and absence of extramedullary disease including CNS involvement.Xx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXDiagnosis of acute leukemia or any patient that has been treated with fludarabine.Xx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smearXx_NEWLINE_xXPatients with hematologic malignancies (includes patients with myelodysplastic syndrome/acute myeloid leukemia)Xx_NEWLINE_xXFor expansion, subjects may have a pathologically confirmed diagnosis of MF or PV as noted above; there are two expansion cohorts for patients with myelodysplasia/myeloproliferative neoplasm (MDS/MPN) (chronic myelomonocytic leukemia [CMML], atypical chronic myelogenous leukemia [aCML], refractory anemia with ringed sideroblasts and thrombocytosis [RARS-T] or MDS/MPN-unclassifiable [U]) which warrants treatment; patients with these diagnoses may be eligible, provided they are able to obtain ruxolitinib from commercial supplyXx_NEWLINE_xXT-cell prolymphocytic leukemiaXx_NEWLINE_xXT-cell large granular lymphocytic leukemiaXx_NEWLINE_xXPrior history of acute leukemia or AMLXx_NEWLINE_xXNK cell leukemia.Xx_NEWLINE_xXLymphoid blastic crisis of chronic myelogenous leukemiaXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXCurrent diagnosis of plasma cell leukemiaXx_NEWLINE_xXAcute myelogenous leukemia (AML):Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL):Xx_NEWLINE_xXAny acute leukemia with marrow aplasia or without adequate count recovery.Xx_NEWLINE_xXAcute lymphoblastic leukemia (B- or T-acute lymphoblastic leukemia [ALL])\r\n* Complete response (CR)1-ultra high risk features\r\n** Unfavorable cytogenetics\r\n** Hypodiploidy\r\n** Induction failure\r\n** Minimal residual disease (MRD) positive after consolidation\r\n* CR2\r\n** Any of the high risk features listed in CR1\r\n** B-ALL: any relapse considered eligible for transplant \r\n** T-ALL\r\n* CR 3-anyXx_NEWLINE_xXMixed phenotype acute leukemia MRD > 1% after consolidationXx_NEWLINE_xXParticipants must have a diagnosis of AML or acute leukemia of ambiguous lineage (acute undifferentiated leukemia or mixed phenotype acute leukemia) and meet the criteria below:\r\n* Refractory leukemia, defined as persistent leukemia after at least two courses of induction chemotherapy, OR\r\n* Early relapsed leukemia, defined as the re-appearance of leukemia after the achievement of remission and within one year of diagnosis, OR\r\n* Relapsed leukemia that is refractory to at least one course of salvage therapy (i.e., therapy given after the relapse has occurred), OR\r\n* Second or greater relapse\r\nPatients in all categories above must have >= 5% blasts in the bone marrow as assessed by morphology or flow cytometry; however, if an adequate bone marrow sample cannot be obtained, patients may be enrolled if there is unequivocal evidence of leukemia with >= 5% blasts in the peripheral blood; in addition, patients in all categories must not be eligible to undergo curative therapy, such as immediate stem cell transplantation (SCT)Xx_NEWLINE_xXPatients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, or bone marrow failure syndromes are not eligibleXx_NEWLINE_xXNewly diagnosed with acute myelogenous leukemia (except acute promyelocytic leukemia) and has failed one or two prior standard induction attempts. Failure is defined as:Xx_NEWLINE_xXSubjects with any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)Xx_NEWLINE_xXParticipants with a history of myelodysplastic syndrome or acute myeloid leukemiaXx_NEWLINE_xXSubject has BCR-ABL-positive leukemia (Chronic myeloid leukemia [CML] in blast crisis).Xx_NEWLINE_xXSubject is diagnosed as acute promyelocytic leukemia (APL).Xx_NEWLINE_xXDiagnosis of acute leukemiaXx_NEWLINE_xXPatient has newly diagnosed acute lymphoblastic leukemia (ALL) or acute undifferentiated leukemia with >= 25% blasts in the bone marrow (M3), with or without extramedullary disease; patients with T-cell ALL are eligible; patients with bilineage or biphenotypic acute leukemia are eligible, provided the morphology and immunophenotype are predominantly lymphoidXx_NEWLINE_xXPatients with mature B-cell ALL or acute myelogenous leukemia (AML)Xx_NEWLINE_xXAcute Lymphoblastic Leukemia (ALL) in first complete remission (CR1) that is NOT considered favorable-risk as defined by the presence of at least one of the following: Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), other Mixed Lineage Leukemia (MLL) rearrangements; White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL)at diagnosis; Recipient age older than 30 years at diagnosis; Time to CR greater than 4 weeksXx_NEWLINE_xXAcute Myelogeneous Leukemia (AML) in CR1 that is NOT considered as favorable-risk. Favorable risk is defined as having one of the following: t(8.21) without CKIT mutation, inv(16) without CKIT mutation or t(16;16), normal karyotype with mutated NPM1 and not FLT-ITD, normal karyotype with double mutated CEBPA, Acute promyelocytic leukemia (APL) in first molecular remission at end of consolidationXx_NEWLINE_xXParticipant has confirmed ongoing morphologically documented AML in CR1. For the purposes of randomization, CR1 will be defined as < 5% blasts with no morphologic characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.Xx_NEWLINE_xXPathologically confirmed myelodysplastic syndrome (MDS) diagnosis (regardless of initial International Prognostic Scoring System [IPSS] risk category) or oligoblastic acute myeloid leukemia (AML) with 21-30% bone marrow (BM) blasts in whom DNMTi have failed; patients who have developed AML after DNMTi therapy can be enrolled as long as they have initiated DNMTi therapy while they were in the MDS or oligoblastic AML (20-30% BM blasts) phase and the study chair agrees; failure of DNMTis is defined as: failure to achieve a complete response (CR), partial response (PR) or hematologic improvement (HI) after at least 4 cycles of DNMTi or progressed after such therapyXx_NEWLINE_xXPatients with a diagnosis of acute myeloid leukemia (AML) not transformed from MDS or transformed from MDS with > 30% blasts in bone marrow or white blood cells (WBC) > 25 x 10^3/LXx_NEWLINE_xXPlasma cell leukemia (defined by plasma cell >20%, and/or an absolute plasma cell count of >2 x 10e9/L in peripheral blood).Xx_NEWLINE_xXAcute progranulocytic leukemia (APL, M3)Xx_NEWLINE_xXActive or prior plasma cell leukemia (defined as either 20% of peripheral WBC comprised of plasma/CD138+ cells or an absolute count of 2 x 10^9/L).Xx_NEWLINE_xXHave current hematologic malignancies, acute or chronic leukemia.Xx_NEWLINE_xXHas acute GVHD.Xx_NEWLINE_xXKnown prior progression to acute myeloid leukemia (AML) defined by at least 20% blasts in the blood or bone marrow.Xx_NEWLINE_xXAcute or chronic skin and/or microvascular disordersXx_NEWLINE_xXDiagnosed with acute promyelocytic leukemia (APL, M3)Xx_NEWLINE_xXAcute promyelocytic leukemia (APL, French-American-British (FAB) subtype M3), according to WHO classification.Xx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXLeukemia other than CMMLXx_NEWLINE_xXAML as defined by the WHO Classification persisting or recurring following one or more treatment courses except promyelocytic leukemia (APML) and except AML secondary to prior myelodysplastic syndrome. For Germany only: AML as defined by the WHO Classification either persisting/refractory after at least 2 primary induction courses (ie, no response after at least 2 prior chemotherapy cycles) or recurring after having achieved an initial response to chemotherapy except promyelocytic leukemia (APML) and except AML secondary to prior myelodysplastic syndrome.Xx_NEWLINE_xXleukemiaXx_NEWLINE_xXHigh grade lymphomas (Burkitts or lymphoblastic), plasma cell leukemia.Xx_NEWLINE_xXPatient must have a B cell acute lymphoblastic leukemia (ALL) (inclusive of ALL blast transformation from chronic myelogenous leukemia [CML]) or lymphoma and must have relapsed or refractory disease after at least one standard chemotherapy regimen and one salvage regimen; in view of the principal investigator (PI) and the primary oncologist, there must be no available alternative curative therapies and subjects must be either ineligible for allogeneic stem cell transplant (SCT), have refused SCT, recurred after SCT, or have disease activity that prohibits SCT at the time of enrollmentXx_NEWLINE_xXAcute lymphoblastic leukemia, excluding known mature B-cell ALL by the presence of any of the following: surface immunoglobulin, L3 morphology, t(8;14)(q24;q32), t(8;22), or t(2;8)Xx_NEWLINE_xXPatients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation and have one of the following diagnoses:\r\n* Acute lymphocytic leukemia in first or subsequent remission\r\n* Acute myeloid leukemia in first or subsequent remission \r\n* Acute lymphocytic leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 (Arms A or C only)\r\n* Acute myeloid leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 (Arms A or C only)\r\n* Refractory anemia with excess blasts (RAEB-1 and RAEB-2) (if the patient has received previous induction chemotherapy within 60 days)\r\n* Chronic myelogenous leukemia with a history of accelerated phase or blast crisis (if the patient has received at least one course of induction chemotherapy)\r\n* Other acute leukemia or related neoplasm (including but not limited to ‘biphenotypic’, ‘undifferentiated’ or ‘ambiguous lineage’ acute leukemia, blastic plasmacytoid dendritic cell neoplasm or lymphoblastic lymphoma)Xx_NEWLINE_xXGroup A: CD19+ B-acute lymphoblastic leukemia (ALL) undergoing allogeneic HSCT orXx_NEWLINE_xXCD19+ leukemiaXx_NEWLINE_xXSubjects must have histologically documented acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPD), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) or multiple myeloma (MM) as follows:\r\n* Acute myeloid leukemia (AML) with one or more of the following criteria:\r\n** Poor risk cytogenetics, including -5, 5q-, -7, 7q-, t(9;22); complex cytogenetics (>= 3 abnormalities); or normal cytogenetics with Fms-like tyrosine kinase 3 (Flt3) internal tandem duplications (ITD), in first or subsequent complete remission (CR)\r\n** Relapsed or primary refractory AML with =< 10% blasts in the peripheral blood\r\n** Subjects in CR1 who required two cycles of induction to achieve remission may be included at the discretion of the treating physician\r\n** Standard risk or intermediate risk cytogenetics in second or subsequent CR (enrolled at the discretion of the treating physician)\r\n* Acute lymphoblastic leukemia (ALL) with one of the following criteria:\r\n** Second or subsequent CR\r\n** Any partial remission (PR) (no circulating blasts)\r\n** High-risk ALL in first CR including (Philadelphia chromosome positive [Ph+], t(4:11)), complex karyotype, hypodiploidy (< 44 chromosomes), positive minimal residual disease (MRD) after induction, and other high risk features in adults per treating physician\r\n* Myelodysplasia, intermediate-2 (score 1.5-2.0) or high risk (score > 2.5) by the International Prognostic Score System\r\n* Myeloproliferative disorders (include chronic myelomonocytic leukemia [CMML], agnogenic myeloid metaplasia [AMM] or idiopathic myelofibrosis, and juvenile myelomonocytic leukemia [JMML]) with excess blasts (> 5%)\r\n* Chronic myeloid leukemia (CML) with one of the following criteria:\r\n** Second or subsequent chronic phase\r\n** Accelerated phase\r\n** Blast crisis\r\n* Non-Hodgkin's lymphoma (NHL) meeting one of the following criteria:\r\n** Relapse after autologous stem cell transplantation with evidence of responsive disease\r\n** Subject with chemosensitive relapse who have no option for autologous stem cell transplantation due to blood or marrow involvement or failure to mobilize autologous stem cells or are not considered eligible for autologous transplant by their treating physician\r\n* Hodgkin’s lymphoma: relapse after autologous hematopoietic cell transplant (HCT), chemorefractory disease\r\n* Multiple myeloma: per National Comprehensive Cancer Network (NCCN) guidelinesXx_NEWLINE_xXPatients with pathologically confirmed smoldering or chronic adult T- cell leukemia as defined by ShimoyamaXx_NEWLINE_xXMust have relapsed or refractory precursor B-cell acute lymphoblastic leukemia or acute lymphoblastic lymphomaXx_NEWLINE_xXHave known acute or chronic leukemia or current hematologic malignancies (except iNHL for patients in Part B5) that, in the judgment of the investigator and sponsor, may affect the interpretation of resultsXx_NEWLINE_xXAcute myeloid leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia:\r\n* All patients must be in CR as defined by hematologic recovery and < 5% blasts by morphology/flow cytometry in a representative bone marrow sample with cellularity >= 15% for age; patients who do not have high-risk features (for example preceding myelodysplastic syndrome [MDS], high-risk cytogenetics, >= 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia or >= CR2) must be discussed with the principal investigator (PI) prior to enrollment and at the Patient Care Conference or equivalent group such as the pediatric leukemia board as an alternative\r\n* Patients in whom adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the PI prior to enrollment; patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approvalXx_NEWLINE_xXVery high risk pediatric/young adult patients with acute myeloid leukemia (AML): Patients =< 25 years, however, are eligible with (M2 marrow) with =< 25% blasts in marrow after having failed one or more cycles of chemotherapy; this group of patients will be analyzed separatelyXx_NEWLINE_xXAcute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia:\r\n* All patients must be in CR as defined by < 5% blasts by morphology; flow cytometry in a representative bone marrow sample with cellularity >= 15% for age; patients who do not have high-risk disease (high risk CR1, greater than one cycle to obtain CR or >= CR2) must be discussed with the PI prior to enrollment and at the Patient Care Conference or equivalent group such as the pediatric leukemia board as an alternative\r\n* Patients in whom adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the principal investigator Ann Dahlberg prior to enrollment; patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approvalXx_NEWLINE_xXChronic myelogenous leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylateXx_NEWLINE_xXPatients with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smearXx_NEWLINE_xXPatients with one of the high risk myeloid diseases as outlined below. Patients must have less than 5% blasts on the last bone marrow (BM) evaluation prior to starting the conditioning regimen. Diseases included on this protocol include:\r\n* Acute myeloid leukemia (AML) in first complete remission (CR1) with intermediate or high risk features as defined below:\r\n** Cytogenetic abnormalities which are not considered “good risk” cytogenetic features (i.e t(8:21), t(15:17), inv 16 without c-kit mutations. And/or\r\n** Therapy related AML with history of antineoplastic therapy (radiation and/or chemotherapy) And/or\r\n** Normal karyotype with mutations of FLT3, RUNX1, TP53 mutation, ASXL1 or any others that are considered to be high risk\r\n* AML in >= 2nd remission\r\n* Myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/myeloproliferative neoplasms (MPN) overlap syndrome with:\r\n** International prognostic scoring system risk score intermediate-2 (INT-2) or high risk at the time of transplant evaluation. And/or\r\n** Any risk category if life-threatening cytopenia exists And/or\r\n** Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.\r\n* Chronic myelomonocytic leukemia (CMML): CMML-1 or CMML-2.\r\n* Chronic myeloid leukemia (CML) with the following features:\r\n** Patients who have failed or are intolerant to BCR-ABL tyrosine kinase inhibitors. And/or\r\n** CML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition (e.g T351l mutation)\r\n* Patients with severe aplastic anemia.Xx_NEWLINE_xXConfirmed diagnosis of relapsed or refractory acute leukemia (acute myeloid leukemia, acute lymphoblastic leukemia, blast crisis of chronic myeloid leukemia [CML], secondary AML from prior myelodysplastic syndrome [MDS] / myeloproliferative neoplasm [MPN]); minimum of 5% blasts in the bone marrow or 10% blasts in circulationXx_NEWLINE_xXPatients with myeloid diseases (AML, myeloid blast crisis of CML) will be eligible for arm A with cytarabine; patients with lymphoid diseases (ALL, lymphoid blast crisis of CML) will be eligible for arm B with liposomal vincristine; patients with leukemia of ambiguous lineage or bi-phenotypic leukemia (e.g. B/myeloid) may be treated on either arm A or B, at discretion of treating physicianXx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (M3 classification)Xx_NEWLINE_xXPatients with first relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)Xx_NEWLINE_xXPatients with Philadelphia chromosome (Ph)-positive ALL or Burkitt leukemiaXx_NEWLINE_xXParticipants must have a diagnosis of acute lymphoblastic leukemia and disease meets at least one of the following criteria:\r\n* Relapsed or refractory to chemotherapy as defined by ? 5% leukemic blasts in the bone marrow\r\n* Relapsed after hematopoietic stem cell transplantation (HSCT)Xx_NEWLINE_xXDocumented malabsorptive syndromes including enteropathies, gastroenteritis (acute or chronic) or diarrhea (acute or chronic)Xx_NEWLINE_xXEligible patients with a histopathological confirmed diagnosis of hematologic malignancy in one of the following categories:\r\n* Acute myelogenous leukemia:\r\n** Patients with de novo or secondary disease in unfavorable risk group including poor risk cytogenetics according to National Comprehensive Cancer Network (NCCN) guidelines for acute myelogenous leukemia (AML) i.e., monosomal karyotype, -5, 5q-, -7, 7q-, 11q23-non t (9;11), inv (3), t (3;3), t (6;9), t (9;22) and complex karyotypes (>= 3 unrelated abnormalities), or all patient in intermediate risk groups accept patients with FLT3-NPM1+ disease\r\n** Patients with active disease\r\n** Patients with chemosensitive active disease\r\n* Acute lymphocytic leukemia:\r\n** Patients with de novo or secondary disease according to NCCN guidelines for acute lymphocytic leukemia (ALL) hypoploidy (< 44 chromosomes); t (v;11q23): MLL rearranged; t (9;22) (q34;q11.2); complex cytogenetics (5 or more chromosomal abnormalities); high white blood cell (WBC) at diagnosis (>= 30,000 for B lineage or >= 50,000 for T lineage); iAMP21loss of 13q, and abnormal 17p\r\n** Patients with active disease\r\n** Patients with chemosensitive active disease\r\n* Myelodysplastic syndrome in high-intermediate (int-2) and high risk categoriesXx_NEWLINE_xXConcurrent symptomatic amyloidosis or plasma cell leukemiaXx_NEWLINE_xXThe patient must have a disease (listed below) with treatment-responsiveness that the treating transplant physician believes will benefit from an allogeneic stem cell transplant. The diseases include:\r\n* Acute leukemia – Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)\r\n* Chronic leukemia – Chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL)\r\n* Myelodysplasia\r\n* Myeloproliferative disorder\r\n* Myelofibrosis\r\n* Lymphoma – Non-Hodgkin lymphoma (NHL) or Hodgkin’s disease\r\n* Plasma cell disorder, including myeloma, Waldenstrom’s macroglobulinemia.Xx_NEWLINE_xXThis study is open to patients with acute myeloid leukemia (AML) evaluated within 30 days of the start of conditioning regimen and in first or second complete remission (CR)Xx_NEWLINE_xXPatients with acute myelogenous leukemia (AML) who are in first or second complete remissionXx_NEWLINE_xXSubject has acute promyelocytic leukemiaXx_NEWLINE_xXPatients with a known diagnosis of plasma cell leukemiaXx_NEWLINE_xXSubjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of \r\nmyelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).Xx_NEWLINE_xXDiagnosis of relapsed or refractory (R/R) acute myeloid leukemia (AML)Xx_NEWLINE_xXAcute myelogenous leukemia (AML):\r\n* Complete first remission (CR1) at high risk for relapse such as any of the following:\r\n** Known prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder.\r\n** Therapy-related AML.\r\n** White cell count at presentation > 100,000.\r\n** Presence of extramedullary leukemia at diagnosis.\r\n** Any unfavorable subtype by French-American-British (FAB) or World Health Organization (WHO) classification.\r\n** High-risk cytogenetics (e.g. those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) or high risk molecular abnormalities.\r\n** Requirement for 2 or more inductions to achieve CR1.\r\n** Any patient with newly diagnosed AML with intermediate risk cytogenetics who elects allograft with curative intent over consolidation chemotherapy.\r\n** Any patient unable to tolerate consolidation chemotherapy as would have been deemed\r\nappropriate by the treating physician.\r\n** Other high risk features not defined above.\r\n* Complete second remission (CR2).\r\n* Primary refractory or relapsed AML with less than 10% blasts before transplant. Persistent/relapsed AML with cytogenetic, flow cytometric, or molecular aberrations in >= 10% of cells are eligible.Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL):\r\n* Complete first remission (CR1) at high risk for relapse such as any of the following:\r\n** White cell count at presentation > 30,000 for B-cell lineage and > 100,000 for T-cell lineage.\r\n** Presence of any high-risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality.\r\n** Failure to achieve complete remission after four weeks of induction therapy.\r\n** Persistence or recurrence of minimal residual disease on therapy.\r\n** Any patient with newly diagnosed ALL >= 50 years-old.\r\n** Any patient unable to tolerate consolidation and/or maintenance chemotherapy as would have been deemed appropriate by the treating physician.\r\n** Other high risk features not defined above.\r\n* Complete second remission (CR2).\r\n* Primary refractory or relapsed ALL with less than 5% blasts before transplant. Persistent/relapsed ALL with cytogenetic, flow cytometric or molecular aberrations in >= 5% of cells are eligible.Xx_NEWLINE_xXPatients can be in chronic phase (CP) with bone marrow (BM) blast count =< 10% or after progression to acute myeloid leukemia (AML) and achieved =< 5% BM blasts (morphologic complete remission [CR] prior to transplant);Xx_NEWLINE_xXChronic lymphocytic leukemia and Richter's transformation, and prolymphocytic leukemia (NHL subjects)Xx_NEWLINE_xXPatients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)Xx_NEWLINE_xXPatient with AML according to 2016 WHO criteria (excluding acute promyelocytic leukemia [APL] [AML-M3])Xx_NEWLINE_xXARMS A-G: RR AML: Patients with AML who are refractory or relapsed (any salvage) with no available therapies or not candidates for available therapies. For patients with prior MDS or chronic myelomonocytic leukemia (CMML) or myeloproliferative neoplasm (MPN) who transformed to AML, therapy received for MDS, CMML, or MPN is NOT considered as prior therapy for AML.Xx_NEWLINE_xXAcute promyelocytic leukemia (APL).Xx_NEWLINE_xXPatients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), or features suggestive of MDS/AMLXx_NEWLINE_xXPatients with Plasma Cell LeukemiaXx_NEWLINE_xXDiagnosis of Burkitt's leukemia/lymphoma according to WHO classification or chronic myelogenous leukemia lymphoid blast crisisXx_NEWLINE_xXExperimental therapies for MDS or Acute Myeloid Leukemia (AML).Xx_NEWLINE_xXParticipant has the following: a. Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2016 for Acute Myeloid Leukemia.Xx_NEWLINE_xXParticipant has acute promyelocytic leukemiaXx_NEWLINE_xXKnown history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)Xx_NEWLINE_xXSubjects with a histologically confirmed diagnosis of MDS, including both MDS and refractory anemia with excess blasts in transformation (RAEB-T) (acute myeloid leukemia [AML] with 20-30% blasts and multilineage dysplasia by French-American-British [FAB] criteria) by World Health Organization (WHO), and chronic myelomonocytic leukemia (CMML) are eligibleXx_NEWLINE_xXHave a confirmed diagnosis of:\r\n* International Prognostic Scoring System (IPSS) intermediate-1, intermediate-2 or high-risk MDS including chronic myelomonocytic leukemia (CMML) OR\r\n* Low blast count AML with =< 30% blasts previously classified as refractory anemia with excess blasts in transformation and, who have not been previously treated with a hypomethylating agentXx_NEWLINE_xXPatients with the following hematologic malignancies:\r\n* Acute myelogenous leukemia (AML): High-risk AML including:\r\n** Antecedent hematological disease (e.g., myelodysplasia [MDS])\r\n** Treatment-related leukemia\r\n** Complete remission (CR1) with poor-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, complex cytogenetics)\r\n** CR2 or CR3\r\n** Induction failure or 1st relapse with =< 10% blasts in the marrow\r\n* Acute lymphoblastic leukemia (ALL)\r\n** High-risk CR1 including:\r\n*** Poor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22) or 11q23 rearrangements)\r\n*** Presence of minimal disease by flow cytometry after 2 or more cycles of chemotherapy\r\n** No CR within 4 weeks of initial treatment\r\n** Induction failure with =< 10% blasts in the marrow\r\n** CR2 or CR3\r\n* Myelodysplastic syndromes (MDS), intermediate, high or very high risk by the revised international prognostic scoring system (IPSS-R)\r\n* Chronic myelogenous leukemia (CML) in second chronic phase after accelerated or blast crisis\r\n* Myelofibrosis (MF):\r\n** Intermediate-2 or high risk by Dynamic International Prognostic Scoring System (DIPSS)-plus OR\r\n** Monosomal karyotype OR\r\n** Presence of inv(3)/i(17q) abnormalities OR\r\n** Other unfavorable karyotype OR leukocytes >= 40 x 10(9)/L AND\r\n** Circulating blasts =< 9%\r\n* Relapsed or refractory lymphoid malignancies (including non-Hodgkin lymphoma, Hodgkin lymphoma) meeting the following criteria:\r\n** Disease status: Stable disease, partial remission or 2nd and 3rd complete remission\r\n** Have relapsed after autologous transplant or who have failed to collect for an autologous transplantXx_NEWLINE_xXDiagnosis of acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma.Xx_NEWLINE_xXThe patient must have a diagnosis of one of the following (one must be yes):\r\n* Bone marrow failure disorders:\r\n** Acquired bone marrow failure disorders include aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH):\r\n*** SAA must have failed at least one cycle of standard immunosuppressive therapy with calcineurin inhibitor plus anti-thymocyte globulin (ATG)\r\n*** PNH must have failed treatment or not tolerated treatment with eculizumab or progressed during or after treatment with eculizumab\r\n** Hereditary bone marrow failure disorders include Diamond-Blackfan anemia, Shwachman-Diamond syndrome, Kostmann syndrome, and congenital amegakaryocytic thrombocytopenia\r\n* Other non-malignant hematologic or immunologic disorders that require transplantation:\r\n** Quantitative or qualitative congenital platelet disorders (including but not limited to congenital amegakaryocytopenia, absent-radii syndrome, Glanzmann’s thrombasthenia)\r\n** Quantitative or qualitative congenital neutrophil disorders (including but not limited to chronic granulomatous disease, congenital neutropenia)\r\n** Congenital primary immunodeficiencies (including but not limited to severe combined immunodeficiency syndrome, Wiskott-Aldrich syndrome, CD40 ligand deficiency, T-cell deficiencies)\r\n** Hemoglobinopathies (including sickle cell disease and thalassemia)\r\n* Acute leukemias:\r\n** Acute myeloid leukemia (AML) - antecedent myelodysplastic syndrome, secondary\r\nAML, intermediate cytogenetics, high risk cytogenetic abnormalities or normal cytogenetics with high-risk\r\nmolecular mutations (including but not limiting to Flt3-ITD mutation), or other high risk features as per clinical judgment of the study principal investigator (PI) (or in the absence of the study PI, another equally qualified clinician)\r\n** Acute lymphoblastic leukemia (ALL) - B cell or T cell\r\n* Chronic myelocytic leukemia (CML):\r\n** Chronic phase (intolerant or unresponsive to imatinib and/or tyrosine kinase inhibitors)\r\n** Second chronic phase or accelerated phase who are ineligible for conventional myeloablative transplantation\r\n* Myeloproliferative and myelodysplasia syndromes:\r\n** Myelofibrosis (with/without splenectomy) with intermediate to high risk features\r\n** Advanced polycythemia vera not responding to therapy\r\n** Myelodysplastic syndrome (MDS) with an Revised International Prognostic Scoring System (IPSS-R) score of intermediate or higher\r\n** Secondary MDS with any IPSS score\r\n** Chronic myelomonocytic leukemia (CMML)\r\n* Lymphoproliferative disease:\r\n** Chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin lymphoma (NHL) (recurrent or persistent) cytotoxic therapy refractory or with less than 6 months duration of complete response (CR) between courses of conventional therapy\r\n** Multiple myeloma (MM) progressive disease after auto bone marrow transplantation (BMT), tandem allo after prior auto\r\n** Waldenstrom’s macroglobulinemia (failed one standard regimen)\r\n** T or B cell lymphoma with poor risk features\r\n** Hodgkin disease:\r\n*** Received and failed frontline therapy\r\n*** Failed or not eligible for autologous transplantationXx_NEWLINE_xXPatients with previously untreated AML (except acute promyelocytic leukemia [APL]) who have at least one of the following:\r\n* Adverse genetic features as per the European Leukemia Net guidelines\r\n* Treatment related AML or AML with antecedent myelodysplastic syndrome (MDS); (patient who have received treatment with hypomethylating agents for MDS and have now transformed to AML are eligible)\r\n* Are over the age of 55 years and considered fit for chemotherapy\r\n* Patients with AML with MDS-related changesXx_NEWLINE_xXCD19+22+ leukemiaXx_NEWLINE_xXPatients must have relapsed (first or greater relapse) or refractory T-cell acute lymphoblastic leukemia (T-ALL) with: \r\n* Relapsed T-ALL with an M2 (blasts >= 5 to =< 25%) or M3 (> 25% blasts) marrow with or without an extramedullary site of relapse; including central nervous system (CNS) 2 OR\r\n* Refractory disease after induction failure of newly diagnosed patients OR no more than two more cycles of therapy OR\r\n* Refractory disease with no more than one prior salvage attempt following the current relapseXx_NEWLINE_xXSubjects diagnosed with Acute Promyelocytic Leukemia.Xx_NEWLINE_xXHistory of or active bone marrow disorders expected to interfere with study therapy (e.g. acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma)Xx_NEWLINE_xXRelapsed acute myeloid leukemiaXx_NEWLINE_xXPOEMS syndrome or active plasma cell leukemia;Xx_NEWLINE_xXAcute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or myelodysplastic syndrome (MDS) in confirmed relapse based on bone marrow examination after allogeneic HCT; biopsy confirmed myeloid sarcoma or extramedullary AML may also be consideredXx_NEWLINE_xXPatients must have no active acute or chronic GVHDXx_NEWLINE_xXHas morphologically confirmed diagnosis of myelodysplastic syndromes (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) (i.e., with white blood cell [WBC] <13,000/?L) or low-blast acute myelogenous leukemia (AML).Xx_NEWLINE_xXWithin 7 days prior to administration of study treatment: No features suggestive of myelodysplastic syndrome/acute myeloid leukemia on peripheral blood smear.Xx_NEWLINE_xXA diagnosis or suspicion of myelodysplastic syndrome/acute myeloid leukemia.Xx_NEWLINE_xXAcute myeloid leukemia (AML) – must have < 5% marrow blasts at the time of transplantXx_NEWLINE_xXAcute lymphocytic leukemia (ALL) – must have < 5% marrow blasts at the time of transplantXx_NEWLINE_xXChronic myeloid leukemia (CML) – patients in CP1 must have failed or be intolerant of tyrosine kinase inhibitors (TKIs); patients beyond CP1 will be accepted if they have < 5% marrow blasts at time of transplantXx_NEWLINE_xXMyelodysplasia (MDS)/myeloproliferative syndrome (MPS)/chronic myelomonocytic leukemia (CMML) – patients must have < 5% marrow blasts at time of transplantXx_NEWLINE_xXPatients with a diagnosis of chronic myelomonocytic leukemia (CMML) who have not received induction chemotherapyXx_NEWLINE_xXAcute promyelocytic leukemia (APL); patients with brief exposure to all-trans retinoic acid (ATRA), arsenic trioxide (ATO) or similar product for suspected APL, who later turn out not to have APL, are eligible for the studyXx_NEWLINE_xXPatients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)Xx_NEWLINE_xXPatient must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)Xx_NEWLINE_xXDiagnosis of hematologic malignancy (i.e. acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma) in complete remission at the time of transplantXx_NEWLINE_xXAcute viral or active autoimmune, alcoholic, or other types of acute hepatitisXx_NEWLINE_xXPatients ?18 and ?75 years old with relapsed or primary refractory acute myeloid leukemia.Xx_NEWLINE_xXPatients enrolled onto the dose-finding phase of the study must have an identified donor and transplant strategy prior to initiation of the lymphodepletion regimen. Patients enrolled in the Expansion Phase of the Study: Relapsed/Refractory Cohort • Patients ?18 years old with relapsed or primary refractory acute myeloid leukemia. Patients Enrolled in the Dose-Escalation Phase of the Study •Patients ?18 years and ?75 years old (The 3 first patients at Dose Level 1 will be <65 years old. Enrollment of patients ? 65 years old must be approved by the DSMB after the completion of cohort 1) Newly Diagnosed Cohort • Patients with newly diagnosed, untreated Acute Myeloid Leukemia (as defined by World Health Organization (WHO) criteria,) who meet criteria for the European Leukemia Net (ELN) Adverse genetics prognostic group. Eligibility criteria for UCART123 administrationXx_NEWLINE_xXAcute Promyelocytic LeukemiaXx_NEWLINE_xXKnown myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)Xx_NEWLINE_xXRelapsed or refractory CD19-positive B-lineage acute lymphoblastic leukemia having received at least 1 prior line of therapyXx_NEWLINE_xXPhiladelphia chromosome/BCR-ABL1-positive B-lineage acute lymphoblastic leukemia (ALL) must have failed at least 1 second or third generation tyrosine kinase inhibitor (TKI) or be intolerant to TKIsXx_NEWLINE_xXInclusion Criteria:\n\n        AML confirmed subjects aged ? 60 years who have achieved complete remission (CR or CRi)\n        after induction/consolidation Ara-C based therapy, that have MRD positive status and are\n        not planned for stem cell transplantation.\n\n        Exclusion Criteria:\n\n        Subjects diagnosed with acute promyelocytic leukemia or with extramedullary AML or subjects\n        who have achieved CR or CRi following treatment for AML. Subjects who have received\n        treatment with hypomethylating agents.Xx_NEWLINE_xXChronic myelomonocytic leukemia (CMML)Xx_NEWLINE_xXAcute myeloblastic leukemia (AML) that was previously treated with HMA and is unfit for intensive chemotherapy\r\n* Patient must be within 6 months of prior treatment with HMA and must be willing to be treated with the same agent on this studyXx_NEWLINE_xXPatients with a diagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXRelapsed and/or refractory Philadelphia negative acute lymphoblastic leukemia or lymphoblastic lymphoma (Lead-in and Phase 2)Xx_NEWLINE_xXRelapsed and/or refractory Philadelphia positive acute lymphoblastic leukemia, Burkitt leukemia/lymphoma or “double-hit” leukemia/lymphoma (2 separate cohorts, phase II only)Xx_NEWLINE_xXPatients with a diagnosis of histologically confirmed relapsed or refractory (R/R) acute myeloid leukemia or R/R acute lymphoblastic leukemia for which no available standard therapies are indicated or anticipated to result in a durable responseXx_NEWLINE_xXPatients must have advanced AML, ALL or high-risk MDS meeting one of the following descriptions:\r\n* AML or ALL beyond first remission (i.e., having relapsed at least one time after achieving remission in response to a treatment regimen)\r\n* AML or ALL representing primary refractory disease (i.e., having failed to achieve remission at any time following one or more prior treatment regimens)\r\n* AML evolved from myelodysplastic or myeloproliferative syndromes\r\n* MDS expressed as refractory anemia with excess blasts (RAEB)\r\n* Chronic myelomonocytic leukemia (CMML) by French-American-British (FAB) criteriaXx_NEWLINE_xXPatients with active (blood or bone marrow blasts > 5%) relapsed or refractory CD33+ acute myeloid leukemia (AML) de novo, or secondary. a. Relapsed AML is defined as patients that had a first complete remission (CR) before developing recurrent disease. b. Refractory AML defined as patients that have not achieved a CR after 2 cycles of induction chemotherapy.Xx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL M3): t(15;17)(q22;q12); (promyelocytic leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded.Xx_NEWLINE_xXPatients can be in chronic phase (CP) with bone marrow (BM) blast count =< 10% or after progression to acute myeloid leukemia (AML) and achieved =< 5% BM blasts (morphologic complete remission [CR] prior to transplant)Xx_NEWLINE_xXPatients must have a confirmed diagnosis of one of the following:\r\n* Newly diagnosed AML (excluding acute promyelocytic leukemia [APL]) \r\n* Newly diagnosed intermediate-2 (INT-2) or high-risk MDS\r\n* Relapsed or refractory AML, or INT-2 or high-risk MDSXx_NEWLINE_xXPHASE I: Diagnosis of CD22-positive acute lymphoblastic leukemiaXx_NEWLINE_xXPHASE I: Patients who have/are either:\r\n* Transplanted in hematologic first complete remission with evidence of minimal residual disease within 45 days of allogeneic transplantation\r\n** Pre- or post-transplant minimal residual disease defined by:\r\n*** Any detectable acute lymphocytic leukemia (ALL) (by flow cytometry, cytogenetics, or polymerase chain reaction [PCR] techniques) as per clinical indication\r\n* In second or third complete remission at the time of allogeneic transplantation\r\n* Treated with reduced intensity regimens\r\n* Lymphoid blast crisis of chronic myelogenous leukemia (CML)\r\n* Are relapsed or refractory to at least 1 line of chemotherapyXx_NEWLINE_xXPHASE II: Diagnosis of CD22-positive acute lymphoblastic leukemiaXx_NEWLINE_xXMust have one of the following hematologic malignancies: a. Acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics, flt3 mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndrome (MDS), Langerhan's cell histiocytosis, any disease beyond first remission. b. Myelodysplastic syndrome (MDS): MDS International Prognostic Scoring System (IPSS) INT-1 will be enrolled only if the subjects have failed previous leukemia treatments and are transfusion-dependent. MDS may be primary or therapy related, including patients that will be considered for transplant. Including the following categories: 1) Revised IPSS intermediate and high risk groups, 2) MDS with transfusion dependency, 3) Failure to respond or progression of disease on hypomethylating agents, 4) Refractory anemia with excess of blasts, 5) Transformation to acute leukemia, 6) Chronic myelomonocytic leukemia, 7) Atypical MDS/myeloproliferative syndromes, 8) Complex karyotype, abn(3g), -5/5g-, -7/7g-, abn(12p), abn(17p). c. Acute lymphoblastic leukemia (ALL) patients with the following will be considered: induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease. Patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time: with translocations 9;22 or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure, and/or evidence of minimal residual disease, or acute biphenotypic leukemia which excludes > 7 chromosomal abnormalities, or double hit non-Hodgkin's lymphoma. Non-Hodgkin's lymphoma (NHL) in second or third complete remission or relapse (including relapse post autologous hematopoietic stem cell transplant), or relapsed double hit lymphoma. Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease with progression after standard of care therapy or have failed/been intolerant to ibrutinib. Chronic myelogenous leukemia (CML) second chronic phase or accelerated phase. Hodgkin's disease (HD): Induction failure after the first complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant), or those with active disease.Xx_NEWLINE_xXDiagnosis of acute myeloid leukemia (AML) and meets one of the following disease criteria:\r\n* Primary induction failure:\r\n** De Novo AML: No CR after 2, 3 or 4 induction attempts with high dose chemotherapy\r\n** Secondary AML (from myelodysplastic syndrome [MDS] or treatment related): No CR after 1, 2 or 3 cycles of high dose chemotherapy\r\n* Relapsed:\r\n** Not in CR after 1 or 2 cycles of standard re-induction therapy\r\n*** For patients > 60 years of age, the minimum of 1 cycle of standard chemotherapy is not requiredXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXParticipants that have acute promyelocytic leukemia (APL).Xx_NEWLINE_xXDiagnosis of acute myeloid leukemia (AML) (other than acute promyelocytic leukemia [APL]) with refractory/relapsed disease; patients with relapsed/refractory high-risk ([intermediate-2 or higher by International Prognostic Scoring System [IPSS] and/or >= 10% blasts]). Myelodysplastic syndrome (MDS) will also be eligible. (Treatment approach for relapsed/refractory AML is very similar to that of high risk MDS)Xx_NEWLINE_xXAcute promyelocytic leukemia with PML-RARA or t(15;17)Xx_NEWLINE_xXPatients with history of CD 19 positive B-lymphoid malignancies (acute lymphoblastic leukemia [ALL], chronic lymphocytic leukemia [CLL], non-Hodgkin's lymphoma [NHL]) who have received at least 2 lines of standard chemoimmunotherapy or targeted therapy and have persistent disease.Xx_NEWLINE_xXSubjects with a histologically confirmed diagnosis of MDS, including both MDS and refractory anemia with excess blasts (RAEB)-T (acute myeloid leukemia [AML] with 20-30% blasts and multilineage dysplasia by French-American-British [FAB] criteria) by World Health Organization (WHO) and chronic myelomonocytic leukemia (CMML) are eligibleXx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML)Xx_NEWLINE_xXPatients with acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myelomaXx_NEWLINE_xXPatients with acute leukemias, accelerated/blast phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myelomaXx_NEWLINE_xXPatients must have a confirmed diagnosis of either:\r\n* Acute lymphoblastic leukemia\r\n* Lymphoblastic lymphoma with detectable abnormal blasts in the bone marrowXx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AMLXx_NEWLINE_xXAcute promyelocytic leukemia (APL, M3 subtype of AML) or patients with a t(9:22) cytogenetic translocation.Xx_NEWLINE_xXPlasma cell leukemia (greater than 2,000 cells/mcL of circulating plasma cells by standard differential)Xx_NEWLINE_xXThe following malignancies will be considered eligible if progressive or persistent:\r\n* Chronic lymphocytic leukemia (CLL)\r\n* Non-Hodgkin lymphoma (NHL)\r\n* Hodgkin lymphoma (HL)\r\n* Multiple myeloma (MM)\r\n* Acute leukemia (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL])\r\n* Myelodysplastic syndrome (MDS)\r\n* Myeloproliferative neoplasms (MPN)\r\n* Chronic myeloid leukemia (CML)Xx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemiaXx_NEWLINE_xXPatients may not have features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXAML ONLY: Acute promyelocytic leukemia (PML-RARA rearranged- AML-M3)Xx_NEWLINE_xXPatients with acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myelomaXx_NEWLINE_xXMyeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatmentXx_NEWLINE_xXConcurrent treatment with any other anti-leukemia agentXx_NEWLINE_xXDiagnosis of T acute lymphoblastic leukemia (T-ALL) or Burkitt’s leukemia/lymphomaXx_NEWLINE_xXDiagnosed with one of the following high-risk malignancies, which require hematopoietic cell transplant (HCT) but do not have an available human leukocyte antigen (HLA)-matched (8/8) related or unrelated donor\r\n* High risk acute lymphoblastic leukemia (ALL) in first complete remission (CR1) or greater\r\n* High risk acute myelogenous leukemia (AML) in CR1 or greater\r\n* High risk undifferentiated acute leukemia\r\n* High risk myelodysplastic syndrome (MDS)\r\n* Chronic myelogenous leukemia (CML) failing or intolerant to tyrosine kinase inhibitors (TKIs) or in accelerated, blastic phase, or in second or subsequent chronic phase\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Lymphoma, (Hodgkin and non-Hodgkin lymphoma [NHL] including marginal zone, follicular lymphoma, chemotherapy-sensitive large-cell, mantle cell lymphoma, gray zone, and Burkitt’s lymphoma in remission)Xx_NEWLINE_xXIMMUNE RECONSTITUTION STUDY ONLY: Diagnosed with one of the following high-risk malignancies, which require HCT but do not have an available HLA-matched (8/8) related or unrelated donor\r\n* High risk acute lymphoblastic leukemia (ALL) in CR1 or greater\r\n* High risk acute myelogenous leukemia (AML) in CR1 or greater\r\n* High risk myelodysplastic syndrome (MDS)\r\n* Chronic myelogenous leukemia (CML) failing or intolerant to TKIs or in accelerated, blastic phase, or in second or subsequent chronic phase\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Lymphoma, (Hodgkin and NHL including marginal zone, follicular lymphoma, chemotherapy-sensitive large-cell, mantle cell lymphoma, gray zone, and Burkitt's lymphoma in remissionXx_NEWLINE_xXRefractory acute leukemia (> 5% blasts) or progressive diseaseXx_NEWLINE_xXAcute myeloid leukemia (AML): second or greater complete remission (CR); first CR (CR1) in patients >= 60 years old; CR1 in < 60 years old that is NOT considered as favorable risk\r\n* Favorable risk AML is defined as having one of the following:\r\n* t(8,21) without cKIT mutation\r\n* inv(16) or t(16;16) without cKIT mutation\r\n* Normal karyotype with mutated NPM1 but FLT3-ITD wild type\r\n* Normal karyotype with double mutated CEBPA\r\n* Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidationXx_NEWLINE_xXAcute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL; high risk ALL is defined as having one of the following:\r\n* Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1\r\n* Recipient age 30 years and older at diagnosis\r\n* White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis\r\n* Central nervous system (CNS) leukemia involvement during the course of disease \r\n* Slow cytologic response (> 10% lymphoblasts in bone marrow on day 14 of induction therapy)\r\n* Evidence of persistent immunophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapyXx_NEWLINE_xXChronic myelogenous leukemia in chronic or accelerated phase; chronic phase patients must failed at least two different TKIs, been intolerant to all available TKIs or have T315I mutationXx_NEWLINE_xXMRD positive leukemia (AML, ALL or accelerated/blast phase chronic myelogenous leukemia [CML]); selected patients in morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD negative statusXx_NEWLINE_xXPatients with high risk myeloid or lymphoid malignancies prior to stem cell transplant with increased risk of disease relapse after stem cell transplant, including but not limited to conditions listed below\r\n* Refractory acute myelogenous or lymphoid leukemia\r\n* Relapsed acute myelogenous or lymphoid leukemia\r\n* Myelodysplastic syndromes with 5% or more blasts or with residual dysplastic changes prior to stem cell transplant, or with poor risk cytogenetic changes, such as -5, -7 or complex karyotype, or with poor molecular mutations, especially p53 mutation\r\n* Chronic myelogenous leukemia in chronic phase 3 or more, blast phase presently, or second accelerated phase\r\n* Recurrent or refractory malignant lymphoma or Hodgkin’s disease with high risk relapse features or not in complete remission\r\n* High risk chronic lymphocytic leukemia not in complete remission or with high risk relapse features, such as p53 mutation, or 17p deletion et al.\r\n* Acute leukemia (including AML, ALL) with minimal residual disease determined by accepted methods, including multiple color flow cytometry; next generation sequencing (NGS) or molecular testing\r\n* Acute leukemia with poor risk cytogenetic changesXx_NEWLINE_xXPatients with cytologically confirmed and documented de novo, secondary or therapy-related AML, excluding acute promyelocytic leukaemia (APL, French-American British M3 classification):Xx_NEWLINE_xXAcute or chronic pancreatic disease within the last year prior to enrollmentXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXAcute lymphocytic leukemia (ALL) in complete remission (CR)1 with high-risk features including adverse cytogenetic such as t(9;22), t(1;19), t(4;11), or MLL gene rearrangements; in second or greater morphologic remission; persistent minimal residual diseaseXx_NEWLINE_xXAcute myeloid leukemia (AML) in CR1 with intermediate-risk disease and persistent detectable minimal residual disease (MRD), or with high-risk features defined as: greater than 1 cycle of induction therapy required to achieve remission; preceding myelodysplastic syndrome (MDS) or myeloproliferative disease; presence of FLT3 mutations or internal tandem duplications, DNMT3a, TET2, MLL-partial tandem duplication (PTD), ASXL1, PHF6; FAB M6 or M7 classification; adverse cytogenetics including: -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8, complex [> 3 abnormalities]Xx_NEWLINE_xXMDS with International Prognostic Scoring System (IPSS) intermediate-2 or higher, therapy-related MDS or chronic myelomonocytic leukemia (CMML)Xx_NEWLINE_xXChronic myeloid leukemia (CML) >= 1st chronic phase, after failed >=2 lines of tyrosine kinase inhibitors; patients who progressed to blast phase must be in morphologic remission at transplantXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXPatients with AML who are refractory (up to salvage 2) or relapsed (up to 2nd relapse); for patients with prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or myeloproliferative neoplasm (MPN) who transformed to AML, therapy received for MDS, CMML, or MPN is NOT considered as prior therapy for AMLXx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemiaXx_NEWLINE_xXHave acute leukemia.Xx_NEWLINE_xXKnown history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)Xx_NEWLINE_xXIsolated extramedullary leukemia without also meeting bone marrow criteria for leukemiaXx_NEWLINE_xXFor patients with newly diagnosed disease: diagnosis of “high-grade” MDS (>= 10% blasts by morphology) or AML other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2016 World Health Organization (WHO) classification; for patients with relapsed/refractory disease: prior diagnosis of “high-risk” MDS or non-APL AML, with relapsed/refractory disease according to 2003 recommendations of the International Working Group, requiring first or subsequent salvage therapy; patients with mixed phenotype acute leukemia (MPAL) are eligibleXx_NEWLINE_xXMyeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatmentXx_NEWLINE_xXPrior therapy with hydroxyurea, interferon, anagrelide, ruxolitinib, hypomethylating agents, revlimid, thalidomide, steroids, other JAK inhibitors is allowed; for acute myeloid leukemia (AML) patients who are back in chronic phase myeloproliferative neoplasm (MPN), prior induction therapy is allowedXx_NEWLINE_xXThe patient must have a disease (listed below) with treatment-responsiveness that the treating transplant physician believes will benefit from an allogeneic stem cell transplant. The diseases include:\r\n* Acute leukemia – acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)\r\n* Chronic leukemia – chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL)\r\n* Myelodysplasia\r\n* Myelofibrosis\r\n* Lymphoma – non-Hodgkin's lymphoma (NHL) and Hodgkin’s disease\r\n* Plasma cell disorder, including myeloma, Waldenstrom’s macroglobulinemiaXx_NEWLINE_xXPathological confirmation by bone marrow documenting the following:\r\n* Acute myeloid leukemia (AML) which has relapsed after complete remission\r\n* AML which has been refractory to two prior induction attempts\r\n* Acute lymphoblastic leukemia (ALL) which has relapsed after complete remission\r\n* ALL which has been refractory to two prior induction attemptsXx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXRelapsed ALL, biphenotypic/bilineal leukemia, or acute myeloid leukemia (AML) with =< 10% blasts in the bone marrow prior to transplantationXx_NEWLINE_xXAcute biphenotypic or bilineal leukemia in first or greater complete remissionXx_NEWLINE_xXChronic myelomonocytic leukemia (CMML)Xx_NEWLINE_xXChronic myeloid leukemia (CML) who have failed or are intolerant to BCR-ABL tyrosine kinase inhibitorsXx_NEWLINE_xXChronic lymphocytic leukemia with high risk disease as defined by the European Society for Blood and Marrow Transplantation (EBMT) consensus criteriaXx_NEWLINE_xXPatients with acute promyelocytic leukemiaXx_NEWLINE_xXPatients with high-risk hematologic malignancies with anticipated poor prognosis with non transplant therapy, including those in remission or with induction failure and after treated or untreated relapse; Diagnoses to be included a) Acute myeloid leukemia; b) Acute lymphocytic leukemia; c) Chronic myeloid leukemia; d) Chronic lymphoproliferative disorder; e) Myelodysplastic syndrome; f) Myeloproliferative syndromes; g) Non-Hodgkin's lymphoma; h) Hodgkin's Lymphoma; i) Multiple myelomaXx_NEWLINE_xXPatients must have histologically or cytologically documented newly diagnosed de novo acute myeloid leukemia (non-acute promyelocytic leukemia [APL]) that has not yet been treated; hydrea and all-trans retinoic acid (ATRA) previous treatments are acceptableXx_NEWLINE_xXPatients must not have a secondary acute myeloid leukemia (AML) (defined as a history of prior radiation therapy or systemic chemotherapy, antecedent myelodysplastic syndrome [MDS], myeloproliferative neoplasm [MPN] or chronic myelomonocytic leukemia [CMML])Xx_NEWLINE_xXPatients who have received any therapy other than hydroxyurea or ATRA with the purpose of treating their AML or patients with acute promyelocytic leukemia are not eligibleXx_NEWLINE_xXAny of the following hematologic malignancies that has relapsed or remains refractory after prior allogeneic hematopoietic cell transplantation (HCT) (this includes any stage of disease - such as refractory due to induction failure, refractory in relapse, or in any complete remission (CR) - as long as the hematologic malignancy remained persistent or returned after a previous allogeneic HCT): acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), myeloid sarcoma, chronic myelogenous leukemia (CML), juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL)Xx_NEWLINE_xXAcute promyelocytic leukemia (APL) with t(15;17)(q22;q12) PML-RARAXx_NEWLINE_xXChronic myeloid leukemia (CML) in any phaseXx_NEWLINE_xXPatients must have histologically confirmed AML or ALL, excluding acute promyelocytic leukemia (APL); for histological confirmation, a bone marrow biopsy and aspirate must be reviewed at Oregon Health & Science University (OHSU)Xx_NEWLINE_xXAcute promyelocytic leukemia (M3 leukemia, per French-American-British classification)Xx_NEWLINE_xXPHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Patients with myelodysplastic syndrome/acute myeloid leukemia or pneumonitis; or baseline features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXHas previously untreated, de novo, non-M3 acute myeloid leukemia (AML) with intermediate-risk disease (intermediate-I or intermediate-II) as defined by ELN criteria OR normal cytogenetics (after analysis of 20 or more metaphases) with mutated nucleophosmin (NPM1) without FMS-related tyrosine kinase 3-internal tandem duplication (FLT3-ITD); monoallelic CEBPA mutations are not considered favorable risk and are therefore eligibleXx_NEWLINE_xXDiagnosis acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA)Xx_NEWLINE_xXPhiladelphia chromosome positive acute lymphoblastic leukemiaXx_NEWLINE_xXMyeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for CML-directed tyrosine kinase inhibitor treatment (excluding sorafenib)Xx_NEWLINE_xXPatients must have one of the following hematologic malignancies: acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics including complex karyotype, abnormal [abn][3q], -5/5q-, -7/7q-, abn[12p], abn[17p], myeloid/lymphoid or mixed-lineage leukemia [MLL] gene re-arrangement and t [6;9]47, fms related tyrosine kinase 3 [flt3] mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndromes (MDS), any disease beyond first remissionXx_NEWLINE_xXMyelodysplastic syndrome (MDS): Primary or therapy related, including patients that will be considered for transplant; these include any of the following categories: 1) revised International Prognostic Scoring System (IPSS) intermediate and high risk groups, 2) malondialdehyde (MDA) with transfusion dependency, 3) failure to respond or progression of disease on hypomethylating agents, 4) refractory anemia with excess of blasts, 5) transformation to acute leukemia, 6) chronic myelomonocytic leukemia, 7) atypical MDS/myeloproliferative syndromes, 8) complex karyotype, abn(3g), -5/5g-, -7/7g-, abn(12p), abn(17p)Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL): Induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease; patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time: with translocations 9;22 or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure, and/or evidence of minimal residual disease or acute biphenotypic leukemia, or double hit non-Hodgkin's lymphomaXx_NEWLINE_xXChronic myeloid leukemia (CML) second chronic phase or accelerated phaseXx_NEWLINE_xXAcute myeloid leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in =< 60 years old that is NOT considered as favorable-risk; favorable risk AML is defined as having one of the following:\r\n* t(8,21) without cKIT mutation\r\n* inv(16) or t(16;16) without cKIT mutation \r\n* Normal karyotype with mutated NPM1 and wild type FLT-ITD\r\n* Normal karyotype with double mutated CEBPA\r\n* Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidationXx_NEWLINE_xXAcute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL; high risk ALL is defined as having one of the following:\r\n* Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1\r\n* 30 years of age or older at diagnosis\r\n* White blood cell counts of greater than 30,000/mcL (B cell [B]-ALL) or greater than 100,000/mcL (T cell [T]-ALL) at diagnosis\r\n* Central nervous system (CNS) leukemia involvement during the course of disease\r\n* Slow cytologic response (> 10% lymphoblasts in bone marrow on day 14 of induction therapy)\r\n* Evidence of persistent immunophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapyXx_NEWLINE_xXChronic myelogenous leukemia in chronic or accelerated phase, or chronic myelogenous leukemia (CML) blast crisis in morphological remission (< 5% blasts): chronic phase patients must have failed at least two tyrosine kinase inhibitors been intolerant to all available tyrosine kinase inhibitors (TKIs) or have T315I mutationXx_NEWLINE_xXPlasma Cell Leukemia after initial therapy if achieved at least in partial remission; or relapsed and achieved subsequent remission (CR/PR)Xx_NEWLINE_xXPatients at least eighteen (18) years of age with histologically or cytologically proven Multiple Myeloma (MM), Hodgkins Disease (HD), Non-Hodgkins Lymphoma (NHL), Chronic Myelogenous Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Acute Myelogenous Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL), who have responded to standard, first-line antineoplastic therapy, as defined using standard response criteria for the specific hematologic malignancy (HM), and have no additional potentially curative therapeutic intervention available, will be eligible to participate in this study.Xx_NEWLINE_xXChronic myeloid leukemia (CML) in AP or BPXx_NEWLINE_xXALL patients who have relapsed or have residual disease following treatment with curative intent; ALL patients must have ROR1 expressed on > 90% of the leukemia blasts to be eligibleXx_NEWLINE_xXPatients diagnosed with a leukemia or lymphoma as follows:\r\n* Chronic or acute leukemia forms of HTLV-1 associated adult T-cell leukemia;\r\n* Peripheral T-cell lymphoma (angioimmunoblastic, hepatosplenic, or not otherwise specified); or,\r\n* Cutaneous T-cell lymphoma stage III or IV with circulating monoclonal cells (B1 or B2) and/or erythrodermia (T4)\r\n* T-cell prolymphocytic leukemia (T-PLL)\r\n* NOTE: Diagnosis must be validated by the Pathology Department, National Cancer Institute (NCI)Xx_NEWLINE_xXAcute promyelocytic leukemia (APL, M3) unless failed regimens that included tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT candidates for stem cell transplantationXx_NEWLINE_xXPatient with documented acute promyelocytic leukemia (PML) and/or PML- retinoic acid receptor (RAR) transcriptXx_NEWLINE_xXAcute myeloid leukemia: High risk first complete remission (CR1) (as evidenced by preceding myelodysplasia [MDS], high risk cytogenetics, >= 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia, FLT-3 ITD +; second or higher complete response [CR2+]); all patients must be in CR as defined by hematological recovery, AND < 5% blasts by light microscopy within the bone marrow with a cellularity of >= 15%Xx_NEWLINE_xXChronic myelogenous leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylateXx_NEWLINE_xXPlasma cell leukemia after initial therapy, who achieved at least a partial remissionXx_NEWLINE_xXChronic myeloid leukemia (CML) in refractory blast crisisXx_NEWLINE_xXActive plasma cell leukemia (defined as either 20% of peripheral white blood cells comprised of plasma/CD138+ cells or an absolute plasma cell count of 2 x 10^9/L)Xx_NEWLINE_xXAll patients with histologically or cytologically confirmed relapsed or refractory AML (except acute promyelocytic leukemia); relapsed disease or refractory (refractory to a non-high-dose cytarabine-containing regimen only); receiving 1st, 2nd or 3rd salvage; any cytogenetic or molecular abnormality; patients with secondary AML (after prior myelodysplasia or therapy for other cancers) will be includedXx_NEWLINE_xXAll patients with histologically or cytologically confirmed relapsed or refractory acute myeloid leukemia (AML) (except acute promyelocytic leukemia) or relapsed or refractory high-risk myelodysplastic syndrome (HRMDS) (intermediate 2 [Int-2] or higher risk by International Prognostic Scoring System [IPSS]); patients with chronic myelomonocytic leukemia (CMML) can be enrolled if they can be classified as HRMDS using MDS criteria; patients should not have received more than one salvage therapy; second induction regimen or stem cell transplant in remission will be considered salvage therapy; refractory subjects, up to second consecutive salvageXx_NEWLINE_xXOne of the following diagnoses:\r\n* Acute myelogenous leukemia (AML) in 1st or subsequent remission\r\n* Acute lymphoblastic leukemia (ALL) in 1st or subsequent remission\r\n* Chronic myelogenous leukemia (CML) in chronic or accelerated phase\r\n* Non-Hodgkin lymphoma (NHL) or Hodgkin’s disease (HD) in 2nd or greater complete remission, partial remission\r\n* Chronic lymphocytic leukemia (CLL)\r\n* Multiple myeloma (MM)\r\n* Myelodysplastic syndrome (MDS)\r\n* Myeloproliferative neoplasm (MPN) excluding primary or secondary myelofibrosisXx_NEWLINE_xXPatients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to leukemia or previous leukemia treatmentXx_NEWLINE_xXAny of the following high risk or recurrent hematological malignancies: \r\n* Hodgkin lymphoma (HL) \r\n* Non-Hodgkin lymphoma (NHL) \r\n* Chronic lymphocytic leukemia (CLL) \r\n* Multiple myeloma (MM) \r\n* Acute myelogenous leukemia (AML) \r\n* Acute lymphocytic leukemia (ALL)\r\n* Chronic myelogenous leukemia (CML)\r\n* Myelodysplastic syndrome (MDS)\r\n** Note: determination that the malignancy is high risk will be made by the investigatorXx_NEWLINE_xXPatients must have histologic evidence of high risk acute myeloid leukemia defined as one of the following:\r\n* Primary refractory non-M3 AML\r\n** Residual leukemia after a minimum of 2 prior courses of chemotherapy (same or different)\r\n** Evidence of leukemia recurrence after a nadir bone marrow biopsy demonstrates no evidence of residual leukemia\r\n** Evidence of leukemia after induction therapy which, in the opinion of the investigator, would be appropriate for reinduction with sirolimus/MEC therapy\r\n* Relapsed non-M3 AML\r\n* Previously untreated non-M3 AML age > 60 with no evidence of favorable karyotype defined by presence of t(8;21)(q22;q22) [AML1-ETO], inversion (inv)16(p13;q22), or t(16;16)(p13;q22) [core-binding factor (CBF)beta; myosin, heavy chain (MYH)11] by cytogenetics, fluorescence in situ hybridization (FISH), or real time-polymerase chain reaction (RT-PCR)\r\n* Previously untreated secondary AML (from antecedent hematologic malignancy or following therapy with radiation or chemotherapy for another disease) with no evidence of favorable karyotype defined by presence of t(8;21)(q22;q22) [AML1-ETO], inv16(p13;q22), or t(16;16)(p13;q22) [CBFbeta;MYH11] by cytogenetics, FISH, or RT-PCRXx_NEWLINE_xXSubjects with French American British (FAB) M3 (t (15; 17) (q22; q21) [promyelocytic leukemia (PML)-retinoic acid receptor (RAR) alpha]) are not eligibleXx_NEWLINE_xXPrior chemotherapy treatment for AML (prior treatment with hydroxyurea and/or leukapheresis to control white blood cell count, or all-trans retinoic acid [ATRA] for suspected acute promyelocytic leukemia [APML] is acceptable); prior chemotherapy for MDS or myeloproliferative neoplasms (MPN) such as azacitidine, decitabine, and thalidomide, is permitted, but such treatments once MDS or MPN has transformed to AML is not permittedXx_NEWLINE_xXAPL (acute promyelocytic leukemia) by WHO criteria [AML with t(15;17)]Xx_NEWLINE_xXPHASE I: No features suggestive of myelodysplastic syndrome/ acute myeloid leukemiaXx_NEWLINE_xXPHASE II: No features suggestive of myelodysplastic syndrome/ acute myeloid leukemiaXx_NEWLINE_xXPatients treated on this study will have:\r\n* Acute myeloid leukemia in morphologic complete remission (CR) not requiring treatment for their disease for 4 weeks\r\n* A history of acute myeloid leukemia (AML) with < 10% residual blasts (use highest count on staging studies) after induction therapy and persisting with < 10% blasts for at least 8 weeks without reinduction and at the time of HSCT\r\n* Refractory anemia (RA) or refractory anemia with ring sideroblasts (RARS) or isolated 5q- \r\n* Refractory anemia with excess blasts (RAEB)-1, refractory cytopenia with multilineage dysplasia (RCMD)+/-ringed sideroblasts (RS), or myelodysplastic syndrome (MDS) not otherwise specified (NOS) with stable disease for at least 3 months\r\n* RAEB-2 must demonstrate chemo-responsiveness; chemo-responsiveness is defined as a persistent blast percentage decrease by at least 5 percentage points to therapy and there must be =< 10% blasts (use highest count on staging studies) after treatment and at the time of transplant\r\n* Hodgkin or Indolent non-Hodgkin’s lymphoma \r\n* Myeloma with < 5% plasma cells in the marrow\r\n* Myeloproliferative disorders (excludes chronic myelomonocytic leukemia [CMML])\r\n* Aplastic anemia\r\n* A hematological or oncological disease (not listed) in which allogeneic HSCT is thought to be beneficial, and the disease is chemoresponsive \r\n* Patients without clear manifestation of their disease status in terms of stage and/or responsiveness should be discussed with the principal investigator (PI) and enrollment analysis should be documented in the study recordsXx_NEWLINE_xXA diagnosis of chronic myelomonocytic leukemia (CMML), unless in morphologic CRXx_NEWLINE_xXDiagnosis of acute leukemia by World Health Organization (WHO) criteria (e.g.-acute myeloid leukemia, acute lymphoblastic leukemia, acute leukemia of ambiguous origin)Xx_NEWLINE_xXAML secondary to any prior chemotherapy unrelated to leukemiaXx_NEWLINE_xXHigh risk for relapse defined as: 1st CR with high risk features for relapse (including history of prior malignancy treated with chemotherapy or radiotherapy, or history of myelodysplastic syndrome, myeloproliferative disorder, chronic myelomonocytic leukemia, myelodysplastic syndrome [MDS]/myeloproliferative neoplasm [MPN] or other hematologic malignancy thought to have evolved to AML [i.e., secondary AML, (sAML)]; high risk cytogenetics at diagnosis; fms-related tyrosine kinase 3 [FLT3] mutated at diagnosis; or presence or minimal residual disease assessed by polymerase chain reaction [PCR], cytogenetics, and/or flow cytometry at time of enrollment) 2nd CR regardless of disease characteristics at the time of diagnosisXx_NEWLINE_xXPatients who are in blast transformation of chronic myeloid leukemia (CML); prior MDS or CMML is acceptableXx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXPatients with a history of CD19+ lymphoid malignancy defined as acute lymphoblastic leukemia, acute biphenotypic leukemia, non-Hodgkin’s lymphoma, small lymphocytic lymphoma, or chronic lymphocytic leukemia with active disease defined by presence of > 5% malignant blasts in bone marrow and/or peripheral blood, and/or minimal residual disease by flow cytometry or molecular analysis for fusion proteins, and/or positive imaging for extramedullary disease; patients must have measurable disease at time of study treatmentXx_NEWLINE_xXAny acute or chronic psychiatric problemsXx_NEWLINE_xXHistologically confirmed diagnosis of relapsed or refractory acute lymphoblastic leukemia (ALL) (including Burkitt leukemia), acute myeloid leukemia (AML), mixed lineage leukemia, biphenotypic leukemia, or chronic myelogenous leukemia (CML) in blast crisis\r\n* Refractory disease defined as: persistent disease after at least two induction cycles\r\n* Relapsed disease: second or subsequent relapse, any relapse refractory to salvage chemotherapyXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXMust have relapsed or refractory acute lymphoblastic leukemia (ALL) or relapsed or refractory lymphoblastic lymphoma (LL). Refractory is defined as persistent disease after at least 2 courses of chemotherapy.Xx_NEWLINE_xXDiagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXNewly diagnosed or relapsed chronic myelogenous leukemia (CML) in lymphoid blast crisisXx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smear (measured within 28 days prior to administration of study treatment)Xx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemiaXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nNo baseline features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nNo baseline features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXPatients must have histologically or cytologically documented relapsed and/or refractory acute myeloid leukemia or granulocytic sarcomaXx_NEWLINE_xXSerum biochemical values with the following limits unless considered due to leukemia:Xx_NEWLINE_xXSubjects with acute promyelocytic leukemia (APL)Xx_NEWLINE_xXPatients likely to have a significantly better durable response to allogeneic transplant alone (better than 60% progression free longer than 2 years) includes: those with myeloproliferative diseases or hemoglobinopathies with over 50% T cell subset engraftment (assessed around 100 days post transplant); it is not anticipated that any such patients would be transplanted within our program, however but those in first remission acute myeloid leukemia (AML) patients with good risk standard genetics or normal genetics with either nucleophosmin (NPM)1 or CCAAT/enhancer binding protein alpha (CEBPA) mutations, first chronic phase chronic myelogenous leukemia (CML) without kinase gene mutations, follicular lymphoma patients in first remission who only required 1 regimen to attain remission all would be excluded from this protocolXx_NEWLINE_xXEligible patients will have a histopathologically confirmed diagnosis of hematologic malignancy in one of the following categories: \r\n* Acute myelogenous leukemia \r\n** In first complete remission (CR1) with poor risk cytogenetics according to National Comprehensive Cancer Network (NCCN) guidelines for acute myeloid leukemia (AML): monosomal karyotype, -5, 5q-,-7,7q-,11q23-non t(9;11), inv (3), t(3;3), t(6;9), t(9;22) and complex karyotypes (>= 3 unrelated abnormalities [abn]) and normal cytogenetics with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplications (ITD) mutation \r\n** In second complete remission (CR2) or third complete remission (CR3) \r\n** With chemosensitive primary refractory disease \r\n* Acute lymphocytic leukemia \r\n** In CR1 with poor risk cytogenetics: \r\n*** For adults according to NCCN guidelines for acute lymphoblastic leukemia (ALL): hypoploidy (< 44 chromosomes); t(v;11q23): mixed lineage leukemia (MLL) rearranged; t(9;22) (q34;q11.2); complex cytogenetics (5 or more chromosomal abnormalities); high white blood cell (WBC) at diagnosis (>= 30,000 for B lineage or >= 50,000 for T lineage) \r\n*** For pediatrics t(9;22), intrachromosomal amplification of chromosome 21 (iAMP21)loss of 13q, and abnormal 17p \r\n** In CR2 or CR3 \r\n** With chemosensitive primary refractory disease \r\n* Myelodysplastic syndrome in high-intermediate (int-2) and high risk categoriesXx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXHas a myeloid or lymphoid malignant disease that is treated with TLI and ATG reduced-intensity conditioning for allogeneic transplant (any of the following: acute myeloid leukemia [AML]; chronic lymphocytic leukemia [CLL]; B or T cell non-Hodgkin lymphoma [NHL]; Hodgkin lymphoma [HL]; myelodysplastic syndrome (MDS); or myeloproliferative disease syndrome [MPD])Xx_NEWLINE_xXAcute leukemia not in remissionXx_NEWLINE_xXChronic myelogenous leukemia (CML)Xx_NEWLINE_xXConcomitant therapies for treatment or control of leukemia.Xx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXIn order to prevent tumor lysis syndrome, acute leukemia patients must have a peripheral blast count under 50 x 10^9/L; this should be achieved with hydroxyurea cytoreduction, prior to starting DT2219Xx_NEWLINE_xXAcute myelogenous leukemia\r\n* In first complete remission (CR1) in addition to one of the criteria outlined\r\n* Second or greater complete remission\r\n* Secondary acute myeloid leukemia (AML) from antecedent myeloid neoplasm, myelodysplasia, or previous chemotherapy (chemo) or radiotherapyXx_NEWLINE_xXAcute lymphocytic leukemia\r\n* In complete first remission (CR1) in addition to one of the criteria outlined\r\n* Second or greater complete remissionXx_NEWLINE_xXChronic myelogenous leukemia\r\n* Chronic phase chronic myelogenous leukemia (CML) having progressed after treatment with breakpoint cluster region (BCR)-ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL) kinase inhibitor or with evidence of T315I BCR-ABL mutation\r\n* Accelerated or blast phase CML\r\n* Not eligible for myeloablative allogeneic HSCTXx_NEWLINE_xXPatients must have histologically or cytologically documented relapsed and/or refractory acute myeloid leukemiaXx_NEWLINE_xXPatients with a known diagnosis of plasma cell leukemiaXx_NEWLINE_xXPatients with the following diseases: acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) undergoing second or above allogeneic (allo)-stem cell transplant (SCT) using the same donor or different donor for disease relapse; patients with other hematologic malignancies, including acute lymphoblastic leukemia (ALL), will be at the discretion of the investigators with discussion with the principal investigator (PI)Xx_NEWLINE_xXHas a diagnosis of acute promyelocytic leukemia.Xx_NEWLINE_xXNewly diagnosed acute lymphoblastic leukemia/lymphomaXx_NEWLINE_xXSerum biochemical values with the following limits unless considered due to leukemia:Xx_NEWLINE_xXPatients with biopsy-proven acute myeloid leukemia or myelodysplastic syndrome with persistent disease or in remissionXx_NEWLINE_xXDocumented prolymphocytic leukemia (prolymphocytes more than 55% in the blood)Xx_NEWLINE_xXDisease status must be complete remission by standard criteria for lymphoma and acute leukemia patientsXx_NEWLINE_xXPatients with T cell acute lymphoblastic leukemia (ALL) must be in complete remission and minimal residual disease (MRD) negative (-) by flow cytometry and molecular studiesXx_NEWLINE_xXBurkitt’s or Burkitt-like leukemia/lymphoma, either previously untreated, or relapsed/refractory, or human immunodeficiency virus (HIV)-related; patients HIV positive will be described and reported separately or relapsed/refractory acute lymphoblastic leukemia (ALL)Xx_NEWLINE_xXPatients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (NCCN) or other standard guidelines as follows:\r\n* Acute lymphoblastic leukemia (ALL) with high-risk features or relapsed disease.\r\n* Hodgkin or non-Hodgkin lymphoma (HL or NHL): relapsed disease where remission duration is less than 1 year, relapse after previous autologous transplant, or failure to achieve complete remission (CR) with chemotherapy\r\n* Myeloid malignancy (acute myeloid leukemia [AML] with intermediate/high-risk features [per NCCN criteria] or relapsed disease, OR chronic myeloid leukemia [CML] in hematological remission or chronic phase)Xx_NEWLINE_xXAcute myelogenous leukemia (AML): high-risk AML including:\r\n* Antecedent hematological disease (e.g., myelodysplasia [MDS])\r\n* Treatment-related leukemia\r\n* Complete remission (first complete remission [CR1]) with poor-risk cytogenetics or molecular markers (e.g. fms-related tyrosine kinase 3 [Flt 3] mutation, 11q23, del 5, del 7, complex cytogenetics)\r\n* Second complete remission (CR2) or third complete remission (CR3) or induction failure or 1st relapse with either\r\n** =< 10% blasts in the marrow or \r\n** =< 5% blasts in the peripheral bloodXx_NEWLINE_xXAcute lymphoblastic leukemia (ALL)\r\n* High-risk CR1 including:\r\n* Poor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22) or 11q23 rearrangements)\r\n* Presence of minimal disease by flow cytometry after 2 or more cycles of chemotherapy\r\n* No complete remission (CR) within 4 weeks of initial treatment\r\n* Induction failure\r\n* CR2 or CR3 with either\r\n** =< 10% blasts in the marrow or \r\n** =< 5% blasts in the peripheral bloodXx_NEWLINE_xXSubjects must meet one of the disease classifications listed below:\r\n* Acute leukemias (includes T lymphoblastic lymphoma); remission is defined as < 5% blasts with no morphological characteristics of acute leukemia (e.g., Auer Rods) in a bone marrow with > 20% cellularity, peripheral blood counts showing absolute neutrophil count (ANC) > 1000/ul, including patients in complete remission with incomplete platelet recovery (CRp)  \r\n** Acute lymphoblastic leukemia in high risk first complete remission (CR1) as defined by at least one of the following: \r\n*** Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), mixed lineage leukemia (MLL) rearrangements \r\n*** White blood cell counts > 30,000/mcL\r\n*** Patients over 30 years of age\r\n*** Time to complete remission > 4 weeks\r\n*** Presence of extramedullary disease\r\n** Acute myelogenous leukemia in high risk CR1 as defined by at least one of the following: \r\n*** Greater than 1 cycle of induction therapy required to achieve remission \r\n*** Preceding myelodysplastic syndrome (MDS) \r\n*** Presence of Fms-like tyrosine kinase 3 (Flt3) abnormalities\r\n*** French-American-British classification (FAB) M6 or M7 leukemia or\r\n*** Adverse cytogenetics for overall survival such as:\r\n**** Those associated with MDS \r\n**** Complex karyotype (>= 3 abnormalities)\r\n**** Any of the following: inv(3) or t(3;3), t(6;9), t(6;11), + 8 [alone or with other abnormalities except for t(8;21), t(9;11), inv(16) or t(16;16)], t(11;19)(q23;p13.1)\r\n** Acute leukemias in 2nd or subsequent remission\r\n** Biphenotypic/undifferentiated leukemias in 1st or subsequent complete remission (CR)\r\n** High-risk MDS status-post cytotoxic chemotherapy\r\n** Myelofibrosis\r\n* Burkitt’s lymphoma: second or subsequent CR\r\n* Lymphoma\r\n** Chemotherapy-sensitive (complete or partial response) large cell, mantle cell or Hodgkin’s lymphomas that have failed at least 1 prior regimen of multi-agent chemotherapy and are ineligible for an autologous transplant or relapsed/progressed after autologous stem cell transplant\r\n** Marginal zone B-cell lymphoma or follicular lymphoma that has progressed after at least two prior therapies (excluding single agent Rituxan) and are ineligible for an autologous transplant or relapsed/progressed after autologous stem cell transplantXx_NEWLINE_xXARM 1 - AML: Research patients enrolled are those patients with relapsed or refractory CD123+ AML de novo, or secondary OR participant who are at high risk for disease recurrence\r\nNOTE: CD123+ biphenotypic acute leukemia or CD123+ acute lymphoblastic leukemia (ALL) may also be considered but only after discussion with the study principal investigator (PI)\r\n* Relapsed AML is defined as patients that had a first complete remission (CR) before developing recurrent disease (increased bone marrow blasts)\r\n* Refractory AML is defined as patients that have not achieved a first CR after 2 cycles of induction chemotherapy; for patients with AML evolving from myelodysplastic syndrome, they should have completed at least one cycle of induction chemotherapyXx_NEWLINE_xXResearch participants with precursor B-cell acute lymphoblastic leukemia/lymphoma or plasma cell dyscrasiasXx_NEWLINE_xXNewly diagnosed or relapsed mixed phenotype acute leukemia (MPAL), which for this protocol, will be defined as follows: bone marrow result interpreted by the reading pathologist (or tissue biopsy for cases of extramedullary disease) as: biphenotypic leukemia, bilineal leukemia, undifferentiated leukemia, mixed lineage leukemia, leukemia of ambiguous lineage, T/myeloid leukemia, B/myeloid leukemia, or other diagnosis indicating the presence of multiple lineages within the cell populationXx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL), AML - M3 by French American British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studiesXx_NEWLINE_xXPatients with a diagnosis of AML, acute biphenotypic leukemia, or high risk MDS (>= 10% blasts or International Prognostic Scoring System [IPSS] >= intermediate-2) will be eligible; patients with CML in myeloid blast phase are also eligibleXx_NEWLINE_xXFor salvage cohort: patients with previously treated, relapsed or refractory AML, acute biphenotypic leukemia, or CML in myeloid blast phase are eligibleXx_NEWLINE_xXAcute promyelocytic leukemia (French-American-British [FAB] M3 AML)Xx_NEWLINE_xXAcute lymphocytic leukemia or acute myelogenous leukemia who are not in first remission or second remission i.e. after failing induction therapy, or in relapse or beyond second remission; (prior therapy with VP-16 and Cytoxan is allowed)Xx_NEWLINE_xXPatients with biopsy-proven acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome in remission or relapseXx_NEWLINE_xXPatients with acute myeloid leukemia (AML) in first remission after one course of induction and with favorable cytogenetics (t[8;21], inv 16, or t[15;17]) and/or molecular profile (nucleophosmin [NPM]1)Xx_NEWLINE_xXPatients with non-measurable MM or primary plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)Xx_NEWLINE_xXDiagnosis of acute lymphoblastic leukemia or lymphoblastic lymphomaXx_NEWLINE_xXPatients with one of the following diseases: acute myeloid leukemia (AML): a. first complete remission with high-risk features defined as: (i) greater than 1 cycle of induction therapy required to achieve remission; (ii) preceding myelodysplastic syndrome (MDS); (iii) presence of FLT3 mutations or internal tandem duplication or other mutations associated with poor-risk AML (e.g. DNMT3A, TET2); (iv) French-American-British Classification (FAB) M6 or M7 classification; (v) adverse cytogenetics: -5, deletion (del) 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype (> 3 abnormalities); (vi) treatment-related AML, or b. second or greater remission; patients beyond second remission have to be in complete remission (CR) at transplant to be eligible, or c. primary induction failure with partial response to therapy who achieve adequate cytoreductionXx_NEWLINE_xXChronic myeloid leukemia (CML): a. failed to achieve cytogenetic remission or have cytogenetic relapse after treatment with at least 2 tyrosine kinase inhibitors, or b. accelerated phase or blast phase at any timeXx_NEWLINE_xXDIAGNOSIS REQUIREMENT FOR PHASE II PATIENTS: Refractory AML without CR after induction therapy (primary induction failure) or relapsed AML after obtaining a CR; favorable-risk core binding factor (CBF) mutated AML and acute promyelocytic leukemia (APL) will be excludedXx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL, French-American-British [FAB] classification M3 or WHO classification of APL with t (15;17)(q22;q12), promyelocytic leukemia protein [PML]/retinoic acid receptor alpha [RARa] and variants)Xx_NEWLINE_xXINCLUSIONS FOR SCREENING AND LEUKAPHERESIS:\r\n* Patients with CD19 expressing acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL)\r\n* Ability to understand and provide informed consent\r\n* Not human immunodeficiency virus (HIV) infectedXx_NEWLINE_xXAcute myeloid leukemia who fail to achieve complete remission with one course of induction chemotherapy or after relapse; patients must have less than 20% bone marrow or peripheral blood blastsXx_NEWLINE_xXAcute myeloid leukemia in first remission with any of the following high risk features defined as:\r\n* Adverse cytogenetics: -5, deletion (del) 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype (> 3 abnormalities)\r\n* Preceding myelodysplastic or myeloproliferative syndrome\r\n* Presence of high risk molecular abnormalities including FLT3 mutations, DNMT3A, TET2; ras; kit\r\n* French–American–British (FAB) monosomy (M)6 or M7 classification\r\n* Treatment related acute myeloid leukemia (AML)\r\n* Residual cytogenetic or molecular abnormalitiesXx_NEWLINE_xXMyelodysplastic syndromes with intermediate, high or very high risk Revised International Prognostic Scoring System (R-IPSS) score, chronic myelomonocytic leukemia (CMML) or therapy related myelodysplastic syndromes (MDS)Xx_NEWLINE_xXChronic myeloid leukemia (CML) which:\r\n* Failed to achieve a cytogenetic remission to tyrosine kinase inhibitor treatment or has a cytogenetic relapse\r\n* Has ever been in accelerated phase or blast crisisXx_NEWLINE_xXHigh risk hematologic malignancy\r\n* High risk acute lymphoblastic leukemia (ALL) in complete remission 1 (CR1); examples include, but not limited to: t(9;22), hypodiploid, minimal residual disease (MRD) > 1% at the end of induction, M2 or greater marrow at the end of induction, infants with mixed-lineage leukemia (MLL) fusion or t(4;11)\r\n* ALL in high risk complete remission 2 (CR2); examples include, but not limited to t(9;22), bone marrow (BM) relapse < 36 months CR1, T-ALL, very early (< 6 months CR1) isolated central nervous system (CNS) relapse\r\n* ALL in complete remission 3 (CR3) or subsequent\r\n* Acute myeloid leukemia (AML) in high risk CR1 (diagnosis of AML includes myeloid sarcoma); examples include but not limited to: preceding myelodysplastic syndrome (MDS), 5q-, -5, -7, French-American-British Cooperative group (FAB) M6, FAB M7 not t(1;22), MRD > or = 5% on day 22 (AML08), MRD > 0.1% after two cycles of induction, M3 marrow after once cycle of induction, M2 marrow after two cycles of induction, fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)\r\n* AML in CR2 or subsequent\r\n* AML in relapse with < 25% blasts in BM\r\n* Therapy related AML, with prior malignancy in CR > 12 months\r\n* MDS, primary or secondary\r\n* NK cell, biphenotypic, or undifferentiated leukemia in CR1 or subsequent\r\n* Chronic myeloid leukemia (CML) in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor\r\n* Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize stem cells for autologous HCT\r\n* Non-Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize stem cells for autologous HCT\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* One of the following hematologic malignancies that are refractory (includes chemoresistant relapse or primary induction failure)\r\n** ALL\r\n** AML\r\n** CML (blast crisis)\r\n** Hodgkin or non-Hodgkin lymphomaXx_NEWLINE_xXPatients must have a histologically and cytological confirmed acute myeloid leukemia, high risk AML defined as:\r\n* Age > 60, or\r\n* Presence of complex cytogenetic abnormalities (with > 3 cytogenetic abnormalities), del (7q, -5, -7), t(9,22), 11q (23) or high risk mutations by fluorescence in situ hybridization (FISH) eg mixed lineage leukemia (MLL) , FMS-like tyrosine kinase 3 positive (FLT-3 +), or\r\n* Secondary AML, or\r\n* A white blood cell count of > 50 x 10^9/L\r\n* Failure to achieve complete remission (CR) with single standard inductionXx_NEWLINE_xXBy definition, patients with hematological malignancies or dyscrasias that require HSCT as part of cure-directed therapy are by definition high-risk and can be treated on this protocol; examples of high risk patients include but are not limited to: \r\n* Acute myeloid leukemia with high risk features as defined by: \r\n** Age greater than or equal to 60 \r\n** Secondary acute myeloid leukemia (AML) (prior therapy or hematologic malignancy) \r\n** Normal cytogenetics but fms-related tyrosine kinase 3 (FLT3)/internal tandem duplication (ITD) positive \r\n** Any relapse or primary refractory disease \r\n** Greater than 3 cytogenetic abnormalities or any one of the following cytogenetic abnormalities: -5/del(5q), -7/del(7q), Abn(9q), (11q), (3q), (21q), (17p), t(6;9), t(6;11), t(11;19), +8, del(12p), inv(3), t(10;11), -17, 11q 23 \r\n** Any single autosomal monosomy\r\n* Acute lymphoid leukemia in 1st or 2nd morphological remission; ALL with any morphological evidence of disease will not be eligible\r\n* Myelodysplasia (MDS) other than refractory anemia (RA), refractory anemia with rare sideroblasts (RARS), or isolated 5q- syndrome subtypes\r\n* Hodgkin’s or Non-Hodgkin’s lymphoma in 2nd or greater remission or with persistent disease\r\n* Myeloma with evidence of persistent disease after front-line therapy\r\n* Chronic myeloid leukemia (CML) resistant to signal transducer inhibitor (STI) therapy \r\n* Myelofibrosis and chronic myelomonocytic leukemia (CMML) \r\n* Essential thrombocytopenia or polycythemia vera with current or past evidence of evolution to acute leukemia\r\n* Patients with chronic lymphocytic leukemia (CLL), follicular non-Hodgkin lymphoma (NHL), or other lymphoid malignancies who have highly adverse cytogenetics (such as p53 deletion), are chemo-insensitive, are not responsive to highly effective novel treatments such as chimeric antigen receptor T-lymphocytes (CART) or Ibrutinib, or who have transformed disease\r\n* Any hematological malignancy not cited above which is thought to be high-risk with increased chance of post HSCT relapse\r\n* Any patient who has an aggressive disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history; examples are patients with previous treatment with radiation therapy precluding TBI, or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen\r\n* Patients with aplastic anemia may be treated on this protocol, with outcomes reported descriptivelyXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXPHASE I: Diagnosis of a hematological malignancy listed below (excluding myelofibrosis) in remission or with stable minimal residual disease\r\n* Acute myelogenous leukemia (AML) in 1st or subsequent remission or in relapse after any remission\r\n* Acute lymphoblastic leukemia (ALL) in 1st or subsequent remission or in relapse after any remission\r\n* Myelodysplastic syndrome either intermediate 1 or 2, or high risk by the International Prognostic Scoring System\r\n* Chronic myelogenous leukemia (CML) in accelerated or second chronic phase\r\n* Non-Hodgkin’s lymphoma (NHL) or Hodgkin’s disease (HD) in 2nd or greater complete remission, partial remission, or refractory relapse\r\n* Chronic lymphocytic leukemia (CLL), Rai stage 2-4, failing at least 2 prior regimens\r\n* Multiple myeloma (MM), stage 2-3\r\n* Myeloproliferative disorder or neoplasmXx_NEWLINE_xXPatients with plasma cell leukemia who are transplant candidatesXx_NEWLINE_xXPatients with >= 18 years of age with relapsed/refractory leukemia with a confirmed diagnosis of acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) who meet the following criteria: \r\n* Age 18-64: Salvage treatment failures only - defined as relapsed or refractory to after least 1 cycle of salvage therapy\r\n* Age >= 65: Refractory to or have relapsed after induction chemotherapy defined as no response to initial therapy\r\n** Given the clinical activity and use of hypomethylating agents in AML patients, for all AML populations, initial therapy and salvage therapy may include hypomethylating agents; furthermore, patients >= 65 with hematologic malignancies including chronic myelomonocytic leukemia (CMML) or myelodysplasia (MDS) that transform to acute leukemia while actively receiving hypomethylating agents (i.e. decitabine or azacytidine) will be considered induction failures and thus are eligible; for Philadelphia positive (Ph+) ALL, initial therapy and salvage therapy may include steroids and imatinib or dasatinib or nilotinibXx_NEWLINE_xXAcute myeloid leukemia (AML) in 1st remission – for patients whose AML does not have ‘good risk’ cytogenetic features (i.e. t8;21, t15;17, inv 16)Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL/LL) in 1st remission clinical or molecular features indicating a high risk for relapse; or ALL >= 2nd remissionXx_NEWLINE_xXChronic myelogenous leukemia (CML) failing to respond to or not tolerating imatinib, dasatinib, or nilotinib in first chronic phase of disease; or CML in accelerated phase or second chronic phaseXx_NEWLINE_xXMyelodysplastic syndrome (MDS): refractory anemia (RA)/refractory cytopenia with multilineage dysplasia (RCMD) with high risk cytogenetic features or transfusion dependence, refractory anemia with excess blasts (RAEB)-1 and RAEB-2 and acute myelogenous leukemia (AML) evolved from MDS, who are not eligible for transplantation under protocol institutional review board (IRB) 08-008Xx_NEWLINE_xXChronic myelomonocytic leukemia (CMML): CMML-1 and CMML-2Xx_NEWLINE_xXHigh risk acute myelogenous leukemia or high risk myelodysplastic syndrome (Revised International Prognosis Scoring System [r-IPSS] score 3 or above) status post allogeneic bone marrow transplant from matched related or unrelated donors; high risk acute myeloid leukemia (AML) patients in this study are defined as AML patients with residual leukemia at the time of transplant, very poor cytogenetics (i.e. deletion 3 or monosomy 3, deletion 7 or monosomy 7 and complex cytogenetics) or secondary AML; patients with acute promyelocytic leukemia are not eligible for this studyXx_NEWLINE_xXPatients will be excluded if they have isolated extra-medullary relapse of acute lymphoblastic leukemia (ALL)Xx_NEWLINE_xXKnown acute or chronic pancreatitisXx_NEWLINE_xXMDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPNXx_NEWLINE_xXBCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).Xx_NEWLINE_xXActive plasma cell leukemiaXx_NEWLINE_xXAcute or sub-acute intestinal obstructionXx_NEWLINE_xXDiagnosed with acute promyelocytic leukemia (APL, M3)Xx_NEWLINE_xXSubjects with acute promyelocytic leukemia (M3)Xx_NEWLINE_xXAML (acute promyelocytic leukemia [APL] excepted) or high-risk MDS (10-19% blasts in marrow by morphology or flow cytometry or blood)Xx_NEWLINE_xXAcute myeloid leukemia as defined by WHO criteriaXx_NEWLINE_xXAny patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied; patients will be considered high-risk if they have any of the following:\r\n* Eastern Cooperative Oncology Group (ECOG) performance status of =< 2\r\n* Acute leukemia: requiring more than one chemotherapy regimen to obtain 1st complete remission (CR); second or greater CR, 1st relapse; any Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)\r\n* Chronic myelogenous leukemia (CML) 2nd chronic phase, accelerated phase, or blastic phase\r\n* Myelodysplastic syndromes (MDS) with International Prognostic Scoring System (IPSS) of intermediate 2 or greater\r\n* Any myeloproliferative disorder\r\n* Hodgkin lymphoma: relapsed, refractory, or primary induction failure\r\n* Non-Hodgkin lymphoma: relapsed, refractory, primary treatment failure, or not eligible for an autologous HSCT\r\n* Other conditions not listed will be assessed as high-risk by the principal investigator (PI)Xx_NEWLINE_xXPatients with a myeloid hematologic malignancy (acute myelogenous leukemia, secondary myelogenous leukemia or myelodysplastic syndrome) unlikely to be cure by standard chemotherapy; this includes patients who have relapsed after standard chemotherapy treatments and patients in first remission with unfavorable prognostics featuresXx_NEWLINE_xXRelapsed or refractory acute leukemia (acute myeloid leukemia or acute lymphoblastic leukemia or lymphoma) in second or subsequent remission, with remission defined as < 5% bone marrow blasts morphologicallyXx_NEWLINE_xXPoor-risk acute leukemia in first remission, with remission defined as < 5% bone marrow blasts morphologically:\r\n* Acute myeloid leukemia (AML) with at least one of the following: AML arising from myelodysplastic syndrome (MDS) or a myeloproliferative disorder, or secondary AML; presence of fms-related tyrosine kinase 3 (Flt3) internal tandem duplications; poor-risk cytogenetics: complex karyotype [>= 3 abnormalities], inv(3), t(3;3), t(6;9), myeloid/lymphoid or mixed-lineage leukemia (MLL) rearrangement with the exception of t(9;11), or abnormalities of chromosome 5 or 7; primary refractory disease\r\n* Acute lymphoblastic leukemia (ALL) (leukemia and/or lymphoma) with at least one of the following: adverse cytogenetics such as t(9;22), t(1;19), t(4;11), or MLL rearrangement; clear evidence of hypodiploidy; primary refractory disease\r\n* Biphenotypic leukemiaXx_NEWLINE_xXInterferon- or imatinib-refractory chronic myelogenous leukemia (CML) in first chronic phase, or non-blast crisis CML beyond first chronic phaseXx_NEWLINE_xXChronic myelomonocytic leukemiaXx_NEWLINE_xXJuvenile myelomonocytic leukemiaXx_NEWLINE_xXChronic myelogenous leukemia (CML) failing to respond to or not tolerating Imatinib or dasatinib in first chronic phase of disease; CML in accelerated phase, second chronic phase, or in CR after accelerated phase or blast crisisXx_NEWLINE_xXMyelodysplastic syndrome (MDS): Refractory anemia (RA)/refractory anemia with ring sideroblasts (RARS)/refractory cytopenia with multilineage dysplasia (RCMD) with high risk cytogenetic features or transfusion dependence, as well as refractory anemia with excess blasts (RAEB)-1 and RAEB-2 and acute myelogenous leukemia (AML) evolved from MDS who are not eligible for transplantation under protocol institutional review board (IRB) 08-008Xx_NEWLINE_xXChronic myelomonocytic leukemia: CMML-1 and CMML-2Xx_NEWLINE_xXAcute lymphoblastic leukemia in high risk first complete remission (CR1) as defined by at least one of the following: \r\n* Adverse cytogenetics including but not limited to t(9;22), t(1;19), t(4;11), mixed lineage leukemia (MLL) rearrangements\r\n* White blood cell counts > 30,000/mcL\r\n* Patients over 30 years of age\r\n* Time to complete remission > 4 weeks\r\n* Presence of extramedullary disease\r\n* Minimal residual disease\r\n* Other risk factors determined by the patient’s attending physician to be high risk features requiring transplantationXx_NEWLINE_xXAcute myelogenous leukemia in high risk CR1 as defined by at least one of the following: \r\n* Greater than 1 cycle of induction therapy required to achieve remission\r\n* Preceding myelodysplastic syndrome (MDS)\r\n* Presence of fms-like tyrosine kinase receptor-3 (Flt3) abnormalities\r\n* French-American-British (FAB) M6 or M7 leukemia, or\r\n* Adverse cytogenetics for overall survival such as: \r\n** Those associated with MDS\r\n** Complex karyotype (>= 3 abnormalities); or \r\n** Any of the following: inv(3) or t(3;3), t(6;9), t(6;11), + 8 [alone or with other abnormalities except for t(8;21), t(9;11), inv(16) or t(16;16)], t(11;19)(q23;p13.1)]\r\n* Other risk factors determined by the patient’s attending physician to be high risk features requiring transplantationXx_NEWLINE_xXPlasma cell leukemia: after induction chemotherapyXx_NEWLINE_xXSubjects with leukemia are not eligible for study participationXx_NEWLINE_xXAcute myeloid leukemia/acute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia: Must have < 5% morphologic marrow blasts in an evaluable marrow sample (> 25% of normal cellularity for age collected less than one month prior to start of conditioning; patients in which adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the principal investigator prior to enrollment; patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with principal investigator (PI) approvalXx_NEWLINE_xXChronic myelogenous leukemia: All types, except refractory blast crisis; chronic phase patients must have failed or been intolerant to Gleevec or other tyrosine kinase inhibitorsXx_NEWLINE_xXAcute myelogenous leukemia (AML): \r\n* Complete first remission (CR1) at high risk for relapse such as: \r\n** Known prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder; \r\n** Therapy related AML; \r\n** White cell count at presentation > 100,000; \r\n** Presence of extramedullary leukemia at diagnosis; \r\n** Any unfavorable subtype by French-American-British (FAB) or World Health Organization (WHO) classification; \r\n** High-risk cytogenetics (e.g. those associated with MDS, abnormalities of 5, 7, 8, Philadelphia chromosome, complex karyotype) or high risk molecular abnormalities;\r\n** Requirement for 2 or more inductions to achieve CR1\r\n** Any patient with newly diagnosed AML with intermediate risk cytogenetics\r\n** Any patient unable to tolerate consolidation chemotherapy as would have been deemed appropriate by the treating physician\r\n* Complete second remission (CR2)Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL): \r\n* Complete first remission (CR1) at high risk for relapse such as: \r\n** White cell count at presentation > 30,000 for B-cell lineage and >100,000 for T-cell lineage; \r\n** Presence of a high-risk cytogenetic abnormality such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality; \r\n** Failure to achieve complete remission after four weeks of induction therapy; \r\n** Any patient with newly diagnosed ALL >= 50 years-old;\r\n** Any patient unable to tolerate consolidation and/or maintenance chemotherapy as would have been deemed appropriate by the treating physician\r\n* Complete second remission (CR2)Xx_NEWLINE_xXChronic myelogenous leukemia (CML) patients who have failed or are intolerant of tyrosine kinase inhibitors or patients with other myeloproliferative diseases who are high risk and the intent of therapy is cureXx_NEWLINE_xXAcute leukemia in morphologic relapse or with morphologic persistent disease (cytogenetic or molecular persistence/relapse in morphologic CR are eligible); MDS or CML or other myeloproliferative disorder with > 5% blasts; aggressive lymphoma or HL with POD after salvage chemotherapyXx_NEWLINE_xXAcute myeloid leukemia/acute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia: Must have < 5% morphologic marrow blasts in an evaluable marrow (> 25% of normal cellularity for age) collected less than one month prior to start of conditioning; patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with the approval of the PI or designeeXx_NEWLINE_xXAcute myelogenous leukemia (AML) at the following stages:\r\n* High risk first complete remission (CR1), defined as:\r\n** Having preceding myelodysplasia (MDS)\r\n** High risk cytogenetics (high-risk cytogenetics: del (5q) –5, -7, abn (3q), t (6;9) complex karyotype (>= 5 abnormalities) with any minimal residual disease (MRD) status\r\n** Requiring >= 2 cycles chemotherapy to obtain complete response (CR)\r\n** High allelic ratio fms-related tyrosine kinase 3 (FLT3)/internal tandem duplications positive (ITD+)\r\n** Standard risk cytogenetics with positive MRD at end of induction \r\n* Second or greater CR\r\n* First relapse with < 25% blasts in bone marrowXx_NEWLINE_xXChronic myelogenous leukemia (CML) in chronic or accelerated phase; prior therapies allowedXx_NEWLINE_xXPatient with FA must have moderately severe aplastic anemia (AA) myelodysplastic syndrome (MDS) or acute leukemia with or without chromosomal abnormalitiesXx_NEWLINE_xXHematologic malignancy (e.g. acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], B cell non-Hodgkin's lymphoma [B-NHL])Xx_NEWLINE_xXDiagnosis of chronic lymphocytic leukemia with no history of previous treatments with monoclonal antibodies or chemotherapy.Xx_NEWLINE_xXChronic myelogenous leukemia in chronic or accelerated phaseXx_NEWLINE_xXAcute lymphocytic leukemia (ALL) at the following stages:\r\n* High risk first remission, as determined by treating physician as per current guidelines\r\n* Secondary remission, defined as:\r\n** Bone marrow relapse < 36 months from induction; or,\r\n** T-lineage relapse at any time; or,\r\n** Isolated CNS relapse or,\r\n** Slow reinduction (M2-3 at day 28) after relapse at any time\r\n* Any third of subsequent complete remission (CR)Xx_NEWLINE_xXBiphenotypic or undifferentiated leukemia in any CR or if in first (1st) relapse must have < 25% blasts in BMXx_NEWLINE_xXAcute myelogenous leukemia (AML)\r\n* High risk first complete remission (CR1), as determined by treating physician as per current guidelines\r\n* Second or greater CR\r\n* First relapse with < 25% blasts in bone marrow\r\n* Patients with therapy-related AML whose prior malignancy has been in remission for at least 12 monthsXx_NEWLINE_xXMyelodysplastic/myeloproliferative disease\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Myelodysplastic syndrome and/or pre-leukemia at any stageXx_NEWLINE_xXAML is of the sub-type of acute promyelocytic leukemiaXx_NEWLINE_xXDiagnosis of acute lymphoblastic leukemia (ALL) or biphenotypic leukemia meeting the following criteria:Xx_NEWLINE_xXBased on European Group for the Classification of Acute Leukemia (EGIL) diagnostic criteriaXx_NEWLINE_xXCNS or testicular leukemia at diagnosis allowedXx_NEWLINE_xXAcute myeloid leukemia (AML) after first relapse or with primary refractory diseaseXx_NEWLINE_xXChronic myelogenous leukemia (CML)Xx_NEWLINE_xXAcute myeloid leukemia: high risk first complete remission (CR)1 as evidenced by: \r\n* High risk cytogenetics; t(4;11) or other mixed lineage leukemia (MLL) rearrangements; chromosome 5, 7, or 19 abnormalities; complex karyotype (> 5 distinct changes)\r\n* >= 2 cycles to obtain complete remission (CR)\r\n*Second CR (CR2) or higher preceding myelodysplasia (MDS)\r\n* All patients must be in CR or early relapse (i.e., < 15% blasts in bone marrow [BM])Xx_NEWLINE_xXRefractory anemia with excess blasts, or leukemiaXx_NEWLINE_xXAcute myeloid leukemia (AML): high risk complete response (CR)1 (as evidenced by preceding myelodysplastic syndromes [MDS], high risk cytogenetics, >= 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia; CR2+; all patients must be in CR as defined by hematological recovery, AND < 5% blasts by light microscopy within the bone marrow with a cellularity of >=15%Xx_NEWLINE_xXAcute lymphocytic leukemia (ALL): high risk CR1 as defined by cytogentics (such as t(9;22), t (1:19), t(4;11), other mixed lineage leukemia (MLL) rearrangements, hypodiploidy, or IKZF1 abnormalities), deoxyribonucleic acid (DNA) index < 0.81, > 1 cycle to obtain CR or presence minimal residual disease (MRD); patients in CR2+ are eligible; all patients must be in CR as defined by hematological recovery, AND < 5% blasts by light microscopy within the bone marrow with a cellularity of >= 15%Xx_NEWLINE_xXChronic myelogenous leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylateXx_NEWLINE_xXPlasma Cell leukemia after initial therapy, who achieved at least a partial remissionXx_NEWLINE_xXAcute myeloid leukemia: high risk first complete remission (CR1) (as evidenced by preceding myelodysplastic syndrome [MDS], high risk cytogenetics such as those associated with MDS or complex karyotype, > 2 cycles to obtain complete response [CR] or erythroblastic and megakaryocytic); second or greater CRXx_NEWLINE_xXAcute lymphoblastic leukemia/lymphoma: high risk CR1 as evidenced by high risk cytogenetics (e.g. t(9;22), t(1;19),t(4;11), other mixed-lineage leukemia (MLL) rearrangements, hypodiploidy or IKAROS family zinc finger 1 [IKZF1]), > 1 cycle to obtain CR or evidence of minimal residual disease (MRD); patients in second or greater CR are also eligibleXx_NEWLINE_xXChronic myelogenous leukemia: all types except refractory blast crisis; chronic phase patients must have failed or been intolerant to GleevecXx_NEWLINE_xXChronic myelogenous leukemia (CML) in refractory blast crisisXx_NEWLINE_xXHistory or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)Xx_NEWLINE_xXDocumented acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) as defined by the criteria below:Xx_NEWLINE_xXConfirmed diagnosis of B-cell Chronic Lymphocytic LeukemiaXx_NEWLINE_xXAcute Leukemia (AML or ALL) patient or allo-HCT recipient with a diagnosis of IAXx_NEWLINE_xXAcute myeloid leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in =< 60 years old that is NOT considered as favorable-risk; favorable risk AML is defined as having one of the following:\r\n* t(8,21) without cKIT mutation\r\n* inv(16) or t(16;16) without cKIT mutation\r\n* Normal karyotype with mutated NPM1 and wild type FLT-ITD\r\n* Normal karyotype with double mutated CEBPA\r\n* Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidationXx_NEWLINE_xXAcute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL; high risk ALL is defined as having one of the following:\r\n* Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1\r\n* 30 years of age or older at diagnosis\r\n* White blood cell counts of greater than 30,000/mcL (B-cell [B]-ALL) or greater than 100,000/mcL (T-cell [T]-ALL) at diagnosis\r\n* CNS leukemia involvement during the course of disease\r\n* Slow cytologic response (> 10% lymphoblasts in bone marrow on day 14 of induction therapy)\r\n* Evidence of persistent immunophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapyXx_NEWLINE_xXChronic myelogenous leukemia excluding refractory blast crisis: to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to one or more tyrosine kinase inhibitorsXx_NEWLINE_xXPlasma cell leukemia after initial therapy, in patients who have achieved at least a partial remissionXx_NEWLINE_xXJuvenile myelomonocytic leukemiaXx_NEWLINE_xXMRD positive leukemia (AML, ALL or accelerated/blast phase chronic myeloid leukemia [CML]); selected patients in morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD negative statusXx_NEWLINE_xXSecondary immune thrombocytopenia from any cause including lymphoma, chronic lymphocytic leukemia, and drug-induced thrombocytopeniaXx_NEWLINE_xXCriteria 4 Plasma cell leukemia (> 2.0 x 109/L circulating plasma cells by standard differential)Xx_NEWLINE_xXDiagnosis of chronic myelogenous leukemia in blast crisis;Xx_NEWLINE_xXMust not have acute leukemiaXx_NEWLINE_xXHas acute promyelocytic leukemia (APL, FAB M3).Xx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXPatients must have one of the following hematologic malignancies: acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics, fms-related tyrosine kinase 3 [FLT3] mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndrome, any disease beyond first remissionXx_NEWLINE_xXAcute lymphoblastic leukemia (ALL): induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease; patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time: with t(9;22) or t(4;11), hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure, and/or evidence of minimal residual disease, or acute biphenotypic leukemia, or double hit non-Hodgkin's lymphomaXx_NEWLINE_xXChronic myeloid leukemia (CML) second chronic phase or accelerated phaseXx_NEWLINE_xXChronic myelomonocytic leukemia (CMML)Xx_NEWLINE_xXPlasma cell leukemia (plasma cells > 2000/cubic mm)Xx_NEWLINE_xXTdT-positive leukemia (ALL, AML, or blastic CML) that has failed at least one standard treatment regimen and for which no standard therapies are expected to result in durable remission. Leukemia is minimally defined as at least 20% blast cells present in marrow or peripheral blood. TdT must be expressed in at least 20% of blast cells present and documented either immunologically or biochemically;Xx_NEWLINE_xXDiagnosis of refractory or relapsed ALL (acute lymphocytic leukemia)Xx_NEWLINE_xXHistory of Richter's transformation or prolymphocytic leukemiaXx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic Syndromes (MDS)/acute myeloid leukemia (AML).Xx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL, or AML M3 subtype).Xx_NEWLINE_xXHas acute promyelocytic leukemia (AML subtype M3)Xx_NEWLINE_xXDiagnosis of untreated “high-grade” myeloid neoplasm (? 10% blasts in blood or bone marrow) or acute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2016 World Health Organization (WHO) classification; outside diagnostic material is acceptable to establish diagnosis; submission of peripheral blood specimen for  flow cytometry performed at the study institution should be considered; diagnostic material must have been submitted for cytogenetic and/or molecular testing as clinically appropriateXx_NEWLINE_xXMyeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatmentXx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)Xx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemiaXx_NEWLINE_xXDiagnosis of acute myeloid leukemia (AML) by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3.Xx_NEWLINE_xXKnown history of primary plasma cell leukemia or evidence of primary or secondary plasma cell leukemia at the time of screeningXx_NEWLINE_xXCOHORT 2: patients with high risk disease having undergone an allogeneic hematopoietic stem cell transplant from a 10/10 human leukocyte antigen (HLA) matched donor with one of the following disease subtypes:\r\n* Acute myeloid leukemia (AML) in CR1 with high risk features (European Leukemia Network [ELN]) at presentation\r\n** Diagnostic sample with either t(6;9), t(9;22), 11q23, inv 3, -5, -7, del17p, complex cytogenetics, NPMwt-flt3ITD+, OR p53 mutation (mut); patients whose samples have mutations in RUNX1 or ASXL1 are also eligible (unless the patient has favorable cytogenetics)\r\n* AML in CR1 with measurable minimal residual disease (MRD) by molecular (e.g., myeloid mutation profile, polymerase chain reaction [PCR] for NPM1, core-binding factor [CBF], mixed lineage leukemia [MLL]) or flow cytometry \r\n* AML not in CR1 (including patients with morphologic CR but with incomplete recovery, CRi)\r\n* Myelodysplastic syndrome (MDS) with complex cytogenetics, 17p deletion or p53 mutation, or JAK2 or RAS mutation\r\n* Treatment-related MDS or AML\r\n* Acute lymphoblastic leukemia (ALL) not in CR1\r\n* ALL with MRD\r\n* Any hematologic malignancy relapsed or with persistent disease after allogeneic hematopoietic stem cell transplant\r\n* Multiple myeloma\r\n* Non-Hodgkin lymphoma (NHL) with chemoresistant disease at time of transplant\r\n* Any patient undergoing allogeneic hematopoietic stem cell transplant and an anticipated rate of relapse > 80% based upon published data and for which there is consensus amongst the Hematologic Malignancies Tumor Study Group that enrollment is appropriateXx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXPatients must have histologically or cytologically documented newly diagnosed acute myeloid leukemia (non-acute promyelocytic leukemia [APL]) that has not yet been treated; hydroxyurea (Hydrea) and tretinoin (ATRA) previous treatments are acceptableXx_NEWLINE_xXPatients with myelodysplastic syndrome(MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.Xx_NEWLINE_xXPatients with acute leukemias, accelerated/blast phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma.Xx_NEWLINE_xXEXPANSION COHORT: Patients must have a diagnosis of newly diagnosed AML with any of the following:\r\n* Confirmed translocation involving 11q23\r\n* Partial tandem duplication (PTD) of the MLL gene (on 11q23)\r\n* FLT3-ITD (internal tandem duplication)\r\n* Increased Fgf2 in serum (2 standard deviations above control serum samples)\r\n* HOX(A9/A10) over-expression in bone marrow (2 standard deviations above control values in CD34+ cells from normal subjects)\r\n* Note: Patients with secondary AML are eligible for enrollment into the trial (in both cohorts); secondary AML is defined as AML that has developed in a person with a history of antecedent blood count abnormalities, or myelodysplastic syndromes (MDS), or a myeloproliferative disorder (excluding chronic myeloid leukemia); or a history of prior chemotherapy or radiation therapy for a disease other than AMLXx_NEWLINE_xXPatients with acute promyelocytic leukemia (APL) are not eligibleXx_NEWLINE_xXPatients with known extramedullary leukemia are not eligibleXx_NEWLINE_xXMalignancies included are:\r\n* Acute leukemia, including Acute myeloid leukemia (AML), biphenotypic acute leukemia or mixed-lineage leukemia, acute lymphoblastic leukemia (ALL); all patients must be in complete response (CR) as defined by < 5% blasts by morphology/flow cytometry in a representative bone marrow sample with adequate cellularity to assess remission status\r\n* Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate (Int)-2 or high risk (i.e., RAEB, RAEBt) or refractory anemia with severe pancytopenia or high risk cytogenetics; blasts must be < 10% by a representative bone marrow aspirate morphology\r\n* Chronic Myeloid Leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to tyrosine kinase inhibitor therapyXx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).Xx_NEWLINE_xXThe subject must have precursor B-cell or T-cell acute lymphoblastic leukemia. B-cell: relapsed or refractory after first or subsequent salvage therapy; or T-cell: relapsed or refractory with first remission duration less than or equal to 12 months in first salvage; or relapsed or refractory after first or subsequent salvage therapyXx_NEWLINE_xXPatients with a diagnosis of relapsed or refractory hematologic malignancy including, but not limited to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Burkitt’s leukemia/lymphoma, prolymphocytic leukemia, biphenotypic acute leukemia, blast-phase of chronic myeloid leukemia (CML), B-cell lymphoma, or Richter’s transformation of chronic lymphocytic leukemia (CLL)Xx_NEWLINE_xXPatients must have a confirmed diagnosis of either B- or T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that is either:\r\n* Arm A: Initially diagnosed at age 40 or later, OR\r\n* Arm B: Relapsed after or failed to respond to >= 1 previous chemotherapy regimenXx_NEWLINE_xXPatients with any of the following diagnoses are eligible: 1) high-risk MDS (i.e. refractory anemia with excess blasts [RAEB-1 or RAEB-2] by World Health Organization [WHO] classification, or any WHO subset with International Prognostic Scoring System [IPSS] intermediate-2 or high, or any patients that has failed prior therapy with hypomethylating agents); 2) chronic myelomonocytic leukemia (CMML); 3) acute myeloid leukemia (AML) by WHO classification; 4) chronic myeloid leukemia in blast phase (CML-BP); patients with myelofibrosis are also eligibleXx_NEWLINE_xXAcute or chronic pancreatic diseaseXx_NEWLINE_xXPatients must have one of the following diagnoses:\r\n* Acute myeloid leukemia fulfilling the criteria of the World Health Organization (WHO) classification, or\r\n* > 5% but < 20% marrow myeloblasts and evidence of a clonal de novo AML genetic abnormality [e.g., t(8;21), inv(16), t(9;11)], or\r\n* Myeloid sarcoma (also referred to as extramedullary myeloid tumor, granulocytic sarcoma, or chloroma), with or without evidence of a leukemia process in the bone marrow or peripheral blood, with confirmation of myeloid differentiation, or\r\n* High grade myelodysplastic syndrome (MDS) with greater than 5% blasts, or\r\n* Patients with treatment related myeloid neoplasms including AML and MDS, provided their cumulative anthracycline dose has not exceeded 230 mg/m^2 doxorubicin equivalentsXx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXBCR-ABL1 chronic myeloid leukemia in blast crisis (CML-BC)Xx_NEWLINE_xXJuvenile myelomonocytic leukemia (JMML)Xx_NEWLINE_xXPatients with a history of or active bone marrow disorders expected to interfere with study therapy (e.g. acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma)Xx_NEWLINE_xXBone marrow blasts ?20%, indicating a diagnosis of acute myeloid leukemia (AML).Xx_NEWLINE_xXPlasma cell leukemia defined as peripheral plasma cell count > 2000/cubic millimeter (mm^3)Xx_NEWLINE_xXParticipants whose leukemia meets WHO diagnostic criteria of mixed phenotype acute leukemia (MPAL) or leukemia of ambiguous lineage are not eligibleXx_NEWLINE_xXCohort Inclusion Criteria - Group A: Subjects must have previously untreated acute myeloid leukemia (AML) according to the WHO classification with no prior treatment other than hydroxyurea. Prior therapy for myelodysplastic syndrome (MDS), myeloproliferative syndromes (MPD), or aplastic anemia is permitted but not with hypomethylating agents.Xx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXParticipants with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)Xx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXPatients with acute promyelocytic leukemia (French-American-British [FAB] class M3 AML)Xx_NEWLINE_xXPatients with acute promyelocytic leukemia (APL) confirmed either by the presence of t(15;17)(q22;q21) or promyelocytic leukemia (PML)/retinoic acid receptor (RAR) alpha transcripts will be excludedXx_NEWLINE_xXPatients must not have blastic transformation of chronic myelogenous leukemiaXx_NEWLINE_xXPatients with secondary AML are eligible for enrollment onto the trial; secondary AML is defined as AML that has developed in a person with a history of antecedent blood count abnormalities, or myelodysplastic syndrome (MDS), or a myeloproliferative disorder (excluding chronic myeloid leukemia); or a history of prior chemotherapy or radiation therapy for a disease other than AML\r\n* NOTE: Prior therapy of MDS with decitabine, low-dose cytarabine, or azacitidine is excludedXx_NEWLINE_xXPatients may not have received prior chemotherapy for AML with the exception of hydroxyurea for increased blast count or leukapheresis for leukocytosis; patients who have received a limited and short-term exposure of ATRA (all trans retinoid acid) while AML-M3 (acute promyelocytic leukemia) was being ruled out, and which has been discontinued, will be eligibleXx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXSubject has a diagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXDiagnosed with plasma cell leukemia, POEMS syndrome or amyloidosis.Xx_NEWLINE_xXPatients must have an initial diagnosis of AML, biphenotypic acute leukemia, or APL or chronic myelogenous leukemia (CML) in blast crisisXx_NEWLINE_xXTREATMENT: Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS), or with features suggestive of AML/MDS, or who have had prior allogeneic bone marrow transplant or double umbilical cord blood transplantation, should not receive veliparib due to reports of MDS and leukemia secondary to oncology therapy on Cancer Therapy Evaluation Program (CTEP)-sponsored studies utilizing veliparibXx_NEWLINE_xXAdult patients must have a hematological malignancy, as described below:\r\n* Acute leukemias:\r\n** Acute lymphoblastic leukemia (ALL) in first complete remission (CR1) that is NOT considered favorable-risk as defined by the presence of at least one of the following:\r\n*** Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), other mixed lineage leukemia (MLL) rearrangements\r\n*** White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis,\r\n*** Recipient age older than 30 years at diagnosis,\r\n*** Time to CR greater than 4 weeks\r\n** Acute myelogeneous leukemia (AML) in first complete remission (CR1) that is NOT considered as favorable-risk; favorable risk is defined as having one of the following:\r\n*** t(8,21) without CKIT mutation\r\n*** inv(16) without CKIT mutation or t(16;16)\r\n*** Normal karyotype with mutated nucleophosmin (NPM1) and not FLT-IND\r\n*** Normal karyotype with double mutated CCAAT/enhancer binding protein alpha (CEBPA)\r\n*** Acute promyelocytic leukemia (APL) in first molecular remission at end of consolidation\r\n** Acute leukemias in second (2nd) or subsequent\r\n** Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR\r\n* Chronic myelogenous leukemia (CML) excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate\r\n* Myelodysplastic syndrome (MDS): International Prognostic Scoring System (IPSS) intermediate (Int)-2 or high risk (i.e., refractory anemia with excess blasts [RAEB], RAEB in transformation [RAEBt]) or refractory anemia with severe pancytopenia or high risk cytogenetics; blasts must be < 10%\r\n* Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), marginal zone B-cell lymphoma or follicular lymphoma that have progressed after at least two prior therapies; patients with bulky disease (nodal mass greater than 5 cm) should be considered for debulking chemotherapy before transplant\r\n* Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy in CR1+ or first or greater partial remission (PR1+)\r\n* Large cell non-Hodgkin lymphoma (NHL) > CR2/> PR2; patients in CR2/PR2 with initial short remission (< 6 months) are eligible\r\n* Lymphoblastic lymphoma, Burkitt lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year\r\n* Multiple myeloma beyond PR2; patients with chromosome 13 abnormalities, first response lasting less than 6 months, or beta-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapy\r\n* Natural killer (NK) cell leukemiaXx_NEWLINE_xXPediatric patients must have a hematological malignancy as described below:\r\n* AML: high risk CR1 (preceding MDS, intermediate to high risk cytogenetics, >= 2 cycles to obtain CR, French-American-British classification system [FAB] M6); CR2+, first relapse with < 25% blasts in bone marrow; morphologic complete remission with incomplete blood count recovery; therapy-related AML for which prior malignancy has been in remission for at least 12 months\r\n* ALL: high risk CR1 (Philadelphia chromosome positive [Ph+] ALL, MLL rearrangements with slow early response, hypodiploidy, end of induction M3 bone marrow, end of induction M2 with M2-3 at day 42, evidence of minimal residual disease [MRD]); high risk CR2 (Ph+ALL, bone marrow relapse < 36 months from induction, T-lineage relapse at any time, very early isolated central nervous system (CNS) relapse, slow induction after relapse at any time, evidence of MRD); >= CR3\r\n* NK cell lymphoblastic leukemia in any CR\r\n* Biphenotypic or undifferentiated leukemia in any CR or if in first relapse must have less than 25% blasts in bone marrow\r\n* Myelodysplastic syndrome (MDS) at any stage\r\n* Chronic myelogenous leukemia (CML) in chronic or accelerated phase\r\nEvidence of CNS leukemia must be treated and in CNS CR to be eligible for the studyXx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smearXx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AMLXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXKnown history of acute or chronic pancreatitisXx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smearXx_NEWLINE_xXPatients must have histologic confirmation of relapsed and or refractory hematologic malignancy, locally advanced or metastatic colon/rectal carcinoma, or refractory and/or relapsed soft tissue sarcomas and have failed at least one standard line of therapy; patients will be eligible if they have either declined standard treatment regimens or if there is no standard approach to curative salvage therapy per National Comprehensive Cancer Network (NCCN) guidelines in the setting of relapsed/refractory disease; in addition, patients for whom a potential 29-day delay in treatment will not interfere with the subject’s potential therapeutic options can be eligible per the treating physician's discretion\r\nMalignancies can include:\r\n* Acute myeloid leukemia\r\n* Myelodysplastic syndrome\r\n* Acute lymphoblastic leukemia\r\n* Chronic myeloid leukemia\r\n* Chronic lymphocytic leukemia\r\n* Non Hodgkin lymphoma\r\n* Hodgkin lymphoma\r\n* Myeloproliferative syndromes\r\n* Plasma cell myeloma\r\n* Colon/rectal carcinoma\r\n* Sarcomas including but not limited to Ewing’s sarcoma and rhabdomyosarcomaXx_NEWLINE_xXPatients with acute promyelocytic leukemia (APL) as diagnosed by morphologic criteria, flow cytometric characteristics, and rapid cytogenetics or FISH or molecular testingXx_NEWLINE_xXAcute Promyelocytic LeukemiaXx_NEWLINE_xXAcute leukemia, primary refractory or beyond complete remission (CR)1, or minimal residual disease (MRD) positivityXx_NEWLINE_xXChronic myelogenous leukemia (accelerated, blast or second chronic phase)Xx_NEWLINE_xXConfirmed diagnosis of acute lymphoblastic leukemia or lymphoblastic lymphomaXx_NEWLINE_xXFor acute lymphoblastic leukemia: diagnosis should be made by bone marrow aspirate or biopsy demonstrating >= 30% involvement by lymphoblasts, with flow cytometry or immunohistochemistry confirming B-precursor or T-ALL phenotype; while myeloid co-expression on blasts determined to be primarily lymphoid is allowed, patients with leukemia of ambiguous lineage are not eligibleXx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsyXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXChronic myelogenous leukemia all types except blast crisis (note treated blast crisis in chronic phase is eligible)Xx_NEWLINE_xXPatients with refractory leukemia or MDS may be taken to transplant in aplasia after induction or re-induction chemotherapy or radiolabeled antibodyXx_NEWLINE_xXChronic myelogenous leukemia (CML) in refractory blast crisisXx_NEWLINE_xXPatients with newly diagnosed or relapsed/refractory AML, except acute promyelocytic leukemia (APL), requiring intensive induction chemotherapyXx_NEWLINE_xXPatients with acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia (except Rai-stage I), Burkitt lymphoma, plasma cell leukemia, or non-secretory myelomaXx_NEWLINE_xXParticipant has a hematologic malignancy that is positive for MLLr as determined by fluorescent in situ hybridization (FISH) or reverse transcriptase (RT)-PCR, and disease meets at least one of the following criteria:\r\n* Relapsed after or is refractory to chemotherapy\r\n* Relapsed after hematopoietic stem cell transplantation (HSCT)\r\n* Relapsed or refractory secondary leukemia\r\n** Relapse is defined as reappearance of leukemia cells after the attainment of complete remission and refractory is defined as >= 5% blasts at the end of induction; patients that achieved MRD negative status followed by reappearance of blasts at less than 5% are eligibleXx_NEWLINE_xXPatients must have newly diagnosed, previously untreated acute myeloid leukemia (AML) (excluding M3)Xx_NEWLINE_xXPatients who are in the blast phase of chronic myeloid leukemiaXx_NEWLINE_xXBi-phenotypic acute leukemiaXx_NEWLINE_xXPatients with acute promyelocytic leukemia confirmed with t(15;17) (French-American-British Classification [FAB] subtype M3 and M3 variant)Xx_NEWLINE_xXDiagnosis of plasma cell leukemiaXx_NEWLINE_xXLymphoid malignancies requiring allogeneic hematopoietic cell transplantation\r\n* Multiple myeloma including primary or secondary plasma cell leukemia and secondary amyloidosis\r\n* Lymphomas and related chronic lymphoid proliferative disorders: Hodgkin’s lymphoma, non-Hodgkin’s lymphoma of any types (B-cell, T-cell, null/natural killer [NK]-cell type), chronic lymphocytic leukemia (CLL), pro-lymphocytic leukemia (PLL), hairy-cell leukemia, large granular lymphocytic leukemia\r\n* Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma\r\n* Acute lymphoblastic leukemia (ALL) of any typesXx_NEWLINE_xXMyeloid malignancies requiring allogeneic hematopoietic cell transplantation\r\n* Acute myeloid leukemia (AML) and acute leukemia of mixed or undetermined or ambiguous lineage\r\n* Myelodysplastic syndrome (MDS), myeloproliferative disorders (MPD) (chronic myeloid leukemia [CML], primary myelofibrosis, post-polycythemic/post-thrombocythemic myelofibrosis), chronic myelomonocytic leukemia (CMMoL) and acute blastic transformation of these conditionsXx_NEWLINE_xXMDS, myelodysplastic syndrome/myeloproliferative neoplasia overlap disorders (including chronic myelomonocytic leukemia [CMML], and MDS/myeloproliferative neoplasm [MPN] unclassifiable syndromes)Xx_NEWLINE_xXAML, other than acute promyelocytic leukemia (APL), in first or second remission or with minimal residual diseaseXx_NEWLINE_xXRelapse after previous allogeneic stem cell transplant for one of the following hematologic malignancies - acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes (MDS), lymphoma, myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia meeting the following:\r\n* For non-chronic myelogenous leukemia (CML), relapse will be defined based on disease specific morphologic criteria from a bone marrow biopsy and aspirate or recurrence of disease specific cytogenetics; relapse can be determined morphologically; equivocal results for relapse should result in a repeated test after an appropriate time interval (suggested 1 month) to determine eligibility\r\n* For CML, relapse will be defined as any cytogenetic evidence of a Philadelphia chromosome or persistence of breakpoint cluster region (BCR)/c-abl oncogene 1, non-receptor tyrosine kinase (ABL) rearrangements by molecular testing on at least two measurements over a 6 month interval; if cytogenetics are normal and there is polymerase chain reaction (PCR) evidence of a BCR/ABL fusion, patients will be eligible if they have evidence of a quantitative increase in CML measured either by quantitative PCR or by fluorescent in situ hybridization (FISH)\r\n* For chronic phase CML patients only:\r\n** Must have failed (no response in 3 months or incomplete response at 6 months) or refused treatment with a tyrosine-kinase inhibitor (TKI)\r\n** Must have failed (defined as incomplete response or relapse) or refused donor lymphocyte infusion (DLI)Xx_NEWLINE_xXPatients in 1st or 2nd remission with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), who are eligible for stem cell transplant; remission defined as no circulating blasts, < 5% blasts in the bone marrow, normalization of previously detected cytogenetic abnormalities, no extramedullary diseaseXx_NEWLINE_xXPatients with chronic myelomonocytic leukemia (CMML) are allowed to be enrolledXx_NEWLINE_xXPatients with acute promyelocytic leukemiaXx_NEWLINE_xXDiagnosis of plasma cell leukemiaXx_NEWLINE_xXMust have a pathologically confirmed diagnosis by World Health Organization (WHO) criteria of MDS, CMML, or acute myeloid leukemia (AML) (except acute promyelocytic leukemia) with < 30% bone marrow blasts (refractory anemia with excess blasts in transformation [RAEB-t] by French American British criteria)Xx_NEWLINE_xXDiagnoses to be included:\r\n* Acute Myelogenous Leukemia at the following stages:\r\n** First remission (cytogenetic intermediate or high risk)\r\n** Second or subsequent remission\r\n*** Complete remission is defined as the absence of blasts in the peripheral circulation at the time of enrollment and < 5% blasts in the bone marrow\r\n* Chronic Myelogenous Leukemia at the following stages:\r\n** First or subsequent chronic phase:\r\n*** Patient refused tyrosine kinase therapy or is otherwise not suited for it\r\n*** Patient who has failed two lines of tyrosine kinase therapy (e.g., patient has not had a complete hematologic response and/or minor cytogenetic response by 3 months of second line therapy, major cytogenetic response by 12 months of second line treatment, or complete cytogenetic remission (CCyR) by 18 months of second line treatment)\r\n*** Patient who has lost complete hematologic response or major/complete cytogenetic response while on second line of therapy\r\n** Accelerated Phase – any one of the following symptoms:\r\n*** White blood cell (WBC) difficult to control (> 50 x 10^9/L despite therapy)\r\n*** Rapid doubling of WBC (< 5 days)\r\n*** 10% blasts in blood or marrow\r\n*** 20% blasts and/or promyelocytes in blood or marrow\r\n*** 20% basophils and/or eosinophils in blood\r\n*** Anemia or thrombocytopenia unresponsive to standard treatment\r\n*** Persistent thrombocytosis (> 1000 x10^9/L)\r\n*** Cytogenetic abnormalities in addition to Philadelphia positive (Ph+)\r\n*** Increasing splenomegaly\r\n*** Marrow fibrosis\r\n* Myelodysplastic syndromes at any of the following stages:\r\n** Refractory anemia\r\n** Refractory anemia with ringed sideroblasts\r\n** Refractory cytopenia with multilineage dysplasia\r\n** Refractory cytopenia with multilineage dysplasia and ringed sideroblasts\r\n** Refractory anemia with excess blasts-1 (5-10% blasts)\r\n** Refractory anemia with excess blasts-2 (10-20% blasts)\r\n** Myelodysplastic syndrome, unclassified\r\n** MDS associated with isolated del (5q) (only after failing lenalidomide)\r\n** Low risk MDS patients would be eligible only if transfusion-dependent and failing standard therapy (i.e. hypomethylating agents)\r\n** Chronic Myelomonocytic Leukemia\r\n* Primary Myelofibrosis\r\n** Intermediate-2 risk or high risk disease\r\n** Patients should have extinguished standard of care options prior to being considered for this trial\r\n* Chronic Lymphocytic Leukemia\r\n** Complete remission: the disease is completely absent and no relapse occurred prior to the preparative regimen; requires all of the following: \r\n** Nodular partial remission: complete response with persistent lymphoid nodules in bone marrow\r\n** Partial remission: reduction of more than 50% in the disease burden regardless of the number of lines of therapy received\r\n** Eligibility will be limited to those who have at least failed a fludarabine-based regimen\r\n* Mature B cell malignancies (including mantle cell lymphoma, follicular lymphoma, diffuse large B cell lymphoma, non-Hodgkin lymphoma not otherwise specified)\r\n** Patients should have extinguished standard of care options prior to being considered eligible for this trial\r\n** First complete remission (CR1) confirmed: complete disappearance of all known disease; the term “confirmed” is defined as a laboratory and/or pathological or radiographic determination\r\n** CR1 unconfirmed (CRU1): complete disappearance of all known disease with the exception of persistent scan abnormalities of unknown significance; the term “unconfirmed” is defined as scan abnormalities of unknown significance that are not biopsied or otherwise evaluated\r\n** Second complete remission positive (CR2+) confirmed: the recipient relapsed, then achieved complete absence of disease without radiographic evidence of disease\r\n** CR2+ unconfirmed: the recipient has achieved a second or subsequent complete response but has persistent radiographic abnormalities of unknown significance\r\n** Partial remission: reductions of >= 50% in greatest diameter of all sites of known disease and no new sitesXx_NEWLINE_xXPatients must have histologically or cytologically documented relapsed and/or refractory acute myeloid leukemiaXx_NEWLINE_xXPatients must have one of the following disease types:\r\n* Acute myeloid leukemia (AML) with any of the following:\r\n** In first complete remission (CR1) with high-risk features defined by any of the following:\r\n*** Presence of any of the cytogenetics abnormalities: -5/5q-, -7/7q-, t(9:22), t(6;9), inv(3), 9q, 11q23 abnormalities, or complex karyotype with 3 or more abnormalities per clone\r\n*** Need for 2 cycles of induction therapy to achieve CR1\r\n*** Preceding history of myelodysplasia or the prior administration of chemotherapy for a non-myeloid malignancy (i.e., secondary AML)\r\n** Patients in second or subsequent complete remission (CR2, CR3, etc.)\r\n** Primary refractory or relapsed AML with peripheral blood blasts < 2.0x10^9/l or with extramedullary disease (excluding active disease of the central nervous system)\r\n* Acute lymphoblastic leukemia (ALL) with any of the following:\r\n** In CR1 with high-risk features defined by any of the following cytogenetic abnormalities, including Ph+, t(4;11), 11q23 abnormalities, or t(1;9)\r\n** Patients in second or subsequent complete remission (CR2, CR3, etc.)\r\n** Primary refractory or relapsed ALL with peripheral blood blasts < 2.0x10^9/l or with extramedullary disease (excluding active disease of the central nervous system)\r\n* Myelodysplasia with any of the following features: \r\n** Refractory anemia with excess blasts with 11-20% blasts in the bone marrow (RAEB II)\r\n** Refractory anemia with excess blasts with 5-10% blasts (RAEB I) and poor risk cytogenetics (i.e., chromosome 7 abnormalities or complex karyotype with at least 3 abnormalities per clone)\r\n** Refractory cytopenia with multilineage dysplasia (RCMD) and poor risk cytogenetics (i.e., chromosome 7 abnormalities or complex karyotype with at least 3 abnormalities per clone)\r\n* Chronic myelogenous leukemia (CML) with one of the following criteria:\r\n** Accelerated phase, defined by any of the following:\r\n*** Blasts 10-19% of peripheral blood white cells or bone marrow cells\r\n*** Peripheral blood basophils at least 20%\r\n*** Persistent thrombocytopenia (< 100 x 10^9/l) unrelated to therapy, or persistent thrombocytosis (> 1000 x 10^9/l) unresponsive to therapy \r\n*** Increasing spleen size and increasing white blood cell (WBC) count unresponsive to therapy\r\n*** Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase)\r\n*** Resistance to tyrosine kinase inhibitors (e.g., imatinib, dasatinib, nilotinib) defined as no complete cytogenetic response even if the above criteria are not met\r\n** First chronic phase provided a complete hematologic remission was not achieved by 3 months or a complete cytogenetic remission by 18 months and the patient had received in addition to imatinib 400 mg daily at least one of the following options: a) imatinib 600-800 mg daily, b) nilotinib, or c) dasatinib\r\n** Second or subsequent chronic phase provided a complete hematologic remission was not achieved by 3 months or a major cytogenetic remission (< 35 % Philadelphia chromosome + metaphases) by 6 months and the patient had received in addition to imatinib 400 mg daily at least one of the following options: a) imatinib 600-800 mg daily, b) nilotinib, or c) dasatinib\r\n* Patients with aggressive non-Hodgkin’s lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma, who also have one of the following criteria:\r\n** Failure to achieve complete remission to primary induction therapy\r\n** Relapsed and refractory to at least one line of salvage systemic therapyXx_NEWLINE_xXPatients must have chronic phase chronic myeloid leukemia (CML); they must also be under treatment with nilotinib as either first, second or third-line therapyXx_NEWLINE_xXAcute or chronic pancreatitisXx_NEWLINE_xXHematologic malignancies diagnoses:\r\n* Acute lymphoblastic leukemia (ALL) with a history of bone marrow relapse in clinical remission (CR) #2 or greater, or in CR#1 if prior induction failure; or with an M1 marrow if unable to achieve CR\r\n* Philadelphia chromosome positive ALL patients who:\r\n** Have progressed through or relapsed following tyrosine kinase inhibitor (TKI) therapy or conventional myeloablative therapy OR\r\n** Are ineligible to receive tyrosine kinase inhibitor (TKI) therapy AND myeloablative hematopoietic stem cell transplant (HSCT)\r\n* Acute myelogenous leukemia (AML) with a history of bone marrow relapse in remission CR #2 or greater; or with an M1 marrow if unable to achieve CR; or in CR#1 if prior induction failure; or any of the following high-risk categories:\r\n** FMS-like tyrosine kinase 3/internal tandem duplication positive (FLT3/ITD+) with high allelic ratio > 0.4 (HR FLT3/ITD+) regardless of low risk features\r\n** Presence of monosomy 7, monosomy 5, or deletion (del)5q, without inversion (inv)(16)/t(16;16) or t(8;21) cytogenetics or nucleophosmin (NPM) or CCAAT enhancer-binding protein (CEBP) alpha mutations\r\n** AML without inv(16)/t(16;16), t(8;21), NPM, CEPB alpha mutations, monosomy 7, monosomy 5, del5q, or HR FLT3/ITD+, but with evidence of residual AML (>= 0.1%) at end of induction I\r\n* Hodgkin’s and non-Hodgkin’s lymphoma with refractory disease or relapse after at least one salvage regimen, or after autologous stem cell transplant\r\n* Juvenile myelomonocytic leukemia (JMML) with < 10% blasts in marrow and blood, who are not eligible for effective standard therapies\r\n* Chronic myelogenous leukemia (CML) with history of blast crisis (ALL/AML) or progressive disease failing tyrosine-kinase inhibitor (TKI)Xx_NEWLINE_xXSubjects with untreated AML, if not candidates for standard induction chemotherapy or with poor risk AML (i.e. preceding myelodysplastic syndromes [MDS], myeloproliferative syndromes, leukemia due to cytotoxic chemotherapy for another condition, adverse cytogenetics or complex karyotype), acute promyelocytic leukemia (French-American-British [FAB] M3) is excludedXx_NEWLINE_xXAcute promyelocytic leukemia (FAB M3)Xx_NEWLINE_xXPatients with evidence of myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) or abnormal cytogenetics analysis indicative of MDS on the pre-transplant bone marrow examinationXx_NEWLINE_xXChronic lymphocytic leukemia\r\n* Relapse post-fludarabine\r\n* Non-complete remission (CR) after salvage regimenXx_NEWLINE_xXAcute myelogenous leukemia\r\n* CR #1 and “high-risk” (excludes t[8;21], t[15;17], or inv[16])\r\n* CR #2 or greaterXx_NEWLINE_xXAcute lymphocytic leukemia\r\n* CR #1 + “high-risk” (t[9;22] or bcr-abl+; t[4;11], 1[1;19], t[8;14])\r\n* In CR #2 or greaterXx_NEWLINE_xXChronic myelogenous leukemia (CML)\r\n* Chronic phase CML, refractory to imatinib treatment\r\n* Accelerated phase CMLXx_NEWLINE_xXPatients with acute leukemia must have chemotherapy sensitive disease, as defined by at least a 50% reduction in circulating absolute blast count due to the most proximal regimenXx_NEWLINE_xXPatients must have at least one of the following high-risk conditions listed below (criteria are consistent with existing criteria within Children's Oncology Group [COG] protocols):\r\n* Acute lymphocytic leukemia (ALL) in first complete remission (CR1) as defined by at least one of the following:\r\n** Hypodiploidy\r\n** Induction failure\r\n** Minimal residual disease (MRD) after consolidation\r\n* Acute myeloid leukemia (AML) in CR1 with high risk features defined as:\r\n** High allelic ratio fms-related tyrosine kinase 3 (FLT3)/internal tandem duplications (ITD) positive (+)\r\n** Monosomy 7\r\n** Del (5q)\r\n** Standard risk cytogenetics with positive minimal residual disease at the end of Induction I chemotherapy (for patients being treated on or according to COG AAML1031 who have had MRD studies sent to Seattle or performed at their local institution where the flow assay is sensitive enough to detect >= 0.1% blasts)\r\n* Acute leukemias in 2nd or subsequent complete remission (CR) (CR >= 2)\r\n* Mixed phenotype/undifferentiated leukemias in 1st or subsequent CR\r\n* Secondary or therapy related leukemias in CR >= 1\r\n* Natural killer (NK) cell leukemia or NK cell lymphoblastic leukemia/lymphoma CR >= 1\r\n* Myelodysplastic syndrome (MDS)\r\n* Juvenile myelomonocytic leukemia (JMML) (patients are eligible if they are not eligible for COG1221)\r\n* Prior transplant eligible if =< 18 years old (yo), >= 1 year has elapsed since BMT, and patient is off immunosuppression for >= 3 months with no GVHD; patients who have had a prior chemotherapy based preparative regimen are allowed to receive a TBI based prep, regardless of their disease\r\n* No known active central nervous system (CNS) involvement or extramedullary involvement by malignancy; such disease treated into remission is permitted\r\n* Remission is defined as morphology with < 5% blasts with no morphological characteristics of acute leukemia (e.g., Auer Rods) in a bone marrow with > 20% cellularityXx_NEWLINE_xXSubject has a diagnosis of primary acute myeloid leukemia (AML) or AML secondary to myelodysplastic syndrome (MDS) according to WHO classification (2008) as determined by pathology review at the treating institute.Xx_NEWLINE_xXSubject was diagnosed as acute promyelocytic leukemia (APL).Xx_NEWLINE_xXSubject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).Xx_NEWLINE_xXAcute Promyelocytic Leukemia (AML subtype M3).Xx_NEWLINE_xXSubject has Relapsed or Refractory Acute Myeloid Leukemia (rrAML) after at least 2 prior induction attempts:Xx_NEWLINE_xXSubject has French-American-British classification (FAB) type M3 leukemia (acute promyelocytic leukemia) or identification of t(15;17).Xx_NEWLINE_xXPatients with life-threatening acute leukemia (high-risk ALL in 1st CR, ALL in 2nd CR, high-risk AML in 1st CR, AML in 2nd CR.) or myelodysplastic syndromes. Morphological CR must be documented and minimal residual disease measurement before transplantation is recommended.Xx_NEWLINE_xXKnown history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)Xx_NEWLINE_xXPatients must not have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).Xx_NEWLINE_xXPatients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [surface Immunoglobulin (sIg) positive and kappa or lambda restricted positivity] ALL, with FAB L3 morphology and /or a MYC translocation)Xx_NEWLINE_xXSubjects must have confirmation of Acute Myeloid Leukemia (AML) by WHO criteria and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidity or other factors.Xx_NEWLINE_xXSubject has acute promyelocytic leukemia.Xx_NEWLINE_xXSubject has known acute or chronic pancreatitis.Xx_NEWLINE_xXUnequivocal diagnosis of AML based on the WHO classification, excluding acute promyelocytic leukemiaXx_NEWLINE_xXThe patient has a diagnosis of AML or BPDCN according to WHO classification (AML; excluding acute promyelocytic leukemia [APL, FAB M3]) or confirmed by hematopathology (BPDCN)Xx_NEWLINE_xXThe patient has a diagnosis of AML or BPDCN according to WHO classification (AML; excluding acute promyelocytic leukemia [APL, FAB M3]) or confirmed by hematopathology (BPDCN)Xx_NEWLINE_xXThe patient has a diagnosis of acute promyelocytic leukemia (APL; FAB M3).Xx_NEWLINE_xXAcute promyelocytic leukemia (FAB M3 classification)Xx_NEWLINE_xXPlasma cell leukemia, primary amyloidosis or POEMS syndromeXx_NEWLINE_xXActive plasma cell leukemiaXx_NEWLINE_xXHave acute T-cell lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL).Xx_NEWLINE_xXPatients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [sIg positive and kappa or lambda restricted positivity] ALL, with FAB L3 morphology and /or a MYC translocation)Xx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXAcute leukemia of ambiguous lineage (biphenotypic leukemia)Xx_NEWLINE_xXNewly diagnosed, histologically confirmed de novo AML or AML secondary to prior myelodysplastic disease or CMML (Chronic myelomonocytic leukemia)Xx_NEWLINE_xXParticipants with hematologic malignancies or hematologic disorders for whom allogeneic stem cell transplantation is deemed clinically appropriate; eligible diseases and stages include:\r\n* Non-Hodgkin's lymphoma, or Hodgkin's lymphoma in second (2nd) or subsequent complete remission or in partial remission with documented chemosensitivity to the most recent chemotherapy regimen; prior autologous transplantation is required, unless deemed medically inappropriate by the treating physician\r\n* Multiple myeloma: relapsed but with chemosensitive disease; bone marrow plasma cells may not exceed 20% of the total cellularity\r\n* Chronic lymphocytic leukemia: any Rai stage III or IV, lymphocyte doubling time of 6 months, or stage I-II with progression after >= 2 chemotherapy regimens, in partial remission with documented chemosensitivity to the most recent chemotherapy regimen\r\n* Acute myelogenous or acute lymphoblastic leukemia in second or subsequent complete remission or in first remission with adverse cytogenetic/molecular features or a documented antecedent hematologic disorder\r\n* Myelodysplastic disorder\r\n* Myeloproliferative disorder including myelofibrosis, chronic myelogenous leukemia resistant to tyrosine kinase inhibitors\r\n* Aplastic anemia with no response to immunosuppressive therapyXx_NEWLINE_xXCentral confirmation of the categorization of the MDS risk classification, as per the Revised - International prognostic scoring system (IPSS-R) Intermediate risk with >10% blasts or poor or very poor cytogenetics, or IPSS-R High or Very High risk (Results of central pathology review required prior to receiving the first dose of IP). Acute myeloid leukemia (AML) Cohort:Xx_NEWLINE_xXCentral confirmation of intermediate or poor risk status, based on Cytogenetics for Acute Myeloid Leukemia.Xx_NEWLINE_xXSuspected or proven acute promyelocytic leukemia (French-American-British (FAB) M3) based on morphology, immunophenotype, molecular assay, or karyotype; AML associated with t(9;22) karyotype, biphenotypic acute leukemia or AML with previous hematologic disorder such as chronic myelogenous leukemia or myeloproliferative neoplasms.Xx_NEWLINE_xXAcute myeloid leukemia associated with inv(16), t(8;21), t(16;16), t(15;17) karyotypes or molecular evidence of such translocations if not associated with a c-Kit mutation.Xx_NEWLINE_xXActive plasma cell leukemiaXx_NEWLINE_xXPOEMS syndrome, Plasma cell leukemia, Waldenstrom's macroglobulinemia or AmyloidosisXx_NEWLINE_xXDiagnosis of Burkitt's Leukemia, or lymphoid blast crisis of chronic myelogenous leukemia (CML)Xx_NEWLINE_xXCohort 4: Participants must have chronic lymphocytic leukemia.Xx_NEWLINE_xXHave malabsorptive syndromes, enteropathies, gastroenteritis (acute or chronic), or diarrhea (acute or chronic).Xx_NEWLINE_xXFor patients registered to the relapsed/refractory cohort (Cohort 2), patients must have a previous morphologically confirmed diagnosis of acute myeloid leukemia (AML)\r\n* For patients registered to the myelodysplastic syndromes (MDS) transformed to AML cohort (Cohort 1), patients must have a previous morphologically confirmed diagnosis of MDS/chronic myelomonocytic leukemia (CMML); patients may have received previous non-intensive therapy (e.g. azacitidine, decitabine, low-dose cytarabine [LDAC], lenalidomide) given for treatment of MDS/CMML (with up to 20% blasts); at the time of registration they must have a morphologically confirmed diagnosis of AML\r\n* Note: This protocol uses the World Health Organization (WHO) diagnostic criteria for AML; patients with acute promyelocytic leukemia (APL, French American British [FAB], M3) or blastic transformation of chronic myelogenous leukemia are not eligibleXx_NEWLINE_xXAtypical chronic myeloid leukemia (CML): Philadelphia chromosome-negative patients with a diagnosis of atypical CMLXx_NEWLINE_xXDiagnosis of acute myeloid leukemia (AML) or high or very high-risk MDS by International Prognostic Scoring System revised for whom transplant is recommendedXx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL)Xx_NEWLINE_xXPlasma cell leukemia, primary amyloidosis or POEMS syndromeXx_NEWLINE_xXAcute Promyelocytic LeukemiaXx_NEWLINE_xXAcute myeloid leukemia (AML)Xx_NEWLINE_xXNo Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDSXx_NEWLINE_xXA history of other primary invasive malignancy that has not been in remission for at least 3 years or a current diagnosis of myelodysplastic syndrome (MDS) or an immature leukemia such as acute myeloid leukemia (AML)Xx_NEWLINE_xXPatient has concurrent symptomatic amyloidosis or plasma cell leukemiaXx_NEWLINE_xXPathologically confirmed, relapsed or refractory acute myelogenous leukemiaXx_NEWLINE_xXCD30 expressing acute myeloid leukemia (AML), as identified by flow cytometric analysis, or by immunohistochemistry when 2+ or 3+ staining is present in greater than or equal to 20% of the myeloblasts in the bone marrow specimenXx_NEWLINE_xXDiagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXThe diagnosis of AML-M3 (acute promyelocytic leukemia) characterized by translocations involving the retinoic acid receptor-alpha (RAR-alpha) geneXx_NEWLINE_xXAML M3 Acute Promyelocytic Leukemia (APL) or patients with a t(9:22) cytogenetic translocation.Xx_NEWLINE_xXKnown symptomatic acute or chronic pancreatitis.Xx_NEWLINE_xXB-ALL patients with testicular leukemia are not eligible for AALL0932Xx_NEWLINE_xXPatients must have morphologically confirmed newly diagnosed acute myelogenous leukemia (AML) with blood or bone marrow disease; patients with only extramedullary disease in the absence of bone marrow or blood involvement are eligible; note: this protocol uses World Health Organization (WHO) diagnostic criteria for AML; patients with acute promyelocytic leukemia (APL, French-American-British Classification [FAB], M3) or blastic transformation of chronic myelogenous leukemia (CML) are not eligibleXx_NEWLINE_xXPatients who have received prior induction chemotherapy for AML or myelodysplastic syndrome (MDS); temporary prior measures such as apheresis or hydroxyurea are allowed; patients who have received a limited and short-term exposure of ATRA (all trans retinoic acid) while AML-M3 (acute promyelocytic leukemia) was being ruled out, and which has been discontinued, will be eligibleXx_NEWLINE_xXPatients presenting with an AHNMD requiring immediate cytoreductive therapy or targeted drugs (e.g. acute myeloid leukemia [AML])Xx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXPlasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)Xx_NEWLINE_xXRelapsed acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) >= 60 days after allogeneic stem cell transplant (SCT)Xx_NEWLINE_xXTo be considered at high risk for induction mortality patients must have 1 or 2 of the following risk factors (patients >= 60 must have at least 1 risk factor, patients < 60 must have at least 2 risk factors) present; at least one risk factor in every patient must be an AML-related factor: \r\n* AML-related factors include: \r\n** Antecedent hematologic disorder (AHD) (MDS, chronic myelomonocytic leukemia [CMML], or MPD) or history of exposure to cytotoxic chemotherapy [therapy-related (t)-AML]), or WHO-defined AML with MDS-related changes or apparent de novo AML with MDS-associated karyotype\r\n** Unfavorable cytogenetics as defined by the European Leukemia Net\r\n* Patient-related factors:\r\n** Age >= 70\r\n** ECOG performance status (PS) >= 2\r\n* Co-morbidities:\r\n** Serum creatinine > 1.3 g/dLXx_NEWLINE_xXPatients with acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) with relapsed or refractory disease who are not eligible for stem cell transplantation or other standard therapiesXx_NEWLINE_xXPatients with acute promyelocytic leukemia are excludedXx_NEWLINE_xXMyeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatmentXx_NEWLINE_xXINCLUDING: any non-Hodgkin's B cell malignancy such as chronic lymphocytic leukemia (CLL) and rare non-Hodgkin's B- cell subtypes such as hairy cell leukemia, Waldenström macroglobulinemia (WM), mantle cell leukemia (MCL), and transformed NHL histologiesXx_NEWLINE_xXAdults with acute myeloid leukemia (AML), excluding the M3 subtype (acute promyelocytic leukemia), that are not likely to respond to conventional therapy, including:\r\n* Relapsed or refractory AML after one to four prior induction regimens (not counting consolidation therapies while in complete response [CR], and not counting autologous transplant while in CR),\r\n* Newly diagnosed AML patient’s age not fit for standard therapyXx_NEWLINE_xXPatients must be newly diagnosed with de novo acute myelogenous leukemiaXx_NEWLINE_xXPatients with any of the following oncologic diagnoses are not eligible:\r\n* Any concurrent malignancy\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Philadelphia chromosome positive AML\r\n* Biphenotypic or bilineal acute leukemia\r\n* Acute promyelocytic leukemia\r\n* Acute myeloid leukemia arising from myelodysplasia\r\n* Therapy-related myeloid neoplasms\r\nNote: enrollment may occur pending results of clinically indicated studies to exclude these conditionsXx_NEWLINE_xXAcute or chronic pancreatic diseaseXx_NEWLINE_xXRelapsed/refractory AML (>= 5% blasts in bone marrow or extramedullary leukemia) or newly diagnosed AML patients who are not candidates for (age >= 70 years; adverse cytogenetics, e.g., as defined by the Medical Research Council [MRC] Prognostic Groupings; secondary AML; organ dysfunction arising from significant co-morbidities not directly linked to leukemia; Eastern Cooperative Oncology Group [ECOG] = 2) or not willing to undergo intensive chemotherapy; Note that both relapsed/refractory and newly diagnosed AML patients will be eligible for the dose escalation part of the study, but only newly diagnosed patients will be eligible for the dose expansion cohortXx_NEWLINE_xXAcute promyelocytic leukemia with t(15;17)(q22;q12) and/or PML-RARA molecular rearrangementXx_NEWLINE_xXPatients with a history of or active bone marrow disorders expected to interfere with study therapy (e.g. acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma)Xx_NEWLINE_xXPatients with myelodysplastic syndrome (MDS)/ treatment-related acute myeloid leukemia (t-AML) or with features suggestive of MDS/AMLXx_NEWLINE_xXAcute Leukemias or T lymphoblastic lymphoma in 1st or subsequent complete remission (CR): Acute lymphoblastic leukemia (ALL)/T lymphoblastic lymphoma; acute myelogenous leukemia (AML); acute biphenotypic leukemia (ABL); acute undifferentiated leukemia (AUL)Xx_NEWLINE_xXChronic myeloid leukemia (CML) in 1st or subsequent chronic phase characterized by <10% blasts in the blood or bone marrow.Xx_NEWLINE_xXSubject was diagnosed as acute promyelocytic leukemia (APL).Xx_NEWLINE_xXSubject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).Xx_NEWLINE_xXPatients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other bone marrow failure syndromes are not eligibleXx_NEWLINE_xXDose Escalation: Acute Promyelocytic LeukemiaXx_NEWLINE_xXHave active, relapsed or refractory Acute Myeloid Leukemia (AML). Active, relapsed or refractory AML is defined as either (1) primary induction failure (PIF) after 2 or more cycles of chemotherapy, (2 first early relapse after a remission duration of fewer than 6 months, (3) relapse refractory to salvage combination chemotherapy containing high-dose AraC, and (4) second or subsequent relapseXx_NEWLINE_xXHave acute promyelocytic leukemia and the associated cytogenic translocation t:(15/17)Xx_NEWLINE_xXRelapsed and/or primary refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) with subtype refractory anemia with excess blasts (RAEB)-2 defined as high or very high-risk that is recurrent or refractory, or the patient is intolerant to established therapy.Xx_NEWLINE_xXImmediately life-threatening, severe complications of leukemia.Xx_NEWLINE_xXDiagnosis of Burkitt's leukemia/lymphoma according to WHO classification or chronic myelogenous leukemia lymphoid blast crisisXx_NEWLINE_xXEligible diagnoses:\r\n* Myelodysplastic syndrome (MDS) including chronic myelomonocytic leukemia (CMML) with at least one of the following poor-risk features:\r\n** Poor-risk cytogenetics\r\n** International Prognostic Scoring System (IPSS) score of intermediate (INT)-2 of greater\r\n** Treatment-related or secondary MDS\r\n** MDS diagnosed before age 21\r\n** Progression on or lack of response to standard deoxyribonucleic acid (DNA)-methyltransferase inhibitor therapy\r\n** Life-threatening cytopenias, including those requiring frequent transfusions\r\n* Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) with 17p deletion, or with progression < 6 months after second or greater treatment regimen; must have the following to be an acceptable candidate as well:\r\n** =< 20% of bone marrow cellularity involved by SLL/CLL (to lower risk of graft rejection)\r\n** No lymph nodes >= 5 cm in any dimension\r\n** No massive splenomegaly, defined as > 6 cm below the left costal margin\r\n* T-cell prolymphocytic leukemia (PLL) in partial remission (PR) or better prior to transplantation; must also have =< 20% of bone marrow cellularity involved by PLL (to lower risk of graft rejection)\r\n* Interferon- or tyrosine kinase-refractory chronic myelogenous leukemia (CML) in first chronic phase, tyrosine kinase inhibitor (TKI)-intolerant CML in first chronic phase, or CML in second or subsequent chronic phase\r\n* Philadelphia chromosome negative myeloproliferative disease (including myelofibrosis)\r\n** Intermediate-2 or high risk score by Dynamic International Prognostic Scoring System (DIPSS) plus is required for a diagnosis of myelofibrosis\r\n* Multiple myeloma or plasma cell leukemia with a PR or better to the last treatment regimen, based on the International Myeloma Working Group (IMWG) criteria\r\n* Hematologic malignancy in complete remission with minimal residual disease (MRD) non detectable OR detectable by conventional cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, or molecular testing or hematologic malignancies in partial remissionXx_NEWLINE_xXKnown history of acute or chronic pancreatitisXx_NEWLINE_xXHas acute promyelocytic leukemia, clinically uncontrolled disseminated intravascular coagulation, or peripheral cytopeniaXx_NEWLINE_xX“High-risk SMM” per Mayo Clinic or Spanish PETHEMA (Treatment of Newly Diagnosed Patients with Acute Promyelocytic Leukemia) criteriaXx_NEWLINE_xXAcute or chronic pancreatic diseaseXx_NEWLINE_xXDiagnosis of AML-M3 (or acute promyelocytic leukemia)Xx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXPatients with acute leukemias, accelerated/blast phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myelomaXx_NEWLINE_xXPatients with one of the following diagnoses:\r\n* Acute myeloid leukemia (AML)\r\n* Acute lymphoblastic leukemia (ALL)\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Myelodysplastic syndrome (MDS)Xx_NEWLINE_xXAlanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x IULN except when in the opinion of treating physician is due to direct involvement of leukemia (e.g. hepatic infiltration or biliary obstruction due to leukemia) or Gilbert's diseaseXx_NEWLINE_xXTotal bilirubin =< 2 x IULN except when in the opinion of treating physician is due to direct involvement of leukemia (e.g. hepatic infiltration or biliary obstruction due to leukemia) or Gilbert’s diseaseXx_NEWLINE_xXAcute promyelocytic leukemia (AML with t[15;17][q22;q11] and variants)Xx_NEWLINE_xXPlasma cell leukemia (> 2.0 × 109/L circulating plasma cells by standard differential)Xx_NEWLINE_xXParticipants may not have any features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXParticipant has acute promyelocytic leukemia (French-American-British Class M3 AML).Xx_NEWLINE_xXSubject has a history of myeloproliferative neoplasm (MPN) including polycythemia vera, myelofibrosis, essential thrombocythemia, or chronic myelogenous leukemia.Xx_NEWLINE_xXAdults with pathologically confirmed acute myelogenous leukemia, in pathologically confirmed complete remission; patients with refractory anemia with excess blasts-2 (RAEB-2), who are in remission following therapy, can also be eligibleXx_NEWLINE_xXDiagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXActive refractory or relapsed acute leukemiaXx_NEWLINE_xXConfirmed Philadelphia Chromosome positive Chronic Myeloid Leukemia or Confirmed BCR-ABL1 (Abelson-break point cluster) Positive if Philadelphia Chromosome negative Chronic Myeloid Leukemia (from initial diagnosis).Xx_NEWLINE_xXAny Chronic Myeloid Leukemia disease phase, as long as the patient is unable to receive treatment with imatinib, dasatinib and/or nilotinib for any reason.Xx_NEWLINE_xXRefractory or relapsed chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) or non-Hodgkin lymphoma (NHL) (including those of T cell origin)Xx_NEWLINE_xXAcute promyelocytic leukemia (APL, M3) unless failed regimens that included tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT candidates for stem cell transplantationXx_NEWLINE_xXPatients with acute promyelocytic leukemia (French-American-British Cooperative group [FAB] M3)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed: \r\n* Pathologically confirmed intermediate or poor risk newly diagnosed AML (subtypes M0, 1, 2, 4-7), but excluding newly diagnosed core-binding factor (CBF) (t(8;21) or M4eo subtype (inv(16) or t(16;16) AMLs and acute promyelocytic leukemia (acute promyelocytic leukemia [APL], M3)\r\n* MDS with high risk features as defined by intermediate (INT)-2 or high International Prognostic Scoring System (IPSS) score with > 10% blasts in the bone marrow\r\n* Chronic myelomonocytic leukemia-2 (CMML-2) defined as having > 10% blasts (including promonocytes) in the bone marrow or 5-19% blasts (including promonocytes) in the peripheral bloodXx_NEWLINE_xXRichter's Syndrome and Prolymphocytic Leukemia Transformation only: biopsy proven DLBCL Richter's transformation or prolymphocytic leukemia transformation.Xx_NEWLINE_xXNo plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)Xx_NEWLINE_xXAcute promyelocytic leukemia [t(15;17)]Xx_NEWLINE_xXConfirmed diagnosis of Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase :Xx_NEWLINE_xXHistory of Richter's transformation or prolymphocytic leukemiaXx_NEWLINE_xXSubject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to WHO classification (2008) documented within 28 days prior to enrollment.Xx_NEWLINE_xXSubject was diagnosed as acute promyelocytic leukemia (APL) or AML with good risk cytogenetics; t(8;21), inv(16) or t(16;16). (Subjects with pending cytogenetics that require treatment may enroll. Any subject that is found to have good risk cytogenetics after initiation of treatment will discontinue ASP2215 and be taken off trial).Xx_NEWLINE_xXSubject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).Xx_NEWLINE_xXPlasma cell leukemia (> 20% circulating plasma cells) during screening studiesXx_NEWLINE_xXPatients with myelodysplastic syndrome/acute leukemia or with features suggestive thereof.Xx_NEWLINE_xXHas a history of acute or chronic pancreatitisXx_NEWLINE_xXTreatment-related AML or acute promyelocytic leukemia (APL)Xx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXAcute myeloid leukemia (AML) diagnosed by morphologic, histochemical or cell surface marker criteria.Xx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXPatients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation and have one of the following diagnoses:\r\n* Acute lymphocytic leukemia in first or subsequent remission\r\n* Acute myeloid leukemia in first or subsequent remission \r\n* Acute lymphocytic leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3\r\n* Acute myeloid leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 \r\n* Refractory anemia with excess blasts (RAEB-1 and RAEB-2) \r\n* Chronic myelogenous leukemia with a history of accelerated phase or blast crisis\r\n* Other acute leukemia (including but not limited to ‘biphenotypic’, ‘undifferentiated’ or ‘ambiguous lineage’ acute leukemia)Xx_NEWLINE_xXAcute myelogenous leukemia (AML) in complete morphological remission at study screening (Complete Remission with Incomplete Platelet Recovery (CRp) acceptable).Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL) in complete morphological remission at study screening (Complete Remission with Incomplete Platelet Recovery (CRp) acceptable).Xx_NEWLINE_xXPatients with chronic myelogenous leukemia (CML) in myeloid blast crisis are eligible if their disease has failed to respond, and/or they are intolerant, to the available tyrosine kinase inhibitors (TKIs)Xx_NEWLINE_xXPatients with high risk myeloid or lymphoid malignancies at stem cell transplant following American Society for Blood and Marrow Transplantation (ASBMT) criteria, including but not limited to conditions listed; these criteria apply BEFORE cyto-reductive therapy given within 28 days of planned conditioning:\r\n* Refractory acute myelogenous or lymphoid leukemia\r\n* Relapsed acute myelogenous or lymphoid leukemia\r\n* Myelodysplastic syndromes with 5% or more blasts\r\n* Chronic myelogenous leukemia in chronic phase 3 or more, blast phase presently, or second accelerated phase\r\n* Recurrent or refractory malignant lymphoma or Hodgkin’s disease with less than a partial response at transplant\r\n* High risk chronic lymphocytic leukemia defined as no response or stable disease to the most recent treatment regimen\r\n* Diseases in response or remission at high risk of relapse at the discretion of the attending physician: some examples include but are not limited to:\r\n** Acute myeloid leukemia (AML) in remission with monosomy 5 or 7, deletion of 5q or 7q, 11q23 mixed-lineage leukemia (MLL) rearrangement or complex karyotype (>= 3 chromosome abnormalities)\r\n** Non-Hodgkin's lymphoma (NHL) in response that is double hit or triple hit (which are characterized by a recurrent chromosome translocation in combination with a v-myc avian myelocytomatosis viral oncogene homolog [MYC]/8q24 breakpoint; these include but not limited to B-cell chronic lymphocytic leukemia [CLL]/lymphoma [BCL]2+/MYC+; BCL6+/MYC+; cyclin D1 (CCND1)+/MYC+; and BCL2+/BCL6+/MYC+)\r\n** Bi-phenotypic lineage leukemia\r\n** CLL with 17p deletion\r\n** Acute lymphoblastic leukemia (ALL) with t(4,11) et al.Xx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL)Xx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXPatients with acute promyelocytic leukemiaXx_NEWLINE_xXPatients must have histologic evidence of newly diagnosed acute myeloid leukemia (non-M3 AML) as documented by the presence of > 20% myeloid blasts in the bone marrow or a pathological diagnosis of granulocytic sarcoma, leukemia cutis or other pathologically confirmed extramedullary involvement of AMLXx_NEWLINE_xXSubjects with acute promyelocytic leukemia (APL) - French-American-British Cooperative group (FAB) M3 (t(15;17)(q22;q21)[promyelocytic leukemia (PML)-retinoic acid receptor (RAR)]) are not eligibleXx_NEWLINE_xXAcute or chronic pancreatic diseaseXx_NEWLINE_xXDiagnosis of AML-M3 (or acute promyelocytic leukemia)Xx_NEWLINE_xXDiagnosis of acute or chronic pancreatitisXx_NEWLINE_xXHistologically or cytologically confirmed advanced and/or aggressive hematologic malignancy (including acute myeloid leukemia [AML] in complete remission [CR] and myelodysplastic syndrome with < 10% blasts in the bone marrow) unlikely to be cured by alternative therapiesXx_NEWLINE_xXCytologically/histologically confirmed acute myeloid leukaemia (AML) according to WHO classification; (except for acute promyelocytic leukaemia (APL).Xx_NEWLINE_xXDe novo or secondary International Prognostic Scoring System (IPSS) low- or intermediate-1- risk myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML)Xx_NEWLINE_xXAcute or chronic pancreatitisXx_NEWLINE_xXPatient has acute promyelocytic leukemia (APL).Xx_NEWLINE_xXPatients must have a diagnosis of AML or acute leukemia of ambiguous lineage according to World Health Organization (WHO) classification with >= 5% of disease in bone marrow (BM); patients with blast count < 5% are eligible if immunophenotype, molecular or cytogenetic signature are consistent with AML as determined by primary treating oncologist; patients with extramedullary disease, or biopsy-proven isolated myeloid sarcoma (myeloblastoma, chloroma, including leukemia cutis) are eligible regardless of marrow involvementXx_NEWLINE_xXAML or acute leukemia of ambiguous lineage:\r\n* If relapse AML or acute leukemia of ambiguous lineage:\r\n** Must have a prior diagnosis of AML or acute leukemia of ambiguous lineage and be in 1st or greater relapse as evidenced by morphology, immunophenotype, molecular or cytogenetic signature\r\n** Must not have received prior reinduction therapy for this relapse\r\n* If primary refractory AML or acute leukemia of ambiguous lineage:\r\n** Must have had a prior diagnosis of AML or acute leukemia of ambiguous lineage and\r\n** Must not have received more than 3 previous induction attempts\r\n* If primary AML or acute leukemia of ambiguous lineage newly diagnosed or in remission\r\n** Primary treating oncologist must have deemed patient unable to complete standard treatment therapy and selected FLAG as appropriate alternative regimen\r\n* If prior diagnosis of acute lymphoblastic leukemia must have evidence of transformation to AML or acute leukemia of ambiguous lineage as evidenced by morphology, immunophenotype, molecular or cytogenetic signature\r\n* Patients meeting above criteria are eligible regardless of central nervous system (CNS) classificationXx_NEWLINE_xXAcute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21) or inv16 if known at the time of randomization.Xx_NEWLINE_xXDisease associated with secondary MF such as metastatic carcinoma, lymphoma, myelodysplasia, hairy cell leukemia, mast cell disease or acute leukemia (including M7 disease or acute panmyelosis with MF)Xx_NEWLINE_xXAcute myeloid leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia\r\n* All patients must have acute myeloid leukemia (AML) that is considered best treated by stem cell transplant by the referring physician and the attending transplant physician\r\n* All patients must be in complete remission (CR) as defined by < 5% blasts by morphology/flow cytometry in a representative bone marrow sample with cellularity >= 15% for age\r\n* Patients in which adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the principal investigator prior to enrollmentXx_NEWLINE_xXAcute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia\r\n* High risk first complete remission (CR1) (for example, but not limited to: t(9;22), t(1;19), t(4;11) or other mixed-lineage leukemia [MLL] rearrangements, hypodiploid); or high risk (HR) as defined by referring institution treatment protocol greater than 1 cycle to obtain CR; second complete remission (CR2) or greater\r\n* All patients must be in CR as defined by < 5% blasts by morphology/flow cytometry in a representative bone marrow sample with cellularity >= 15% for age\r\n* Patients in which adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the principal investigator prior to enrollmentXx_NEWLINE_xXChronic myelogenous leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to tyrosine kinase inhibitor therapyXx_NEWLINE_xXThe patient must not have acute promyelocytic leukemia or t(15;17) observed by FISHXx_NEWLINE_xXDiagnosis of relapsing/refractory or previously untreated chronic lymphocytic leukemiaXx_NEWLINE_xXDiagnosis of high risk hematological malignancy:\r\n* Any acute leukemia in first complete remission (CR) considered at high risk for relapse, or second or third CR, or relapse/refractory less than 10% blasts in bone marrow, or aplasia post-therapy; this includes de novo acute leukemia or acute leukemia that is therapy related or arising from an antecedent hematologic disorder including myelodysplasia (MDS), chronic myeloid leukemia (CML) or other myeloproliferative disorder\r\n* Juvenile myelomonocytic leukemia (JMML) in CR, or relapse with less than 10% bone marrow blasts \r\n* CML with tyrosine kinase inhibitor failure in chronic or accelerated phase or evolved to acute leukemia (blast crisis, see above)\r\n* MDS or other myeloproliferative disorder with life-threatening cytopenia(s), and/or red blood cell or platelet transfusion dependence, or patients with aplasia, or patients with excess blasts less than 10% blasts in the bone marrow at work-up\r\n* Aggressive lymphoma: patients in first complete remission (CR1) with disease at high risk of relapse or CR2-3 \r\n* Indolent lymphoma or chronic lymphocytic leukemia (CLL): any disease status provided any transformed component is in CR\r\n* Hodgkin lymphoma that is primary refractory or relapsed not suitable for other therapy and in partial remission (PR) or CR or small volume stable diseaseXx_NEWLINE_xXAcute myelogenous leukemia diagnosed by World Health Organization (WHO) criteria with one of the following:\r\n* Primary refractory disease following >= 1 cycle of induction chemotherapy\r\n* First relapse or higher; patients with primary or secondary acute myelogenous leukemia are eligible; patients with biphenotypic leukemia are eligibleXx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXRecipients of first ASCT from related or unrelated donor for the treatment of hematologic malignancies (acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome, Hodgkin and non-Hodgkin lymphoma) who are 1-antigen or 1-allele mismatched or fully matched at human leukocyte antigen (HLA)-A, -B, -C and –DR as defined by high resolution typingXx_NEWLINE_xXSubjects with plasma cell leukemia (PCL)Xx_NEWLINE_xXEnrolled in University Of Minnesota study MT2001-10 “Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy” and fitting into one of the following disease categories:\r\n* Acute myelogenous leukemia - high risk first complete remission (CR1) (as evidenced by preceding myelodysplastic syndrome [MDS], intermediate to high risk cytogenetics, >= 2 cycles to obtain complete remission (CR), erythroblastic or megakaryocytic leukemia; second complete remission (CR2)+; all patients must be in CR as defined by hematological recovery (absolute neutrophil count [ANC] > 0.5 x 10^9/L), AND < 5% blasts by light microscopy within the bone marrow with a cellularity of >= 15%\r\n* Acute lymphocytic leukemia - high risk CR1 [t(9;22), t (1:19), t(4;11) or other mixed-lineage leukemia [MLL] rearrangements] or > 1 cycle to obtain CR; CR2+; all patients must be in CR as defined by hematological recovery (ANC > 0.5 x 10^9/L), AND < 5% blasts by light microscopy within the bone marrow with a cellularity of >= 15%\r\n* Chronic myelogenous leukemia all types except blast crisis (note treated blast crisis in chronic phase is eligible)\r\n* Non-Hodgkin lymphoma or Hodgkin’s lymphoma demonstrating chemosensitive disease\r\n* Myelodysplastic syndrome with severe pancytopenia, leading to either transfusion dependency or increased risk for infectionsXx_NEWLINE_xXPatients who are considered candidates for an allogeneic stem cell transplantation as treatment for any of the following hematologic disorders:\r\n* Acute leukemia\r\n* Myelodysplastic syndrome\r\n* Other myeloproliferative disorder (i.e. myelofibrosis, chronic myelomonocytic leukemia, or chronic myelogenous leukemia)\r\n* Non Hodgkin's lymphoma\r\n* Hodgkin's disease\r\n* Multiple myelomaXx_NEWLINE_xXDocumented plasma cell leukemia or known amyloidosis. (Plasma cell leukemia is defined as the presence of >20% plasma cells in the peripheral blood and an absolute plasma cell count of ?2000 muLXx_NEWLINE_xXCurrent acute or chronic myelogenous leukemiaXx_NEWLINE_xXPatients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS. Prior allogeneic bone marrow transplant or double umbilical cord blood transplantationXx_NEWLINE_xXPatients with high-risk hematologic malignancies with anticipated poor prognosis with non-transplant therapy, including those in remission or with induction failure and after treated or untreated relapse; diagnoses to be included are:\r\n* Acute myeloid leukemia\r\n* Acute lymphocytic leukemia\r\n* Chronic myeloid leukemia\r\n* Chronic lymphocytic leukemia\r\n* Myelodysplastic syndrome \r\n* Myeloproliferative syndromes\r\n* Non-Hodgkin lymphoma\r\n* Hodgkin lymphoma\r\n* Multiple myelomaXx_NEWLINE_xXFAB subtype M0 (minimally differentiated acute myeloblastic leukemia), M6 (acute erythroid leukemias, including erythroleukemia (M6a) and pure erythroid leukemia (M6b)), or M7 (acute megakaryoblastic leukemia)Xx_NEWLINE_xXUntreated histologically confirmed acute myeloid leukemia OR advanced myelodysplastic syndrome (intermediate [INT]-2 or High risk) not previously treated with anthracycline-based chemotherapy OR a therapy-related myeloid neoplasmXx_NEWLINE_xXAcute promyelocytic leukemia (French-American-British [FAB] M3 AML)Xx_NEWLINE_xXPatients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).Xx_NEWLINE_xXPrior treatment for chronic lymphocytic leukemia.Xx_NEWLINE_xXPatients with the diagnosis of Acute Myeloid or Lymphocytic Leukemia (AML or ALL) in first or second complete remission.Xx_NEWLINE_xXPatients with advanced myelodysplastic syndromes (MDS), including those with International Prognostic Scoring System (IPSS) Int-2 and high-risk disease with less than 10% marrow blasts and no circulating myeloblasts after most recent therapy. Patients with acute leukemia that develops from a pre-existing MDS must meet the inclusion criteria for patients with AML detailed above.Xx_NEWLINE_xXAcute or chronic pancreatic diseaseXx_NEWLINE_xXParticipants must have a diagnosis of chronic myelogenous leukemia as confirmed by fluorescent in situ hybridization (FISH) for BCR/ABL translocation and/or standard cytogenetics analysisXx_NEWLINE_xXHave an acute leukemiaXx_NEWLINE_xXMyelodysplastic syndrome criteria:\r\n* Diagnosis of MDS classifiable by the World Health Organization (WHO) system as:\r\n** Refractory anemia\r\n** Refractory cytopenia with multilineage dysplasia \r\n** MDS-unclassified\r\n** Refractory cytopenias with multilineage dysplasia and ringed sideroblasts, refractory anemia with excess blasts-1\r\n** Refractory anemia with excess blasts-2\r\n** Chronic myelomonocytic leukemia (CMML)\r\n** MDS transformed to acute leukemiaXx_NEWLINE_xXPatients with evolution to AML are required to be in a morphologic leukemia free-state with blasts < 5%Xx_NEWLINE_xXMyeloproliferative disorders to be included:\r\n* Idiopathic myelofibrosis\r\n* Polycythemia vera\r\n* Essential thrombocythemia\r\n* Chronic myelomonocytic leukemia\r\n* Chronic neutrophilic leukemia\r\n* Chronic eosinophilic leukemia\r\n* Philadelphia chromosome-negative chronic myelogenous leukemia (CML)\r\n* Hypereosinophilic syndrome\r\n* Systemic mastocytosisXx_NEWLINE_xXPatients with t-AML are required to be in a morphologic leukemia free-state with blasts < 5%Xx_NEWLINE_xXBi-phenotypic acute leukemiaXx_NEWLINE_xXPlasma cell leukemia at time of study entry.Xx_NEWLINE_xXBiphenotypic leukemiaXx_NEWLINE_xXPatients of all ages with newly diagnosed, previously untreated CD-20+ acute lymphoblastic leukemia (ALL), or lymphoblastic lymphoma, Burkitt leukemia/lymphoma or having achieved complete remission (CR) with one course of induction chemotherapyXx_NEWLINE_xXAcute or chronic renal disease or pancreatitisXx_NEWLINE_xXAcute lymphocytic leukemia\r\n* Adult: (>= 22 years) >= second complete remission (CR2) OR first CR (CR1) with a high risk feature:\r\n** Matched sibling donor for recipient treated on adult leukemia regimen\r\n** t(9:22) or breakpoint cluster region (bcr)-Abelson (abl)+; t(4:11), t(1:19), t(8:14), 11q23 (mixed lineage leukemia [MLL] rearrangements) complex cytogenetics (5 or more chromosomal abnormalities), hypodiploidy (< 44 chromosomes.; note that patients with acute lymphoblastic leukemia (ALL) blast crisis who emerge from chronic myelogenous leukemia (CML) are also eligible\r\n** Primary induction failure, defined as failure to achieve CR with primary induction chemotherapy\r\n** High white blood cell (WBC) (> 30,000 for B-cell ALL and > 100,000 for T-cell ALL) at diagnosis\r\n** Persistence of minimal residual disease despite induction chemotherapy\r\n* Pediatric (< 22 years): >= CR2 OR CR1 with high risk features\r\n** Matched sibling donor for recipient treated on adult leukemia regimen\r\n** Primary induction failure (M3 [> 25% with greater 200 cells counted] marrow at day 29), M2 (5-25% blasts with greater than 200 cells counted) bone marrow or minimal residual disease (MRD) > 1% at day 29 who then fail at day 43 with either M2 or M3 bone marrow (BM) or MRD > 1%\r\n** Persistent leukemia and t(9;22) (MRD > 1% day 29 or MRD > 0.01% end-consolidation)\r\n** 11q23 (MLL) rearrangements detected by cytogenetic or polymerase chain reaction (PCR) at initial diagnosis who are slow early responders (M2/M3 at day 14 or MRD > 0.01% at day 29)\r\n** Extreme hypodiploidy (< 44 chromosomes or deoxyribonucleic acid [DNA] index of < 0.81) detected by cytogenetic/ploidy analysisXx_NEWLINE_xXChronic myelomonocytic leukemiaXx_NEWLINE_xXChronic myelogenous leukemia who have failed second generation (2G)-tyrosine kinase inhibitors (TKI)Xx_NEWLINE_xXPatients must have advanced AML, ALL or high-risk MDS meeting one of the following descriptions:\r\n* AML or ALL beyond first remission (i.e., having relapsed at least one time after achieving remission in response to a treatment regimen)\r\n* AML or ALL representing primary refractory disease (i.e., having failed to achieve remission at any time following one or more prior treatment regimens)\r\n* AML evolved from myelodysplastic or myeloproliferative syndromes; or \r\n* MDS expressed as refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) by French-American-British (FAB) criteriaXx_NEWLINE_xXActive plasma cell leukemiaXx_NEWLINE_xXPatients with a diagnosis of chronic myelomonocytic leukemia (CMML)Xx_NEWLINE_xXKey Inclusion Criteria (Phase 1):\n\n        - Confirmed hematologic malignancy, including Acute Myeloid Leukemia (AML), Chronic\n        Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Acute Lymphocytic Leukemia\n        (ALL), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM), Myelofibrosis (MF),\n        Myeloproliferative Neoplasms (MPN) or MDS/MPN overlap diseases. (Once Phase 2 has started\n        subjects with AML will be eligible for inclusion in the Phase 1 portion of the study only\n        if their malignancy has been shown to have c-Cbl mutation, trisomy 3, trisomy 11, inv(16),\n        or elevated FLT3. [Other AML and subjects with MDS will no longer be eligible for\n        inclusion in the Phase 1 portion of the study]).\n\n        Key Inclusion Criteria (Phase 2):\n\n          -  Part A: AML or MDS patients with an acceptable level of EphA3 expression\n\n          -  Part B: MF patients with an acceptable level of EphA3 expression\n\n        Key Inclusion Criteria (Both Phases):\n\n          -  Confirmed hematologic malignancy refractory to or progressed following standard\n             treatments, or subjects not considered medically suitable to receive standard of care\n             treatment or who refuse standard of care treatment\n\n          -  Acceptable level of EphA3 expression\n\n          -  Eastern Cooperative Oncology Group (ECOG) ?1\n\n          -  Acceptable laboratory results\n\n        Key Exclusion Criteria (Both Phases):\n\n          -  For subjects with AML, more than 2 prior therapies for AML (induction and\n             consolidation with or without a hypomethylating agent given in a maintenance setting\n             are considered 1 therapy)\n\n          -  History of or current central nervous system (CNS) involvement that may increase risk\n             of bleeding\n\n          -  Recent major surgery\n\n          -  Ongoing surgical or wound healing complications\n\n          -  Active clinically significant bleeding\n\n          -  Uncontrolled hypertension\n\n          -  Significant intercurrent illness\n\n          -  Known history of prolonged bleeding times or platelet dysfunction\n\n          -  Active infection requiring IV antibiotics, IV antifungals, or IV antivirals within 2\n             weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXKey Inclusion Criteria (Phase 1):\n\n        - Confirmed hematologic malignancy, including Acute Myeloid Leukemia (AML), Chronic\n        Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Acute Lymphocytic Leukemia\n        (ALL), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM), Myelofibrosis (MF),\n        Myeloproliferative Neoplasms (MPN) or MDS/MPN overlap diseases. (Once Phase 2 has started\n        subjects with AML will be eligible for inclusion in the Phase 1 portion of the study only\n        if their malignancy has been shown to have c-Cbl mutation, trisomy 3, trisomy 11, inv(16),\n        or elevated FLT3. [Other AML and subjects with MDS will no longer be eligible for\n        inclusion in the Phase 1 portion of the study]).\n\n        Key Inclusion Criteria (Phase 2):\n\n          -  Part A: AML or MDS patients with an acceptable level of EphA3 expression\n\n          -  Part B: MF patients with an acceptable level of EphA3 expression\n\n        Key Inclusion Criteria (Both Phases):\n\n          -  Confirmed hematologic malignancy refractory to or progressed following standard\n             treatments, or subjects not considered medically suitable to receive standard of care\n             treatment or who refuse standard of care treatment\n\n          -  Acceptable level of EphA3 expression\n\n          -  Eastern Cooperative Oncology Group (ECOG) ?1\n\n          -  Acceptable laboratory results\n\n        Key Exclusion Criteria (Both Phases):\n\n          -  For subjects with AML, more than 2 prior therapies for AML (induction and\n             consolidation with or without a hypomethylating agent given in a maintenance setting\n             are considered 1 therapy)\n\n          -  History of or current central nervous system (CNS) involvement that may increase risk\n             of bleeding\n\n          -  Recent major surgery\n\n          -  Ongoing surgical or wound healing complications\n\n          -  Active clinically significant bleeding\n\n          -  Uncontrolled hypertension\n\n          -  Significant intercurrent illness\n\n          -  Known history of prolonged bleeding times or platelet dysfunction\n\n          -  Active infection requiring IV antibiotics, IV antifungals, or IV antivirals within 2\n             weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXA diagnosis of refractory or relapsed AML, or Ph+ CML (in chronic, accelerated or blast phase, or acute lymphoblastic leukemia, or myelodysplastic syndrome. One of the following parameters is required to meet criteria for accelerated phase CML:Xx_NEWLINE_xXPatients with plasma cell leukemiaXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXPatients must have CD19+ acute lymphoblastic leukemia (ALL) as confirmed by flow cytometry and/or immunohistochemistryXx_NEWLINE_xXLiver function tests (LFTs) (bilirubin, AST, and/or ALT) may be acceptable if the elevation is secondary to leukemia infiltration or leukemia therapy with tyrosine kinase inhibitorsXx_NEWLINE_xXDisease transformation [i.e. Richter's Syndrome (lymphomas) or prolymphocytic leukemia]Xx_NEWLINE_xXSubjects with a diagnosis of Acute Promyelocytic LeukemiaXx_NEWLINE_xXPatients with a diagnosis of acute myeloid leukemia (AML) (World Health Organization classification: >= 20% blasts in the bone marrow and/or peripheral blood) or myelodysplastic syndrome (MDS) (International Prognostic Scoring System intermediate-1 or higher) that at the time of allogeneic transplantation were in: - induction failure, relapsed disease or second or greater remission; patients in first complete remission that required more than 1 cycle of treatment to achieve the remission, or that have AML evolving from MDS, or that had the following abnormalities: FLT3 mutation, deletion of chromosome 5 or 7, mixed-lineage leukemia (MLL) gene rearrangement, or more than or equal to 3 cytogenetics abnormalities; patients with de novo or therapy-related MDS, chronic myelomonocytic leukemia (CMML) or AML are also eligible, regardless of cytogenetics or molecular rearrangementsXx_NEWLINE_xXBiphenotypic leukemia that at the time of allogeneic transplantation was in induction failure, relapsed disease, first, second or greater remissionXx_NEWLINE_xXAcute myelogenous leukemia (AML) in induction failure, relapse, past first remission, or first complete remission (CR1) considered at risk for relapseXx_NEWLINE_xXBiphenotypic leukemiaXx_NEWLINE_xXAcute lymphocytic leukemia with induction failure, first complete remission with high risk cytogenetics (e.g. Philadelphia positive chromosome, t[4:11]; remission requiring more than 2 chemotherapy to achieve remission, or any stage beyond CR1Xx_NEWLINE_xXChronic myelogenous leukemia (CML): second chronic phase, accelerated phase or blast crises with less than 10% blasts in the bone marrow, or CR1 and resistance to Gleevec or other tyrosine kinase inhibitorsXx_NEWLINE_xXChronic lymphocytic leukemia that has failed induction therapy or Rai stages 2-4Xx_NEWLINE_xXAny patient regardless of sex or age with CD19+ B-acute lymphoblastic leukemia (ALL) undergoing allogeneic HSCT (Group A); OR any patient regardless of sex or age with CD19+ B-chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) undergoing allogeneic HSCT (Group B)Xx_NEWLINE_xXAcute myeloid leukemia (AML) must have < 5% marrow blasts at the time of HCTXx_NEWLINE_xXAcute lymphocytic leukemia (ALL) must have < 5% marrow blasts at the time of HCTXx_NEWLINE_xXChronic myeloid leukemia (CML) accepted if they are beyond chronic phase (CP)1 and if they have received previous myelosuppressive chemotherapy or HCT and have < 5% marrow blasts at time of transplantXx_NEWLINE_xXPatients with a diagnosis of chronic myelomonocytic leukemia (CMML)Xx_NEWLINE_xXDisease transformation (active) (ie, Richter's Syndrome, prolymphocytic leukemia)Xx_NEWLINE_xXPatients must have one of the following three characteristics:\r\n* Acute myeloid leukemia fulfilling the criteria of the World Health Organization (WHO) classification\r\n* < 20% marrow myeloblasts and evidence of a clonal de novo AML genetic abnormality [e.g., t(8;21), inv(16), t(9;11)] \r\n* Myeloid sarcoma (also referred to as extramedullary myeloid tumor, granulocytic sarcoma, or chloroma), with or without evidence of a leukemic process in the bone marrow or peripheral blood, with confirmation of myeloid differentiation\r\n* Patients with secondary AML following treatment of primary malignancy are eligibleXx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXJuvenile myelomonocytic leukemia (JMML)Xx_NEWLINE_xXA pathologically confirmed diagnosis of leukemia or myelodysplastic syndrome (MDS)Xx_NEWLINE_xXPatients who have already received an allogeneic hematopoietic cell transplant and have either a documented relapse of leukemia or MDS or have recurrent persistent minimal residual disease as documented by at least 2 sequential testings, separated by 1 week, demonstrating molecular evidence of leukemia or MDS by fluorescence in situ hybridization (FISH), cytogenetics or fluorescent immunocytometryXx_NEWLINE_xXPatients who are to receive an allogeneic hematopoietic cell transplant as treatment for a leukemia or myelodysplastic syndrome that has an expected risk of relapse exceeding 30% will be eligible to have donor-derived WT1 peptide sensitized T cells generated prior to or at the time of transplant for immediate use post transplant at such time that the patient is found to have minimal residual disease or relapse; this includes patients with:\r\n* Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or MDS refractory to primary induction therapy\r\n* ALL or AML at any stage later than first (1 degree) relapse\r\n* Chronic myelogenous leukemia (CML) secondary (2 degree) or greater chronic phase after chemotherapy\r\n* CML in persistent accelerated phase or blast crisis\r\n* High risk MDS (refractory anemia with excess blasts [RAEB] and RAEB in transformation [T]) which has failed to respond or has recurred following induction chemotherapyXx_NEWLINE_xXThe patients' leukemia or MDS blasts must express the WT1 protein detectable by immunohistopathologic analysis, or if an adequate sample is not available for testing, must have a form of leukemia (ALL, AMLs other than M5) or MDS (2 degree MDS, RAEB, RAEBT) known to overexpress WT1 in a high proportion of cases (> 60%); for patients who develop a documented relapse of leukemia or MDS following transplant, marrow aspirates should be evaluated for the proportion of blasts expressing WT1 by immunohistology or fluorescence activated cell sorting (FACS) whenever possibleXx_NEWLINE_xXAcute myelogenous leukemia\r\n* In first complete remission with high-risk cytogenetics\r\n* Primary induction failure\r\n* In second or greater complete remission\r\n* Secondary AML\r\n* In first complete remission with hyperleukocytosis at diagnosisXx_NEWLINE_xXAcute lymphocytic leukemia\r\n* First complete remission, with high-risk cytogenetics\r\n* Primary induction failure\r\n* Second or greater complete remissionXx_NEWLINE_xXChronic myelogenous leukemia (CML)\r\n* Chronic phase CML \r\n* Accelerated phase CML\r\n* Not eligible for myeloablative allogeneic HSCTXx_NEWLINE_xXRecipients with primary or secondary acute leukemia, refractory anemia with excess blasts (RAEB), CML, or other eligible diagnosis in transformation to acute leukemia must have =< 5% blasts in bone marrow and no circulating blasts in peripheral blood at study entry; recipients who do not meet these criteria may be re-evaluated for study eligibility after receiving standard induction therapy for acute leukemia and determined to be in remissionXx_NEWLINE_xXFor patients with chronic phase chronic myelogenous leukemia, patient’s disease must have evidence of never responded to or progressed after receiving a tyrosine-kinase inhibitor (e.g. imatinib mesylate)Xx_NEWLINE_xXPatients with acute leukemia or myelodysplastic syndrome or chronic myelomonocytic leukemia must be in a hematologic remission, defined as < 5% blasts present in both blood and marrow to be referred for evaluation; should a patient have > 5% blasts or a donor not be available by the time the patient is ready for enrollment, the patient will be referred back to their primary hematologist-oncologist for treatment; patients with diseases other than acute leukemia including but not limited to Hodgkin’s and Non-Hodgkin’s lymphoma, CLL/SLL, natural killer T-cell lymphoma (NKTCL), peripheral T-cell lymphoma (PTCL), must have stable disease to their most recent regimen received within 8 weeks if chemo/radiotherapy or within 12 weeks after prior autologous stem cell transplantation; should a patient in either of these scenarios have progressive disease or a donor not be available after enrollment, the patient will be referred back to their primary hematologist-oncologist for treatment; if either of these scenarios are not in the best interest of the patient according to the clinical judgment of the PI, then the patient may receive standard treatment for the malignant disease under the current study; if under either of these settings, it becomes apparent that the patient will not be able to proceed to transplant, then he/she must come off study; recipient-subjects receiving a standard therapy will be told about the therapy, associated risks, benefits alternatives of the proposed therapy, and availability of receiving the same treatment elsewhere, outside of a research protocolXx_NEWLINE_xXPatients must have one of the following hematologic malignancies: acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics, fms-related tyrosine kinase 3 [flt3] mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndrome (MDS), Langerhan's cell histiocytosis, any disease beyond first remission; orXx_NEWLINE_xXAcute lymphoblastic leukemia (ALL): induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease; patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time: with translocations 9;22 or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure, and/or evidence of minimal residual disease, or acute biphenotypic leukemia, or double hit non-Hodgkin's lymphoma; orXx_NEWLINE_xXChronic myelogenous leukemia (CML) second chronic phase or accelerated phase; orXx_NEWLINE_xXRelapsed or refractory Chronic Lymphocytic Leukemia and require treatment in opinion of investigatorXx_NEWLINE_xXRelapsed/refractory acute myeloid leukemia following at least 2 but no more than 3 prior regimensXx_NEWLINE_xXCD123-detectable leukemiaXx_NEWLINE_xXPromyelocytic leukemiaXx_NEWLINE_xXPreviously untreated Philadelphia chromosome negative acute lymphoblastic leukemia/lymphomaXx_NEWLINE_xXLymphoblastic crisis of chronic myelogenous leukemia (CML)Xx_NEWLINE_xXBurkitt's lymphoma/leukemia or chronic myelogenous leukemia lymphoid blast crisis (p210 BCR-ABL+)Xx_NEWLINE_xXPatients with a diagnosis of acute promyelocytic leukemia (according to WHO classification 2008)Xx_NEWLINE_xXParticipants must have relapsed or refractory acute lymphoblastic leukemia or lymphoma:\r\n* Stratum I: T-cell lymphoblastic leukemia or lymphoma in first relapse or refractory to one or two courses of frontline induction therapy\r\n* Stratum II: B-cell or T-cell lymphoblastic leukemia or lymphoma in second or third relapse or refractory to 2 or 3 induction or re-induction attempts; patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) must be refractory or relapsed after treatment with a regimen that included a tyrosine kinase inhibitor (TKI)Xx_NEWLINE_xXAcute myeloid leukemia (AML) in >= first (1st) remission - excluding those in 1st remission with ‘good risk’ cytogenetic features (i.e. t(8;21), t(15;17), inv 16)Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL)/lymphocytic leukemia (LL) in 1st remission with clinical or molecular features indicating a high risk for relapse; or ALL > second (2nd) remissionXx_NEWLINE_xXChronic myeloid leukemia (CML) failing to respond to, progressing on or not tolerating appropriate tyrosine kinase inhibitor (TKI) therapy in first chronic phase of disease; CML in accelerated phase, second chronic phase, or in complete remission (CR) after accelerated phase or blast crisisXx_NEWLINE_xXSubjects with acute or chronic pancreatitis.Xx_NEWLINE_xXNew diagnosis of AML, other than acute promyelocytic leukemia (APL) or poor-risk AMLXx_NEWLINE_xXPatients must have a diagnosis of acute lymphoblastic leukemia (ALL) with ? 25% blasts in the bone marrow (M3), with or without extramedullary disease.Xx_NEWLINE_xXPatients with plasma cell leukemia in >= partial remission are eligibleXx_NEWLINE_xXPatients with known acute promyelocytic leukemia (French-American-British class M3-AML)Xx_NEWLINE_xXRelapsed/refractory acute myeloid leukemia (AML) except for acute promyelocytic leukemiaXx_NEWLINE_xXPatients with CD56 expressing hematological malignancy, as follows: cohort 1: CD56 expressing hematological malignancies including but not limited to acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), natural-killer leukemia, acute lymphoblastic leukemia, accelerated and blast-phase chronic myeloid leukemia (CML) who have failed prior therapy or for which no standard therapy exists; cohort 2: patients with MF (either primary MF, post-polycythemia MF, or post-essential thrombocythemia MF) and CD56 expression who have been on ruxolitinib or JAK-inhibitor therapy for at least 12 weeks and deemed refractory or sub-optimal responders in the opinion of the treating physician; cohort 3: patients with pathological diagnosis of BPDCN with CD56 expression (frontline and relapsed/refractory)Xx_NEWLINE_xXInclusion Criteria:\n\n        Phase 1 and 2: Confirmed advanced hematologic malignancies\n\n          -  Confirmed relapsed or refractory AML with a documented FLT3 mutation, or\n\n               -  60 years with newly diagnosed FLT3+ AML and not eligible for standard induction\n                  chemotherapy or FLT3+\n\n          -  high-risk MDS/CMML (defined as ? 10% peripheral blood or marrow blasts and\n             international Prognostic Scoring System [IPSS] score ? 2) and relapsed or refractory\n             to prior therapy\n\n          -  At least 3 weeks beyond the last cancer treatment for the disease under study, major\n             surgery and recovered from all acute toxicities (? Grade 1). Hydroxyurea used to\n             control peripheral blast counts is permitted during the first 2 cycles.\n\n          -  Adequate performance status ECOG ? 2;\n\n          -  Adequate renal and hepatic function:\n\n               -  creatinine ? 1.5 mg/dL OR calculated creatinine clearance ? 45 mL/minute\n\n               -  total bilirubin ? 2 times the upper limit of normal (ULN) unless due to Gilbert's\n                  disease or thought to be due to underlying AML\n\n               -  ALT and AST ? 5 times ULN\n\n          -  Negative serum pregnancy test within 14 days prior to the first dose of study therapy\n             for women of child-bearing potential\n\n          -  Ability to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  History of clinically significant cardiac impairment, congestive heart failure (CHF)\n             New York Heart Association (NYHA) Class III or IV, unstable angina, or myocardial\n             infarction during the previous 6 months, or serious cardiac arrhythmia\n\n          -  QT interval corrected for rate (QTc) ? 450 msec for males and ? 460 msec for females\n             on the ECG obtained at Screening using Fridericia method for QTc calculation (average\n             of 3 readings)\n\n          -  Concomitant medication(s) that may cause QTc prolongation or induce Torsades de\n             Pointes with the exception of anti-microbials used as standard of care to prevent or\n             treat infections and other such drugs that are considered by the investigator to be\n             essential for the care of the patient. However, if such medications are deemed to be\n             necessary during the study, E6201 will be held during the period of their use. of\n             anti-microbials used as standard\n\n          -  Presence of active central nervous system (CNS) leukemia. Subjects adequately treated\n             for CNS leukemia documented by 2 consecutive cerebrospinal fluid samples negative for\n             leukemia cells are eligible. Subjects with no history of CNS leukemia will not be\n             required to undergo cerebrospinal fluid sampling for eligibility.\n\n          -  Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface\n             antigen (HBsAg), or hepatitis C virus HCV)\n\n          -  Active, uncontrolled infection\n\n          -  Known hypersensitivity to any study drug component\n\n          -  History of another malignancy; Exception: Patients disease-free for 2 years or treated\n             in situ carcinoma\n\n          -  Any other medical intervention or other condition which, in the opinion of the\n             Principal Investigator, could compromise adherence to study requirements or confound\n             the interpretation of study results\n\n          -  Pregnancy or lactationXx_NEWLINE_xXPatients must have one of the following, histologically or cytologically confirmed:\r\n* Acute myeloid leukemia (AML) [non- acute promyelocytic leukemia (APL) AML]\r\n** If previously treated:\r\n*** AML that is relapsed or refractory to at least one prior line of therapy\r\n** If previously untreated, must meet all of the following:\r\n*** >= 60 years of age\r\n*** Secondary or therapy-related AML\r\n*** Does NOT bear favorable cytogenetic and/or molecular features, eg, core-binding factor abnormalities, FLT3 Internal Tandem Duplication (FLT3-ITD) negative/NPM1 mutated, biallelic CCAAT/enhancer binding protein alpha (CEBPA) mutation without FLT3-ITD\r\n* Chronic myeloid leukemia blast crisis (CML-BC)\r\n** Relapsed or refractory to at least one Bcr-Abl-TKI-containing regimen\r\n* Myelodysplastic syndrome (MDS), must meet all of the following:\r\n** Higher risk MDS [intermediate-2 or high risk by the original International Prognostic Scoring System (IPSS)]\r\n** Relapsed, refractory, or intolerant to at least one prior line of therapy containing hypomethylating agents (deoxyribonucleic acid [DNA] methyltransferase inhibitors)Xx_NEWLINE_xXAcute promyelocytic leukemia (APL, M3)Xx_NEWLINE_xXAcute or chronic pancreatitis.Xx_NEWLINE_xXAcute Myelogenous Leukemia (AML) in high risk 1st or subsequent CRXx_NEWLINE_xXAcute Lymphoblastic Leukemia (ALL) in CRXx_NEWLINE_xXNK cell lymphoblastic leukemia in any CRXx_NEWLINE_xXBiphenotypic or undifferentiated leukemia in 1st or subsequent CRXx_NEWLINE_xXChronic Myelogenous Leukemia (CML) All subjects with evidence of CNS leukemia must be treated and be in CNS CR to be eligible for trial.Xx_NEWLINE_xXAcute promyelocytic leukemia (French-American-British Class M3 AML).Xx_NEWLINE_xXRichter's transformation or prolymphocytic leukemiaXx_NEWLINE_xXHistory of chronic leukemias (eg, chronic lymphocytic leukemia).Xx_NEWLINE_xXHistory of acute or chronic pancreatitisXx_NEWLINE_xXInclusion Criteria:\n\n        Donors:\n\n          -  Read, understood and provided written informed consent and willing to comply with all\n             study requirements and procedures\n\n          -  6 out of 6 HLA-matched sibling\n\n          -  Negative test for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C\n\n          -  Both male and female patients of childbearing potential enrolled in this trial must\n             use adequate birth control measures\n\n          -  Subjects should be in generally good health and without significant medical\n             conditions, based upon pre-study medical history, physical examination,\n             electrocardiogram (ECG), chest X- ray, and laboratory tests\n\n          -  Meets all criteria to serve as a mobilized blood cell donor in accordance with all\n             applicable individual Transplant Center criteria\n\n        Recipient:\n\n          -  Read, understood and provided written informed consent and willing to comply with all\n             study requirements and procedures\n\n          -  6 out of 6 HLA-matched sibling\n\n          -  Both male and female patients of childbearing potential enrolled in this trial must\n             use adequate birth control measures\n\n        Diagnosis of one of following:\n\n          -  Acute Myelogenous Leukemia (AML) in 1st remission or beyond\n\n          -  Acute Lymphoblastic Leukemia (ALL) in 1st remission or beyond\n\n          -  Chronic Myelogenous Leukemia (CML)\n\n          -  Chronic Lymphoblastic Leukemia (CLL), relapsing after at least one prior regimen\n\n          -  Myelodysplastic Syndrome (MDS), either intermediate 1,2, or high risk by IPI Scoring\n             System or transfusion dependent\n\n          -  Non-Hodgkins Lymphoma (NHL) or Hodgkins Disease (HD) in 2nd or greater complete\n             remission, partial remission, or in relapse\n\n          -  Meets all criteria to serve as a transplant recipient in accordance with all\n             applicable individual Transplant Center criteria\n\n        Exclusion Criteria:\n\n        Donors:\n\n          -  Unwilling or unable to give informed consent, or unable to comply with the protocol\n             including required follow-up and testing\n\n          -  Prior treatment with any rhuFlt3L product\n\n          -  Any vaccination within 4 weeks prior to CDX-301 dosing\n\n          -  Donation of blood within 8 weeks, or donation of plasma within 2 weeks prior to\n             CDX-301 dosing\n\n          -  Any experimental treatment within 4 weeks prior to CDX-301 dosing\n\n          -  Use of systemic immunosuppressive agents (excluding topical steroids) within 12 months\n             prior to CDX-301 dosing.\n\n          -  History of first degree relatives with primary or secondary immunodeficiency to\n             include type 1 diabetes, multiple sclerosis, rheumatoid arthritis, scleroderma or\n             psoriasis\n\n          -  History of tuberculosis infection\n\n          -  Herpes zoster within 3 months prior to starting study drug\n\n          -  Pregnant or nursing\n\n        Recipient:\n\n          -  Unwilling or unable to give informed consent, or unable to comply with the protocol\n             including required follow-up and testing\n\n          -  Prior allogeneic transplant\n\n          -  More than one prior autologous transplant\n\n          -  Prior treatment with any rhuFlt3L product\n\n          -  Any vaccination within 4 weeks prior to transplant\n\n          -  Uncontrolled infection at the time of the transplant conditioning regimen\n\n          -  Pregnant or nursing\n\n          -  Any condition, which, in the opinion of the clinical investigator, would interfere\n             with the evaluation of the study outcomeXx_NEWLINE_xXProliferative type chronic myelomonocytic leukemia with white blood cell count >12 Gi/L at any time during the 28 days before Day 1Xx_NEWLINE_xXAcute myeloid leukemia (AML), except those patients with RAEB-t who are not candidates for intensive AML therapy.Xx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXBurkitt’s or mixed lineage leukemia, T cell ALLXx_NEWLINE_xXPrior morphological diagnosis of AML other than acute promyelocytic leukemia according to the 2001 World Health Organization (WHO) diagnostic criteria; patients with biphenotypic, RAS-mutated acute leukemia are also eligibleXx_NEWLINE_xXhave one of the following disease states: Acute Myeloid Leukemia (AML) (age <60 years) with relapsed/refractory disease; •Chronic Lymphocytic Leukemia (CLL) with relapsed disease following a fludarabine-based regimen or relapsed disease following an alkylator-based regimenXx_NEWLINE_xXhave diagnosis of AML French-American-British (FAB) classification (FAB) M3 (acute promyelocytic leukemia (APL))Xx_NEWLINE_xXHave an unequivocal histologic diagnosis of acute myeloid leukemia (AML) (including secondary AML)Xx_NEWLINE_xXSubjects with the diagnosis of acute promyelocytic leukemia (t[15;17])Xx_NEWLINE_xXOne of the following:\r\n* Acute leukemia past first remission, in first or subsequent relapse, in second or greater remission; patients in first remission should have with intermediate or high cytogenetic risk factors or fms-related tyrosine kinase 3 (flt3) mutation; patients with relapsed disease; patients with primary induction failure or relapse are eligible if they have < 10% bone marrow blasts, and no circulating blasts\r\n* Myelodysplastic syndrome with intermediate or high risk International Prognostic Scoring System (IPSS) score, or treatment related myelodysplastic syndrome (MDS)\r\n* Chronic myeloid leukemia (CML) resistant to tyrosine kinase treatment in a first or subsequent chronic phase or after transformation to accelerated phase or blast crisis\r\n* Chronic lymphocytic leukemia (CLL), lymphoma or Hodgkin’s disease which has failed to achieve remission or recurred following initial chemotherapy; patients must have at least a PR to salvage therapy, or low bulk untreated relapse (< 2 cm largest mass)\r\n* Multiple myeloma which has relapsed or progressed and has achieved a partial response to salvage chemotherapyXx_NEWLINE_xXPatients must have histologically or cytologically confirmed non–acute promyelocytic leukemia (APL) acute myeloid leukemia (AML)Xx_NEWLINE_xXNot meeting WHO criteria for Polycythemia Vera (PV), Chronic Myeloid Leukemia (CML), Myledysplastic Syndrome (MDS), or other myeloid neoplasmXx_NEWLINE_xXHistory of amyloid, plasma cell leukemia or CNS involvement.Xx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL)Xx_NEWLINE_xXAdult T-cell lymphoma (TCL)/leukemia (human T-cell leukemia virus 1+)Xx_NEWLINE_xXT cell prolymphocytic leukemiaXx_NEWLINE_xXT cell large granular lymphocytic leukemiaXx_NEWLINE_xXPhiladelphia positive Chronic Myeloid Leukemia (CML) in chronic phaseXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXHave known acute or chronic leukemia or current hematologic malignancies that, in the judgment of the investigator and sponsor, may affect the interpretation of results.Xx_NEWLINE_xXAcute lymphoblastic leukemia \r\n* >= second complete remission (CR2) (adults >= 18 years and =< 55 years) \r\n* CR2 in pediatrics (defined as < 18 years) and < 12 months duration of first remission\r\n* >= third complete remission (CR3) or not in remission (pediatric patients < 18 years)\r\n* T cell leukemia >= CR2\r\n* Evidence of pre-transplant minimal residual disease (MRD) by flow cytometry, fluorescence in situ hybridization (FISH) or cytogeneticsXx_NEWLINE_xXChemotherapy refractory acute leukemia (AL) will be defined by not in achieving a hematological remission after two consecutive standard courses of induction therapyXx_NEWLINE_xXAge ? 60 years with relapsed/refractory AML of any type except for acute promyelocytic leukemia (APL; AML M3), after at least 1 prior AML therapy , who have never undergone, and who are not currently eligible for, stem cell transplantation, and are currently deemed unfit for intensive chemotherapy.Xx_NEWLINE_xXIn blast transformation of chronic myeloid leukemia (CML). Prior myelodysplastic syndrome (MDS) is acceptable; prior treatment for MDS does not count as an AML therapy.Xx_NEWLINE_xXTreatment Group B (TGB): Acute Leukemia (Part 3 - acute myeloid leukemia [AML] only), myelodysplastic syndrome (MDS), myelodysplastic /myeloproliferative neoplasms (MDS/MPN) and myelofibrosis (MF)Xx_NEWLINE_xXAll subtypes of Acute Myeloid leukemia (except for acute promyelocytic leukemia)Xx_NEWLINE_xXAdults with pathologically confirmed, relapsed or refractory acute myelogenous leukemia OR those 70 and older who are not candidates for, or decline, conventional frontline chemotherapyXx_NEWLINE_xXDiagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXDiagnosis of relapsed or refractory AML with at least one prior treatment for acute myeloid leukemia and patients with diagnosis of acute myeloid leukemia in complete remission with high risk to relapse.Xx_NEWLINE_xXExpression of CD33 on more than 30% of bone marrow blasts at screening for patients with refractory or relapsed acute myeloid leukemia is required. CD33 positive expression of bone marrow blasts at the time of initial acute myeloid leukemia diagnosis is sufficient for those patients in complete remission with high risk to relapse.Xx_NEWLINE_xXPatients with acute promyelocytic leukemia according to WHO definition.Xx_NEWLINE_xXPatients with refractory or relapsed acute myeloid leukemia > 5.000 blasts in the peripheral blood.Xx_NEWLINE_xXAnti-leukemia therapy within two weeks before first treatment with BI 836858, 4 weeks for biologics. Parallel treatment with Hydroxyurea ia allowed with refractory or relapsed acute myeloid leukemia patients.Xx_NEWLINE_xXPatients with chronic lymphocytic leukemia, prolymphocytic leukemia, or Richter's transformation who are eligible for allogeneic transplantation and are not eligible for protocols of higher priority.Xx_NEWLINE_xXAcute promyelocytic leukemia or AML with a t(15;17) (q22;q12) cytogenetic abnormality or Bcr/Abl positive leukemiaXx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXHave current acute or chronic leukemia.Xx_NEWLINE_xXMorphologically confirmed acute myeloid leukemia (AML), except acute promyelocytic leukemia (APL), including leukemia secondary to prior therapy or antecedent hematologic disorder (e.g., MDS or myeloproliferative disorders), who have failed to achieve CR or who have relapsed after prior therapy and are not candidates for potentially curative therapyXx_NEWLINE_xXIntermediate-2 or High-grade risk MDS (including chronic myelomonocytic leukemia (CMML))Xx_NEWLINE_xXPatients with acute promyelocytic leukemia (APL)Xx_NEWLINE_xXParticipant with acute leukemia must meet one of the following criteria:\r\n* Relapsing acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or acute biphenotypic leukemia in 2nd or greater relapse, or\r\n* Refractory ALL, AML, or acute biphenotypic leukemia failing to achieve CR with >= 2 induction or re-induction attemptsXx_NEWLINE_xXIsolated extramedullary disease (leukemia)Xx_NEWLINE_xXPatient must have one of the following histologically or cytologically documented measurable (may be measureable by tumor markers only, such as quantitative RT-PCR for WT1 transcript for AML, or CA-125 for ovarian carcinoma) advanced stage malignancies: non-small cell lung, ovarian, glioblastoma, and AML (not including acute promyelocytic leukemia), known to overexpress the WT1 protein.Xx_NEWLINE_xXPatients must have one of the following hematologic malignancies: \r\n* Acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics, fms-like tyrosine kinase [flt]3 mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndrome (MDS), Langerhans cell histiocytosis, any disease beyond first remission; or\r\n* Myelodysplastic syndrome (MDS): primary or therapy related; or\r\n* Acute lymphoblastic leukemia (ALL): induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease; patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time: with translocations 9;22 or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure, and/or evidence of minimal residual disease, or acute biphenotypic leukemia, or double hit non-Hodgkin's lymphoma; or \r\n* Non-Hodgkin's lymphoma (NHL): in primary induction failure, second or third complete remission, refractory disease, or relapse (including relapse post autologous hematopoietic stem cell transplant); double hit lymphomas in first remission or more advanced disease; or \r\n* Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease following standard therapy; or,\r\n* Chronic myelogenous leukemia (CML) second chronic phase or accelerated phase; or,\r\n* Hodgkin's disease (HD): induction failures, second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant)Xx_NEWLINE_xXPatient must have relapsed/refractory acute myelogenous leukemia (AML) with ? 5% blast in the bone marrow or biopsy confirmed chloroma. Patient may have CNS 1, 2 or 3 disease. Isolated CNS relapse is not eligible.Xx_NEWLINE_xXDiagnosis of newly diagnosed AML (other than acute promyelocytic leukemia [APL]) or high-risk (intermediate-2 high by International Prognostic Scoring System [IPSS] or > 10% blasts, including chronic myelomonocytic leukemia [CMML]) MDS; prior therapy with Hydrea and the use of a single or a two day dose of cytarabine (up to 3 g/m^2) for emergency use up to 24 hours prior to start of study therapy is allowed; prior therapy for MDS or other antecedent hematologic disease (AHD) is not allowedXx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXA diagnosis of acute promyelocytic leukemia (APL); the study does not require to rule APL out for every subject; however, if there is clinical suspicion for APL, such diagnosis has to be ruled out before initiation of treatmentXx_NEWLINE_xXDe novo or secondary acute myeloid leukemia (AML) (post myelodysplastic syndrome [MDS] or myeloproliferative neoplasm [MPN] or after leukemogenic chemotherapy) according to WHO 2008 criteria For Part A:Xx_NEWLINE_xXAcute promyelocytic leukemia with t(15;17), or its molecular equivalent (PML-RARalpha)Xx_NEWLINE_xXUncontrolled meningeal leukemiaXx_NEWLINE_xXAcute or chronic pancreatitisXx_NEWLINE_xXParticipant has a relapsed or refractory hematologic malignancy (with any measurable disease) with FLT3-ITD or TKD mutations and one of the following diagnoses:\r\n* Acute myeloid leukemia (AML)\r\n* AML with prior myelodysplastic syndrome (MDS)\r\n* Myeloperoxidase (MPO)-positive mixed phenotype acute leukemiaXx_NEWLINE_xXAcute or chronic pancreatitisXx_NEWLINE_xXOne of the following hematologic malignancies that has relapsed or remains refractory after prior allogeneic HCT: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myeloid sarcoma, chronic myelogenous leukemia (CML), juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL)Xx_NEWLINE_xXNewly Diagnosed De novo AML according to WHO criteria except for Acute Promyelocytic Leukemia or patients with known favorable cytogenetics (see exclusion)Xx_NEWLINE_xXNewly diagnosed patients with Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21) or inv16Xx_NEWLINE_xXMust not have leukemia.Xx_NEWLINE_xXHigh-risk hematologic malignancy\r\n* Very high risk acute lymphocytic leukemia (ALL) in first complete remission (CR1); examples include, but not limited to hypodiploid M2 or greater marrow at the end of induction, infants with mixed lineage leukemia (MLL) fusion or t(4;11)\r\n* ALL in high risk second complete remission (CR2); examples include but not limited to bone marrow (BM) relapse < 36 months (mo); CR1, T-ALL, very early (< 6 mo CR1) isolated central nervous system (CNS) relapse\r\n* ALL in third complete remission (CR3) or subsequent\r\n* Acute myeloid leukemia (AML) in high risk CR1; examples include but not limited to preceding myelodysplastic syndromes (MDS), 5q-, -5, -7, French American British (FAB) M6, FAB M7 not t(1;22), minimal residual disease (MRD) >= 5% on day 22 (AML08), M3 marrow after induction 1, M2 marrow after two cycles of induction, fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)\r\n* AML in CR2 or subsequent\r\n* Therapy related AML, with prior malignancy in CR > 12 mo\r\n* MDS, primary or secondary\r\n* NK cell, biphenotypic, or undifferentiated leukemia in CR1 or subsequent\r\n* Chronic myelogenous leukemia (CML) in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor\r\n* Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize stem cells for autologous HCT\r\n* Non-Hodgkin lymphoma in CR2 or subsequent\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Refractory hematologic malignancies (ALL, AML, CML in blast crisis, Hodgkin or non-Hodgkin lymphoma) due to chemoresistant relapse or primary induction failure\r\n* All patients with evidence of CNS leukemia must be treated and be in CNS CR to be eligible for studyXx_NEWLINE_xXDiagnosis: Patients must have documented relapsed/refractory ALL, AML, or acute leukemia of ambiguous lineage and meet the following criteria:Xx_NEWLINE_xXPatients must have at least received an appropriate induction therapy regimen. Patients with persistent leukemia after induction therapy, or with recurrence of leukemia at any time during the course of treatment (including allogeneic HSCT) are eligible;Xx_NEWLINE_xXHigh-risk myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) including chronic myelomonocytic leukemia 2 (CMML2) as defined by 10-19% myeloid blasts in either blood or marrowXx_NEWLINE_xXPast or current plasma cell leukemia.Xx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXSubject was diagnosed as acute promyelocytic leukemia (APL).Xx_NEWLINE_xXSubject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).Xx_NEWLINE_xXPast or current plasma cell leukemia.Xx_NEWLINE_xXAcute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid leukemia, or myeloproliferative neoplasms requiring a matched allogeneic hematopoietic stem cell transplant (HSCT)\r\n* Acute leukemia (acute myeloid leukemia [AML] or acute lymphoblastic leukemia [ALL]) must be in complete remission defined as: < 5% marrow blasts with no morphologic evidence of leukemia, no peripheral blasts, marrow > 20% cellular, and peripheral absolute neutrophil count > 1000/uL (platelet recovery is not required)\r\n* Myelodysplasia (MDS) and chronic myeloid leukemia (CML): must have < 5% marrow blasts\r\n* Myeloproliferative neoplasms (MPN): must have < 5% peripheral/marrow blastsXx_NEWLINE_xXPlasma cell leukemia or circulating plasma cells >= 2 X 10^9/LXx_NEWLINE_xXAcute myeloid leukemia, positive for CD33Xx_NEWLINE_xXA diagnosis of acute promyelocytic (M3) or acute megakaryocytic leukaemia (M7).Xx_NEWLINE_xXPlasma cell leukemia or circulating plasma cells >= 2 × 10^9/LXx_NEWLINE_xXPatients with chronic myelogenous leukemia (CML) in myeloid blasts crisisXx_NEWLINE_xXAcute renal failureXx_NEWLINE_xXAcute promyelocytic leukemia.Xx_NEWLINE_xXPlasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)Xx_NEWLINE_xXRefractory/relapsing blast crisis of chronic myelogenous leukemia (CML)Xx_NEWLINE_xXPatients must have morphologically confirmed newly diagnosed acute myelogenous leukemia (AML) with blood or bone marrow disease; patients with only extramedullary disease in the absence of bone marrow or blood involvement are not eligible; note: this protocol uses World Health Organization (WHO) diagnostic criteria for AML; patients with acute promyelocytic leukemia (APL, French-American-British [FAB], M3) or blastic transformation of chronic myelogenous leukemia (CML) are not eligible; patients with known core binding factor (CBF) or fms-like tyrosine kinase 3 (FLT3) related leukemias are eligible for this study, but should preferentially be placed on National Cancer Institute (NCI)-sponsored protocols specific for these subtypes, if availableXx_NEWLINE_xXDiagnosis of acute myeloid leukemia (AML) (other than acute promyelocytic leukemia) with refractory/relapsed disease; (patients must be primary refractory, in relapse 1, or in relapse 2); NOTE: patients with AML arising from prior myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) would be eligible even if they have not received treatment for the AML; NOTE: patients with relapsed/refractory acute lymphocytic leukemia (ALL) would also be eligible for the phase II part of the study; NOTE: use of hydroxyurea and/or up to 4 doses of cytarabine, for emergent cytoreduction is allowedXx_NEWLINE_xXPathologically confirmed diagnosis of B-lineage acute lymphoblastic leukemia, Burkitt leukemia or lymphoma, or B-lineage lymphoblastic lymphomaXx_NEWLINE_xXDocumented/confirmed acute myelogenous leukemia (AML), except for acute promyelocytic leukemiaXx_NEWLINE_xXSurvivor of childhood acute lymphoblastic leukemia (ALL) or non-Hodgkins's lymphoma (NHL) (treated for ALL or NHL before the age of 21 years old and ?5 years post-treatment)Xx_NEWLINE_xXRefractory/relapsing myeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatmentXx_NEWLINE_xX> 10% blasts or biopsy-documented leukemia cutis or myeloid sarcoma.Xx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXInternational Prognostic Scoring System (IPSS) low- or intermediate-1-risk MDS, including chronic myelomonocytic leukemia (CMML)-1Xx_NEWLINE_xXAcute myelogenous leukemia (AML) in first remission that required more than 1 cycle of treatment to achieve remission or with the following cytogenetic abnormalities: FLT3 mutation, deletion/monosomy of chromosome 5 or 7, MLL gene rearrangement, or more than or equal to 3 cytogenetics abnormalities; also patients in second or greater remissionXx_NEWLINE_xXPatient has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).Xx_NEWLINE_xXPrevious diagnosis of CD123+ acute myeloid leukemia (AML), de novo or secondary.Xx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL).Xx_NEWLINE_xXOne of the following hematologic malignancies that has relapsed or remains refractory after prior allogeneic HCT: \r\n* Acute lymphoblastic leukemia (ALL)\r\n* Acute myeloid leukemia (AML) (including myeloid sarcoma)\r\n* Chronic myelogenous leukemia (CML), juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), Hodgkin or non-Hodgkin lymphoma (NHL)Xx_NEWLINE_xXPlasma cell leukemia or circulating plasma cells ? 2 × 10^9/L.Xx_NEWLINE_xXAcute myelogenous leukemia (AML) in 1st or subsequent remissionXx_NEWLINE_xXAcute lymphoblastic leukemia (ALL) in 1st or subsequent remissionXx_NEWLINE_xXChronic myelogenous leukemia (CML)Xx_NEWLINE_xXActive plasma cell leukemiaXx_NEWLINE_xXAcute renal failureXx_NEWLINE_xXSubjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma refractory to or relapsed from standard therapiesXx_NEWLINE_xXDiagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXDiagnosis of chronic myelogenous leukemia in blast crisisXx_NEWLINE_xXRelapsed, refractory, or progressive acute leukemia in second or subsequent remission, with remission defined as < 5% bone marrow blasts morphologicallyXx_NEWLINE_xXPoor-risk acute leukemia in first remission, with remission defined as < 5% bone marrow blasts morphologically:\r\n* Acute myeloid leukemia (AML) with at least one of the following:\r\n** AML arising from myelodysplastic syndromes (MDS) or a myeloproliferative disorder, or secondary AML\r\n** Presence of FMS-like tyrosine kinase-3 (Flt3) internal tandem duplications\r\n** Poor-risk cytogenetics\r\n** Primary refractory disease\r\n* Acute lymphoblastic leukemia (ALL) (leukemia and/or lymphoma) with at least one of the following:\r\n** Poor-risk cytogenetics\r\n** Clear evidence of hypodiploidy\r\n** Primary refractory disease\r\n* Biphenotypic leukemiaXx_NEWLINE_xXInterferon- or imatinib-refractory chronic myelogenous leukemia (CML) in first chronic phase, or CML in second or subsequent chronic phaseXx_NEWLINE_xXChronic myelomonocytic leukemiaXx_NEWLINE_xXJuvenile myelomonocytic leukemiaXx_NEWLINE_xXAcute or chronic leukemia.Xx_NEWLINE_xXHave current acute or chronic leukemiaXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXHave known current hematologic malignancies or acute or chronic leukemiaXx_NEWLINE_xXPlasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)Xx_NEWLINE_xXThe leukemia is a de novo or secondary AML.Xx_NEWLINE_xXThe patient has acute promyelocytic leukemia with t(15;17) (q22;q12), (PML/RAR?) or variants.Xx_NEWLINE_xXAcute lymphocytic leukemia (ALL) in first complete remission (CR1) with high-risk features including adverse cytogenetics such as t(9;22), t(1;19), t(4;11), or mixed-lineage leukemia (MLL) gene rearrangements; ALL in second or greater remission or ALL with relapsed disease, peripheral blood blasts < 1000/microliter, ALL patients must show response to most recent received chemotherapyXx_NEWLINE_xXAcute myeloid leukemia (AML) in CR1 with intermediate-risk disease or high-risk features defined as: \r\n* Greater than 1 cycle of induction therapy required to achieve remission\r\n* Preceding myelodysplastic syndrome (MDS) or myeloproliferative disease\r\n* Presence of fms-related tyrosine kinase 3 (FLT3) mutations or internal tandem duplications\r\n* French-American-British (FAB) M6 or M7 classification\r\n* Adverse cytogenetics, -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 (> 3 abnormalities), peripheral blood blasts < 1000/microliter, AML patients must show response to most recent received chemotherapyXx_NEWLINE_xXChronic myeloid leukemia (CML) >= 1st chronic phase, after failed >= 2 lines of tyrosine kinase inhibitors; in accelerated or blast phase with > 30% bone marrow blastsXx_NEWLINE_xXPatients with myelofibrosis (Lille > 0, transfusion dependency, progression to blast phase; however, in remission from AML) or chronic myelomonocytic leukemia (CMML); these patients will be treated with the reduced-intensity conditioning regimen #2 and will be subject to the same stopping rule as the group >= 55 years or with comorbiditiesXx_NEWLINE_xXPatients with biopsy-proven acute lymphoblastic leukemia, acute lymphoblastic lymphoma, or acute biphenotypic leukemia in remission or relapseXx_NEWLINE_xXPatients must have a diagnosis of acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (either AML or ALL), AML with prior myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms, or biphenotypic leukemia; patients with treatment-related AML (t-AML) will be eligible, provided they meet all other eligibility criteria; current disease status must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life; patients must meet one of the following criteria:\r\n* First or greater relapse\r\n* Refractory to 1 or more courses of induction or reinduction chemotherapy\r\n* First or greater relapse after allogeneic hematopoietic stem cell transplantation (HSCT)Xx_NEWLINE_xXDiagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXActive or prior plasma cell leukemia (defined as either 20% of peripheral WBC comprised of plasma/CD138+ cells or an absolute count of 2 x 10^9/L).Xx_NEWLINE_xXThe leukemia could be a de novo or secondary AML.Xx_NEWLINE_xXThe patient has acute promyelocytic leukemia with t(15;17)(q22;q12), (PML/RAR?) or variants.Xx_NEWLINE_xXClonal cytogenetic abnormalities associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) on marrow examinationXx_NEWLINE_xXNewly Diagnosed De novo AML according to WHO criteria except for Acute Promyelocytic Leukemia or patients with known favorable cytogeneticsXx_NEWLINE_xXNewly diagnosed patients with Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21) or inv16Xx_NEWLINE_xXActive plasma cell leukemia.Xx_NEWLINE_xXConfirmed diagnosis of:\r\n* Primary myelofibrosis (MF) or post-polycythemia vera (PV)/essential thrombocythemia (ET) MF classified as high risk, intermediate-2 risk, or intermediate-1 risk who are unresponsive or unable to receive current therapy which may or may not include ruxolitinib; OR\r\n* MPN/MDS syndrome (chronic myelomonocytic leukemia [CMML], juvenile myelomonocytic leukemia [JMML], atypical chronic myeloid leukemia [aCML], or MDS/MPN unclassifiable)Xx_NEWLINE_xXAcute promyelocytic leukemia (APL)Xx_NEWLINE_xXPARENT/CAREGIVER: Adult primary caregiver of children treated for acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) or lymphoblastic lymphoma (LL) and daily contact with the childXx_NEWLINE_xXA diagnosis of acute promyelocytic leukemia (APML)Xx_NEWLINE_xXHave a diagnosis of lung cancer (both small cell and non-small cell), central nervous system tumors, acute myeloid leukemia, and acute lymphoblastic leukemia will be excludedXx_NEWLINE_xXAllogeneic hematopoietic cell transplant for hematologic malignancy (i.e. leukemia, lymphoma including acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML], chronic myelogenous leukemia [CML], non-Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL]) in complete remission; myelodysplastic syndrome (active dysplasia and/or blasts are permitted, but must not have active leukemia) or idiopathic severe aplastic anemia (SAA)Xx_NEWLINE_xXAcute or chronic thrombocytopenia in patients with acute leukemia (myeloblastic or lymphoblastic) receiving induction or re-induction chemotherapy that is expected to induce marrow aplasia for at least 2 weeks; orXx_NEWLINE_xXExpected chronic thrombocytopenia in patients with newly diagnosed marrow failure syndromes, myelodysplastic syndromes, aplastic anemia, chronic myelomonocytic leukemia or myelofibrosis or;Xx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXPatients must have one of the following documented diseases:\r\n* Chronic myelogenous leukemia\r\n* Chronic lymphocytic leukemia\r\n* Multiple myeloma\r\n* Myelodysplasia\r\n* Myeloproliferative disorder\r\n* Non-Hodgkin's lymphoma\r\n* Hodgkin's disease\r\n* Acute myelogenous leukemia\r\n* Acute lymphoblastic leukemia\r\n* Acute biphenotypic leukemiaXx_NEWLINE_xXAcute myelogenous leukemia diagnosed by World Health Organization (WHO) criteria with one of the following (patients with biphenotypic leukemia are eligible, provided that the treating physician determines an acute myeloid leukemia (AML) treatment regimen is appropriate)\r\n* Primary refractory disease following >= 1 cycle of induction chemotherapy\r\n* First relapse or higher; patients with primary or secondary acute myelogenous leukemia are eligibleXx_NEWLINE_xXPatients with acute promyelocytic leukemiaXx_NEWLINE_xXPatients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other bone marrow failure syndromes are not eligibleXx_NEWLINE_xXSubject has MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.Xx_NEWLINE_xXCurrently enrolled and receiving treatment for acute lymphoblastic leukemia (ALL) on the TOTXVI therapy protocol at St. Jude Children’s Research HospitalXx_NEWLINE_xXPhase I: Hematologic malignancy diagnosis including any subset of myeloma, lymphoma, leukemia, or myelodysplastic syndromeXx_NEWLINE_xXPhase II: Hematologic malignancy diagnosis including any subset of lymphoma, leukemia, or myelodysplastic syndromeXx_NEWLINE_xXPATIENTS: Refractory or recurrent hematologic malignancy (lymphoma, leukemia, or myeloma, amyloidosis and chronic myelogenous leukemia [CML] - CML can only be accelerated or blast phase).Xx_NEWLINE_xXPATIENTS: Chronic myeloid leukemia (CML) except accelerated or blast phase.Xx_NEWLINE_xXAcute or chronic leukemia diagnosisXx_NEWLINE_xXInterferon? or tyrosine kinase?refractory chronic myelogenous leukemia (CML) in first chronic phase, tyrosine kinase inhibitor (TKI)?intolerant CML in first chronic phase, or CML in second or subsequent chronic phaseXx_NEWLINE_xXAcute leukemia patients (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], acute promyelocytic leukemia [APL], therapy-related myeloid neoplasm [tMN], high grade myelodysplastic syndrome [MDS])Xx_NEWLINE_xXAll categories of AML will be included except for acute promyelocytic leukemia (APL) (AML-M3 as defined by 1976 French-American-British [FAB] classification, or APL with t(15;17)(q22;q12); PML-RARA as defined by the revised 2008 World Health Organization [WHO] classification of myeloid neoplasms and acute leukemias), acute megakaryocytic leukemia (AML-M7 type as per FAB or AML [megakaryoblastic] with t(1;22)(p13;q13); RBM15-MKL1 as per WHO 2008 revised classification) and acute leukemias of ambiguous lineage (as per WHO 2008 revised classification), undergoing 7 + 3 remission IC with cytarabine and an anthracycline (daunorubicin or idarubicin); all cases have to be histopathologically confirmed by a diagnostic bone marrow biopsy; use of granulocyte colony-stimulating factor (G-CSF) for any indication must have been discontinued at least 7 days prior to entry into the studyXx_NEWLINE_xXPatients with secondary AML arising out of myelodysplastic syndrome (MDS) (all subtypes under WHO classification), chronic myelomonocytic leukemia (CMML); therapy-related AML and those with a prior autologous hematopoietic cell transplantation are eligibleXx_NEWLINE_xXPatients must meet diagnostic criteria of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), myelodysplastic syndrome (MDS), myelofibrosis, or severe aplastic anemia; patients will be allowed on study if they are deemed eligible for allogeneic (allo) HCT regardless of remission statusXx_NEWLINE_xXThose with acute leukemia must be in remission at the time of transplantXx_NEWLINE_xXKnown relapsed acute leukemia or myelodysplastic syndromeXx_NEWLINE_xXPatients must meet one of the following:\r\n* Acute myeloid leukemia (AML) in first (1st) remission - for patients whose AML does not have \good risk\ cytogenetic features (i.e. t[8;21], t[15;17], inv 16 without v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [c-kit] mutations)\r\n* Acute leukemias of ambiguous lineage in >= 1st remission\r\n* Secondary AML in remission\r\n* AML in >= second (2nd) remission\r\n* Acute lymphoblastic leukemia (ALL) in 1st remission with clinical or molecular features indicating a high risk for relapse; or ALL >= 2nd remission\r\n* Chronic myelogenous leukemia (CML) failing to respond or not tolerating imatinib, dasatinib or nilotinib in first chronic phase of disease; CML in accelerated phase, second chronic phase, or in complete remission (CR) after accelerated phase or blast crisis\r\n* Non-Hodgkin lymphoma (NHL) with chemo responsive disease in any of the following categories:\r\n** Intermediate or high grade lymphomas who have failed to achieve a first CR or have relapsed following a 1st remission who are not candidates for autologous transplants\r\n** Any NHL in remission which is considered not curable with chemotherapy alone and not eligible/appropriate for autologous transplant\r\n* Myelodysplastic syndrome (MDS): refractory anemia (RA)/refractory cytopenia with multilineage dysplasia (RCMD) with high risk cytogenetic features or transfusion dependence, refractory anemia with excess blasts (RAEB)-1 and RAEB-2\r\n* Chronic myelomonocytic leukemia (CMML): CMML-1 and CMML-2Xx_NEWLINE_xXPatients with:\r\n* Acute lymphoblastic leukemia/lymphoma \r\n* Malignant brain tumor \r\n* Non-central nervous system (CNS) solid tumors \r\n* Acute myeloblastic leukemia\r\n* Non-Hodgkin’s lymphoma \r\n* Hodgkin’s disease\r\n* Head and neck tumorsXx_NEWLINE_xXAny patient with non-acute promyelocytic leukemia (APL) acute leukemia (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], biphenotypic leukemia) undergoing curative intent chemotherapy OR any patient undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for a hematologic disorder (including acute leukemia as above, chronic myelogenous leukemia [CML], chronic lymphocytic leukemia [CLL], myelodysplastic syndrome [MDS], primary or secondary myelofibrosis, hypereosinophilic syndromes, plasma cell disorders, B-cell or T-cell lymphoma)Xx_NEWLINE_xXPlanned peripheral blood stem cell (PBSC) or bone marrow (BM) HCT for the treatment of the following hematologic malignancies:\r\n* Lymphoma (Hodgkin and non-Hodgkin)\r\n* Myelodysplastic syndrome\r\n* Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood; persistent lymphadenopathy on computed tomography [CT] or CT/positron emission tomography [PET] scan without progression is allowed)\r\n* Acute myeloid leukemia in first or second remission\r\n* Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase\r\n* Other hematologic malignancies judged appropriate by the clinical principal investigators (PIs), including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis; patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded\r\n** Adult cases of multiple myeloma (MM) are excluded; adults with aplastic anemia are excluded; patients undergoing a second haploHCT are not eligible (patients who have undergone a previous autologous HCT are eligible)Xx_NEWLINE_xXPoor risk disease/disease status including: chronic myeloid leukemia (CML) in blast crisis, acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) beyond 2nd remission, multiple myeloma, and aplastic anemiaXx_NEWLINE_xXPlanned HCT for the treatment of the following hematologic malignancies:\r\n* Lymphoma (Hodgkin and non-Hodgkin)\r\n* Myelodysplastic syndrome\r\n* Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status needs to be in hematologic remission by bone marrow and peripheral blood; persistent lymphadenopathy on computed tomography [CT] or CT/positron emission tomography [PET] scan without progression is allowed)\r\n* Acute myeloid leukemia in first or second remission\r\n* Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase\r\n* Other hematologic malignancies including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis; patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excludedXx_NEWLINE_xXPatients with the following diagnoses are not eligible:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Juvenile myelomonocytic leukemia (JMML)Xx_NEWLINE_xXPlanned HCT for the treatment of the following hematologic malignancies:\r\n* Lymphoma (Hodgkin and non-Hodgkin)\r\n* Myelodysplastic syndrome\r\n* Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood; persistent lymphadenopathy on computed tomography [CT] or CT/positron emission tomography [PET] scan without progression is allowed)\r\n* Acute myeloid leukemia in first or second remission\r\n* Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase\r\n* Other hematologic malignancies including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis; patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded\r\n* Patients undergoing a second allogeneic (allo) HCT are not eligible (patients who have undergone a previous autologous HCT are eligible)Xx_NEWLINE_xXPatients who are newly diagnosed with acute leukemia and hospitalized to receive their initial 4 weeks of intensive induction chemotherapy for this diseaseXx_NEWLINE_xXPatients with acute myelogenous leukemia (AML) or relapsed acute lymphoblastic leukemia (ALL) that will receive chemotherapy with/without transplant must have, or be scheduled to have, an external tunneled CVC (Broviacs, Hickmans, tunneled PICCs, etc.) and/or non-tunneled PICC that is expected to remain in place for an additional >= 3 monthsXx_NEWLINE_xXPatient must fit 1 of the following 2 categories:                          \r\n* Chemotherapy patients                \r\n** Planned to receive at least 2 consecutive cycles (not required to be the first 2 cycles) of intensive chemotherapy for either:\r\n*** De novo, relapsed or secondary acute myeloid leukemia (AML), or acute leukemia of ambiguous lineage treated with standard AML therapy\r\n*** Relapsed acute lymphoblastic leukemia (ALL)\r\n*** For the purposes of this study, “intensive chemotherapy” is defined as regimens that are predicted by the local investigator to cause neutropenia for > 7 days; examples include, but are not limited to, treatment with “4-drug induction” (anthracycline, vincristine, asparaginase, and steroid), high dose cytarabine, anthracycline/cytarabine, ifosfamide/etoposide, and clofarabine-containing regimens\r\n* Stem cell transplantation patients                \r\n** Planned to receive at least 1 myeloablative autologous or allogeneic HSCT\r\n** For the purposes of this study, myeloablative autologous and allogeneic HSCT are those in which the conditioning regimen is predicted by the local Investigator to cause neutropenia for > 7 daysXx_NEWLINE_xXMust have a high risk hematologic malignancy as defined below; if the patient does not meet defined eligibility requirements as stipulated below, the principal investigator (PI) must be contacted to determine eligibility:\r\n* Acute myeloid leukemia (AML)\r\n** Patients with AML in the first complete remission (CR) with intermediate or high risk disease\r\n** Patients with AML in first CR with high-risk disease as defined by one of the following abnormalities; CR is defined as an M1 marrow (< 5% blasts by morphology), no evidence of extramedullary disease, and an absolute neutrophil count >= 1.0 x 10^9/L; cases where the ANC is < 1.0 x 10^9/L and rising will also be considered; the PI will need to approve such cases for enrollment; complete remissions without platelet recovery (CRp) will be considered complete remissionsXx_NEWLINE_xXPatients with acute undifferentiated, biphenotypic, or bilineal leukemia, which is in 1st or greater complete remission (CR) or partial remission (PR):\r\n* Cr will be defined as an M1 marrow (< 5% blasts), no evidence of extramedullary disease, and an absolute neutrophil count >= 1.0 x 10^9/L; cases where the ANC is < 1.0 x 10^9/L and rising will also be considered; the PI will need to approve such cases for enrollment; CR without platelet recovery (CRp) will be considered complete remissions); PR will be defined as an M2 marrow (5-19% blasts), no evidence of extramedullary disease, and an absolute neutrophil count >= 1.0 x 10^9/L); cases where the ANC is < 1.0 x 10^9/L and rising will also be considered; the PI will need to approve such cases for enrollment\r\n* Chronic myelogenous leukemia (CML):\r\n** Chronic phase with resistance to tyrosine kinase inhibitors\r\n** Accelerated phase (development of cytogenetic abnormality in addition to t(9:22), blood blast percentage >= 10, blood basophil percentage >= 20, platelet count < 100,000 X 10^9/L)\r\n** Blast crisis\r\n** 2nd or greater chronic phase\r\n* Acute Lymphoblastic Lymphoma in 2nd or greater complete remission:\r\n** Complete remission includes confirmed complete response (CR) defined as the disappearance of all evidence of disease from all sites for at least 4 weeks; bone marrow and cerebrospinal fluid (CSF) must be normal and any macroscopic nodules in any organs detectable on imaging techniques shall no longer be present; imaging should include positron emission tomography (PET) scanning; CR will also include unconfirmed complete responses defined as a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest perpendicular diameters (SPD), or any residual lesions in organs that have decreased by > 75%, with a negative PET scan, negative bone marrow and CSF\r\n* Peripheral T cell lymphoma (PTCL):\r\n** In first response (must have at least a partial response)\r\n*** PTCL, unspecified\r\n*** Hepatosplenic gamma-delta T cell lymphoma\r\n** Recurrent PTCL (must be treatment sensitive with at least a partial response); if patient has had a previous autologous transplant, the melphalan and fludarabine conditioning regimen must be utilized\r\n** Chronic myelomonocytic leukemia\r\n** Atypical (breakpoint cluster region- abelson murine leukemia viral oncogene homolog 1 [BCR-ABL] negative) chronic myelogenous leukemia\r\n** Hodgkin lymphoma that has recurred or progressed after an autologous BMT\r\n*** Newly diagnosed or recurrent disease initially refractory to intensive chemotherapy; a partial response or better must be achieved prior to transplantation; eligibility of newly diagnosed cases must be discussed with the study principal investigator (PI)\r\n*** Disease that has recurred or progressed after an autologous BMT; salvage chemotherapy must produce a partial response or better; the melphalan and fludarabine conditioning-regimen must be used for these patients\r\n** Non-Hodgkin lymphoma other than lymphoblastic or peripheral T cell lymphoma\r\n*** Newly diagnosed or recurrent disease initially refractory to intensive chemotherapy; a partial response or better must be achieved prior to transplantation; eligibility of newly diagnosed cases must be discussed with the study PI\r\n*** Disease that has recurred or progressed after an autologous BMT; salvage chemotherapy must produce at least a partial response; the melphalan and fludarabine conditioning-regimen must be used for these patientsXx_NEWLINE_xXAcute abdomenXx_NEWLINE_xXSubjects with any of the following will NOT be eligible for study:\r\n* Bone marrow involvement\r\n* Active myelogenous leukemia, or history of myelogenous leukemia\r\n* PregnancyXx_NEWLINE_xXBe diagnosed with chronic phase chronic myelogenous leukemia (CML)Xx_NEWLINE_xXDiagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); subjects who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).Xx_NEWLINE_xXPatients with acute promyelocytic leukemiaXx_NEWLINE_xXNewly Diagnosed Acute Myeloid Leukemia (AML)Xx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXPatients with history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseasesXx_NEWLINE_xXPatients with a hematologic malignancy other than aplastic anemia or primary myelofibrosis, scheduled to undergo RIC allogeneic SCT with a peripheral blood stem cell graft from an unrelated donor, using fludarabine phosphate (Flu)/busulfan (Bu) conditioning and tacrolimus (Tac)/methotrexate (MTX) GVHD prophylaxis; the following diagnoses are included:\r\n* Acute leukemia - acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or acute biphenotypic leukemia; patients will have documentation of complete remission within 6 weeks prior to their transplant; complete remission is defined as < 5% blasts on a bone marrow biopsy and absence of any known extramedullary disease\r\n* Chronic myelogenous leukemia in any stage, but with documentation of < 5% blasts on a bone marrow biopsy within 6 weeks prior to transplant\r\n* Myelodysplastic syndrome of any subtype, but with documentation of < 5% blasts on a bone marrow biopsy within 6 weeks prior to transplant\r\n* Myeloproliferative disorders other than primary myelofibrosis\r\n* Lymphoma - all types of lymphoma are eligible\r\n* Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL)Xx_NEWLINE_xXPatient must be scheduled to undergo stem cell transplantation for one of the following diagnoses: \r\n* Acute myeloid leukemia (AML) in first complete remission (CR1) (first complete remission, CR or CR with incomplete blood count recovery [CRi]) or second complete remission (CR2) (second complete remission, CR or CRi) \r\n* Acute lymphoblastic leukemia (ALL) in CR1 or CR2, (CR or CRi)\r\n* Myelodysplastic syndrome (MDS) without progression to AML \r\n* Chronic myelogenous leukemia (CML)\r\n* Non-Hodgkin’s lymphoma (NHL) or Hodgkin’s disease (HD)\r\n* Chronic lymphocytic leukemia (CLL)\r\n* Multiple myeloma (MM)Xx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXPlasma cell leukemiaXx_NEWLINE_xXAcute leukemia receiving induction chemotherapyXx_NEWLINE_xXNewly diagnosed with acute leukemia by pathology reportXx_NEWLINE_xXRelapsed/refractory acute myeloid leukemia (AML) patients who received standard of care cytarabine and mitoxantrone as their chemotherapy regimenXx_NEWLINE_xXPatients with a diagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXAcute myeloid leukemia arising de novo (per European LeukemiaNet)Xx_NEWLINE_xXAML subtype M3 (promyelocytic leukemia)Xx_NEWLINE_xXAll acute myelogenous leukemia and high-risk myelodysplastic leukemia patients who are admitted to the leukemia service and those who are referred from other services (i.e. pediatrics, medical oncology, etc.) will be eligible for the studyXx_NEWLINE_xXPatients that are high risk for TLS or potential/intermediate risk for TLS as described below:\r\n* High risk: Hyperuricemia of malignancy (uric acid levels > 7.5); or diagnosis of very aggressive lymphoma/leukemia based on Revised European-American Lymphoma (REAL) classification; acute myeloid leukemia, chronic myelogenous leukemia (CML) in blast crisis; high grade myelodysplastic syndrome only if they have > 10% bone marrow blast involvement and given aggressive treatment similar to acute myeloid leukemia (AML)\r\n* Potential risk: Diagnosis of aggressive lymphoma/leukemia based on (REAL) classification; plus one or more of the following criteria: lactate dehydrogenase (LDH) >= 2 x upper limit of normal (UNL); stage III-IV disease; stage I-II disease with at least 1 lymph node/tumor > 5 cm in diameter; for patients with potential/intermediate risk for TLS-only those planned to receive alternating regimens (or non-standard regimens) in 2 cycles (example; rituximab-hyperfractionated cyclophosphamide-vincristine [vincristine sulfate]-Adriamycin [doxorubicin hydrochloride]-dexamethasone [R-Hyper-CVAD] alternating with methotrexate/arabinofuranosyl cytidine [cytarabine] [MTX/ARA-C]) will be eligibleXx_NEWLINE_xXIntensive induction chemotherapy for a new diagnosis of acute myelogenous leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome receiving standard anthracycline based chemotherapyXx_NEWLINE_xXRe-induction of acute myelogenous or lymphocytic leukemia after primary relapseXx_NEWLINE_xXTransformed acute myeloid leukemia (AML) with marrow fibrosis is allowed, if AML is in complete remission after induction therapyXx_NEWLINE_xXAcute or chronic respiratory diseaseXx_NEWLINE_xXAcute Lymphoblastic Leukemia (ALL) in first complete remission (CR1) that is NOT considered favorable-risk as defined by the presence of at least one of the following:\r\n* Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), other mixed lineage leukemia (MLL) rearrangements\r\n* White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis\r\n* Recipient age older than 30 years at diagnosis\r\n* Time to CR greater than 4 weeksXx_NEWLINE_xXAcute Myelogenous Leukemia (AML) in first complete remission (CR1) that is NOT considered as favorable-risk; favorable risk is defined as having one of the following:\r\n* t(8,21) without CKIT mutation\r\n* inv(16) without CKIT mutation or t(16;16)\r\n* Normal karyotype with mutated nucleophosmin (NPM)1 and not fms-related tyrosine kinase (FLT)-IND\r\n* Normal karyotype with double mutated CCAAT enhancer binding protein alpha (CEBPA)\r\n* Acute promyelocytic leukemia (APL) in first molecular remission at end of consolidationXx_NEWLINE_xXChronic myelogenous leukemia: all types except refractory blast crisis; chronic phase patients must have failed or been intolerant to at least one tyrosine-kinase inhibitorXx_NEWLINE_xXNew diagnosis of de novo ALL, lymphomas (T or B cell), or mixed-phenotype acute leukemiaXx_NEWLINE_xXAcute myeloid leukemiaXx_NEWLINE_xXAcute lymphoblastic leukemia, including T lymphoblastic lymphoma with a history of marrow involvementXx_NEWLINE_xXChronic Myelogenous leukemiaXx_NEWLINE_xXUntreated de novo or secondary acute myeloid leukemia (AML), including AML that has progressed from myelodysplastic syndrome (MDS), and histologically documented diagnosisXx_NEWLINE_xXAcute promyelocytic leukemia (APL) with PML-RARAXx_NEWLINE_xXPatients must have a documented Unequivocal diagnosis of AML according to WHO 2008 classification (>20% blasts in the bone marrow), excluding M3 (acute promyelocytic leukemia).Xx_NEWLINE_xXSubjects with acute leukemia, chronic myelogenous leukemia, or myelodysplasia must have no circulating blasts and < 5% blasts of the bone marrow.Xx_NEWLINE_xXRECIPIENT: Planned HCT for the treatment of the following hematologic malignancies: lymphoma (Hodgkin and non?Hodgkin), myelodysplastic syndrome, acute lymphoblastic leukemia in first or second remission, acute myeloid leukemia in first or second remission, chronic myelogenous leukemia (in first chronic or accelerated phase, or in second chronic phase), chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis (City of Hope [COH] only). Patients with multiple myeloma are excludedXx_NEWLINE_xXDiagnosis of acute myeloid leukemia (AML), acute biphenotypic leukemia, or acute lymphoblastic leukemia (ALL); CML transformed to blast crisis is eligibleXx_NEWLINE_xXThe patient must have a diagnosis of one of the following (one must be yes):\r\n* Acute myeloid leukemia (AML)\r\n* Acute lymphoblastic leukemia (ALL)\r\n* Chronic myelogenous leukemia (CML) (chronic phase intolerant or unresponsive to tyrosine kinase inhibitors, accelerated phase, history of blast crisis)\r\n* Myelodysplastic syndrome (MDS)\r\n* Myeloproliferative neoplasm (MPN)\r\n* Chronic myelomonocytic leukemia (CMML)\r\n* Non-Hodgkin lymphoma (NHL)\r\n* Hodgkin lymphoma (HL) (received and failed frontline therapy or failed autologous transplantation or inability to collect enough peripheral blood stem cells [PBSC] for autologous hematopoietic cell transplant [auto-HCT])\r\n* Multiple myeloma (MM)\r\n* Waldenstrom’s macroglobulinemia\r\n* Severe aplastic anemiaXx_NEWLINE_xXPatients with acute leukemia or chronic myelogenous leukemia with no circulating blasts and with less than 10% blasts in the bone marrowXx_NEWLINE_xXActive acute or chronic GVHDXx_NEWLINE_xXAcute leukemia in complete remission (CR)1 or second/subsequent CRXx_NEWLINE_xXChronic myeloid leukemia, primary myelofibrosis, chronic myelomonocytic leukemiaXx_NEWLINE_xXAcute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative neoplasms, Hodgkin lymphoma, or non-Hodgkin lymphoma requiring a matched allogeneic HSCTXx_NEWLINE_xXAcute leukemia (acute myeloid leukemia [AML] or acute lymphoblastic leukemia [ALL]) must be in complete remission defined as: < 5% marrow blasts with no morphologic evidence of leukemia, no peripheral blasts, marrow > 20% cellular, and peripheral absolute neutrophil count > 1000/uL (platelet recovery is not required)Xx_NEWLINE_xXMyelodysplasia (MDS) and chronic myeloid leukemia (CML): must have < 5% marrow blastsXx_NEWLINE_xXSubjects must have one of the following disease categories:\r\n* Acute myeloid leukemia (AML) beyond 2nd remission or relapsed/refractory disease\r\n* Acute lymphoblastic leukemia (ALL) beyond 2nd remission or relapsed/refractory disease\r\n* Chronic myeloid leukemia (CML) beyond 2nd chronic phase or in blast crises\r\n* Myelodysplastic syndrome (MDS)\r\n* Myeloproliferative disorders including myeloid metaplasia and myelofibrosis\r\n* High risk non-Hodgkin’s lymphoma (NHL) in first remission\r\n* Relapsed or refractory NHL\r\n* Hodgkin’s lymphoma (HL) beyond first remissionXx_NEWLINE_xXAcute myeloid leukemia (AML) with any of the following:\r\n* In first remission (CR1) with intermediate risk or high-risk cytogenetic and/or molecular features\r\n* Patients in second or subsequent complete remission (CR2, CR3, etc.)\r\n* Primary refractory or relapsed AML with no more than any one of the following adverse additional features according to modified Center for International Blood and Marrow Transplant Research (CIBMTR) criteria\r\n** Duration of first CR < 6 months\r\n** Poor risk cytogenetics or molecular features (FLT-3 internal tandem duplication [ITD]; complex karyotype with >= 3 clonal abnormalities, 5q-/-5, 7q-/-7, 11q23 abnormalities, inv(3), monosomal karyotype)\r\n** Circulating peripheral blood blasts at time of enrollment\r\n** Karnofsky performance status < 90%Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL) with any of the following:\r\n* In CR1 or subsequent complete remission (CR2, CR3, etc.)\r\n* Primary refractory or relapsed ALL with no more than one of the following adverse features according to modified CIBMTR criteria\r\n** Second or subsequent relapse\r\n** Bone marrow blasts > 25% at time of enrollment\r\n** Age > 40 yearsXx_NEWLINE_xXMalignant disorders:\r\n* Chronic myeloid leukemia (CML) (chronic phase, accelerated phase or blast crisis)\r\n* Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML)\r\n* Acute lymphoblastic leukemia (ALL)\r\n* Lymphoma (Hodgkin’s and non-Hodgkin’s)Xx_NEWLINE_xXHematologic malignancies - Acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), multiple myeloma (MM) - in complete remission (CR)\r\n* Complete remission is defined per morphologic, cytogenetic, fluorescence in situ hybridization (FISH), molecular, and radiographic imaging studies appropriate for each condition listedXx_NEWLINE_xXAcute myeloid leukemia (AML) – must have < 5% marrow blasts at the time of transplantXx_NEWLINE_xXAcute lymphocytic leukemia (ALL) – must have < 5% marrow blasts at the time of transplantXx_NEWLINE_xXChronic myeloid leukemia (CML) – Patients will be accepted if they have shown intolerance to tyrosine kinase inhibitors or are beyond first chronic phase (CP1) and if they have received previous myelosuppressive chemotherapy or HCT, and have < 5% marrow blasts at time of transplantXx_NEWLINE_xXAcute myeloid leukemia (AML) in first cytomorphological remission (< 5% blasts in the bone marrow) with Disease Risk Index (DRI) intermediate or above, or in second or higher cytomorphological remissionXx_NEWLINE_xXAcute lymphoblastic leukemia (ALL) in first or higher remission (< 5% blasts in the bone marrow)Xx_NEWLINE_xXPrior diagnosis of an acute leukemia or lymphoma or any receipt of HCT for a malignant condition.Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL) second or greater complete remission (CR); first complete remission (CR1) unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL; high risk ALL is defined as having one of the following:\r\n* Evidence of high risk cytogenetics such as t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1\r\n* 30 years of age or older at diagnosis\r\n* White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis\r\n* Central nervous system (CNS) leukemia involvement during the course of disease\r\n* Slow cytologic response (> 10% lymphoblasts in bone marrow on day 14 of induction therapy)\r\n* Evidence of persistent immunophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapyXx_NEWLINE_xXAcute myelogenous leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in =< 60 years old that is NOT considered as favorable-risk; favorable risk is defined as having one of the following:\r\n* t(8,21) without cKIT mutation\r\n* inv(16) or t(16;16) without cKIT mutation\r\n* Normal karyotype with mutated NPM1 and wild type FLT-ITD\r\n* Normal karyotype with double mutated CEBPA\r\n* Acute prolymphocytic leukemia (APL) in first molecular remission at end of consolidationXx_NEWLINE_xXChronic myelogenous leukemia: all types except refractory blast crisis; chronic phase patients must have failed at least two different tyrosine-kinase inhibitors (TKIs), or been intolerant to all available TKIs or have T315I mutationXx_NEWLINE_xXChronic myelogenous leukemia (CML) in blast crisisXx_NEWLINE_xXAcute myeloid leukemia (AML) in first remission with high-risk features or in second or higher remissionXx_NEWLINE_xXAcute lymphoblastic leukemia (ALL) in first remission with high-risk features or in second or higher remissionXx_NEWLINE_xXDiagnosis of acute leukemia (AML/ALL) or advanced MDS (intermediate-2 [INT-2] or high risk) in complete remission (complete remission [CR]/composite complete remission [CRc]/complete remission with incomplete hematologic recovery [CRi]) documented by bone marrow biopsy done within 30 days prior to the initiation of conditioning regimenXx_NEWLINE_xXAcute myelogenous leukemia (AML (ACUTE MYELOID LEUKEMIA) - FAB (FRENCH-AMERICAN-BRITISH) classification: ? 30% blasts in bone marrow). Subjects known to have ? 30% blasts are not eligible for inclusion in this study. Recognizing limitations of blast cell quantification, this protocol will allow subjects with pre-enrollment (screening/baseline) bone marrow blast counts up to 33% to be considered for inclusion.Xx_NEWLINE_xXActive myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukemia (CMML)Xx_NEWLINE_xXKnown symptomatic acute or chronic pancreatitis.Xx_NEWLINE_xXAcute or chronic pancreatitisXx_NEWLINE_xXParticipants with a previously documented diagnosis of myelodysplastic syndrome (or any dysplastic leukocyte morphology suggestive of myelodysplastic syndromes [MDS]) or acute myeloid leukemiaXx_NEWLINE_xXClinical Diagnosis of one of the following: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, LymphomaXx_NEWLINE_xXSubjects with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDSXx_NEWLINE_xXKnown history of primary plasma cell leukemia or evidence of primary or secondary plasma cell leukemia at the time of screeningXx_NEWLINE_xXParticipants must have pathologically confirmed acute myeloid leukemia (AML) in first complete remission (CR1) as defined by:\r\n* Bone marrow biopsy with < 5% blasts\r\n* No clusters or collections of blast cells\r\n* No extramedullary leukemia\r\n* Absolute neutrophil count >= 1000/uL (achieved post-induction at some point)\r\n* Please note that full platelet recovery is not necessary, and thus, patients achieving pathological complete remission (CRp) are eligibleXx_NEWLINE_xXAcute myeloid leukemia (AML)Xx_NEWLINE_xXAcute lymphoblastic leukemia (ALL)Xx_NEWLINE_xXAcute undifferentiated leukemia (AUL)Xx_NEWLINE_xXAcute biphenotypic leukemiaXx_NEWLINE_xXChronic myelogenous leukemia (CML)Xx_NEWLINE_xXPatients with acute leukemia, chronic myelogenous leukemia, myeloproliferative disorder and myelodysplasia with no circulating blasts and with less than 5% blasts in the bone marrow within 4 weeks of the start of transplant conditioning regimenXx_NEWLINE_xXPatients with acute leukemia, chronic myelogenous leukemia or myelodysplasia with no circulating blasts and with less than 5% blasts in the bone marrow.Xx_NEWLINE_xXPatients with secondary acute myeloid leukemia arising from myeloproliferative disease, including Chronic myelomonocytic leukemia (CMML), with evidence of active myeloproliferative features or myelofibrosis in the background.Xx_NEWLINE_xXCOHORT 1: RELAPSED/REFRACTORY LEUKEMIA \r\n* Acute lymphoblastic leukemia, first or greater relapse\r\n* Acute myeloid leukemia, first or greater relapse\r\n* Leukemia refractory to induction chemotherapy\r\n* Other recurrent leukemia\r\n* Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapyXx_NEWLINE_xXCOHORT 2: NEW DIAGNOSIS\r\n* Acute myeloid leukemia, new diagnosis\r\n* New diagnosis infant mixed-lineage leukemia (MLL)-rearranged acute lymphoblastic leukemia (ALL) or low hypodiploid (< 40 chromosomes) ALL\r\n* Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage\r\n* Secondary leukemia\r\n* Myelodysplastic syndrome (MDS) not eligible for stem cell transplantXx_NEWLINE_xXHistologic confirmation of leukemia or myelodysplatic syndrome (MDS) at the time of diagnosis or recurrenceXx_NEWLINE_xXPatients must not have acute promyelocytic leukemia (APL) and must not have evidence of t(15;17)(q22;q21)Xx_NEWLINE_xXPatients with newly diagnosed AML or acute promyelocytic leukemia (APL)Xx_NEWLINE_xXPatients with known extramedullary leukemiaXx_NEWLINE_xXHave an acute or a chronic hematoma and/or acute ecchymosis of the thyroid;Xx_NEWLINE_xXAcute myocardial infarctions or acute coronary syndromesXx_NEWLINE_xXAcute promyelocytic leukemia.Xx_NEWLINE_xXDiagnosis of acute promyelocytic leukemiaXx_NEWLINE_xXActive plasma cell leukemia.Xx_NEWLINE_xXConcurrent symptomatic amyloidosis or plasma cell leukemiaXx_NEWLINE_xXPlasma cell leukemia (> 2.0 X109/L circulating plasma cells by standard differential).Xx_NEWLINE_xXSubject has confirmed morphologically documented AML, excluding acute promyelocytic leukemia (APL), in CR1 (including CRp and CRi). For the purposes of enrollment, CR will be defined as < 5% blasts in the bone marrow with no morphologic characteristics of acute leukemia (e.g., Auer rods) in the bone marrow with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.Xx_NEWLINE_xXConfirmed diagnosis of Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).Xx_NEWLINE_xXHospitalized for newly diagnosed acute leukemiaXx_NEWLINE_xXPatient has a diagnosis of chronic lymphocytic leukemiaXx_NEWLINE_xXNot in acute crisisXx_NEWLINE_xXDONOR: Patient with acute myeloid leukemia (AML) undergoing screening for potential URD HCTXx_NEWLINE_xXDONOR: Potential URD undergoing screening to provide a HCT graft to a patient with acute myeloid leukemia (AML) at a participating institutionXx_NEWLINE_xXMen or women, 18 years of age or older, with a confirmed diagnosis of international prognostic scoring system (IPSS) intermediate-1, intermediate-2 or high-risk MDS including Chronic Myelomonocytic Leukemia (CMML) or AML.Xx_NEWLINE_xXAcute promyelocytic leukemia (M3 classification).Xx_NEWLINE_xXMultiple myeloma/plasma cell leukemia or B cell acute lymphoblastic leukemiaXx_NEWLINE_xXPatients must have suspected refractory or relapsed pre-B cell ALL or mixed phenotype acute leukemia (MPAL), or if newly diagnosed, the patient must be 60 years of age or olderXx_NEWLINE_xXPatients must have histologically or cytologically confirmed by the local institution CD19+ precursor B-acute lymphoblastic leukemia (pre-B cell ALL) OR CD19+ mixed phenotype acute leukemia (MPAL): a) with relapse following or refractory to at least one prior line of therapy if older than 21 years; b) in second or higher relapse or refractory to at least two prior lines of therapy if 21 years old and younger (16-21); c) or they must have a new diagnosis of pre-B cell ALL or CD19+ MPAL but are >= 60 years old and are either not a candidate for or do not wish to receive traditional induction chemotherapyXx_NEWLINE_xXActive leukemia in the testes or isolated extramedullary relapse; patients with a history of treated leukemia in testes but no active disease at the time of enrollment are eligibleXx_NEWLINE_xXAcute promyelocytic leukemiaXx_NEWLINE_xXSubjects with acute promyelocytic leukemia (APL)Xx_NEWLINE_xXPrimary or secondary AML (including erythroleukemia and eosinophilic leukemia, but excluding acute promyelocytic leukemia)Xx_NEWLINE_xXDiagnosis of promyelocytic leukemiaXx_NEWLINE_xXPatients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS), or with features suggestive of AML/MDS, or who have had prior allogeneic bone marrow transplant or double umbilical cord blood transplantation, should not receive veliparib due to reports of MDS and leukemia secondary to oncology therapy on Cancer Therapy Evaluation Program (CTEP)-sponsored studies utilizing veliparibXx_NEWLINE_xX